## Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelsystem.org.

## Overview for Request opi_ahr_wp002_nsdp_v01

Request ID: opi_ahr_wp002_nsdp_v01
Report Description: This report provides the number and proportion of "opioid-tolerant-only" episodes of transdermal fentanyl that were prescribed to patients with evidence of prior-established "opioid tolerance" by dose of transdermal fentanyl. This analysis only assesses the first eligible transdermal fentanyl episode per user, by dose.

## Sentinel Modular Program Tool Used: Ad Hoc Programming

Data Source: Data from January 1, 2009 to December 31, 2013 from 15 Data Partners contributing to the Mini-Sentinel Distributed Database (MSDD) were included in this report. This is the period during which new opioid-tolerant-only dose product treatment episodes started. The request was distributed to two Data Partners in March 2016 and to the remaining 13 participating Data Partners in April 2016. Please see Appendix A for the latest date of available data for each Data Partner.

Study Design: The first eligible transdermal fentanyl episode per user, by dose, was identified and assessed for evidence of prior opioid tolerance, by each of the four tolerance definitions. Two washout periods were used to define new use: [1] No use of transdermal fentanyl in 183 days prior (primary analysis) and [2] No use of transdermal fentanyl in 91 days prior (sensitivity analvsis).
Cohort Eligibility Criteria: Individuals included in the cohort were required to be continuously enrolled in plans with both medical and drug coverage for at least 183 days (for primary analysis) or 91 days (sensitivity analysis) prior to their first eligible transdermal fentanyl episode, during which gaps in coverage of up to 45 days were allowed. Individuals ages 0 through 64 years were included in the analysis. Age groupings are as follows: 0-11, 12-17, 18-24, 25-34, 35-44, 45-54, and 55-64 years. Patients were excluded if they were diagnosed with opioid poisoning in the 183 days (or 91 days for sensitivity analysis) prior to their first eligible transdermal fentanyl episode or if they were hospitalized (inpatient stay) in the 30 days prior to cohort entry. Opioid poisoning was defined using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. Please see Appendix C for a list of codes.
Exposures of Interest: The exposure of interest was new use of opioid-tolerant-only transdermal fentanyl. The exposure was defined using National Drug Codes (NDCs). Please see Appendix B for a list of drugs.
Definition of opioid-tolerance-only doses: All dose formulations are opioid-tolerant-only doses, but results are stratified by dose: $12,25,50,75$, and $100 \mathrm{mcg} / \mathrm{hr}$, as well as any outlier doses.
Definitions of opioid tolerance:
Primary: $\geq 30 \mathrm{mg}$ oxycodone equivalents per day for seven days consecutively in the seven days prior to new opioid-tolerant-only dose index date
Secondary: $\geq 30 \mathrm{mg}$ oxycodone equivalents per day for seven days in the 30 days prior to new opioid-tolerant-only dose index date (seven days not required to be consecutive)
Tertiary: >0 mg (i.e., any dose of oxycodone equivalent) for seven days in the seven consecutive days prior to new opioid-tolerant-only dose index date
Quaternary: $>0 \mathrm{mg}$ (i.e., any dose of oxycodone equivalent) for seven days in the 30 days prior to new opioid-tolerant-only dose index date (seven days not required to be consecutive). All dose formulations are opioid-tolerant-only doses, but results are stratified by dose: $12,25,50,75$, and $100 \mathrm{mcg} / \mathrm{hr}$, as well as any outlier doses.

Limitations: Algorithms to define exposures and events are imperfect and, therefore, may be misclassified.
Notes: Please contact the Sentinel Operations Center Query Fulfillment Team (qf@sentinelsystem.org) for questions and to provide comments/suggestions for future enhancements to this document.

|  | Table of Contents |
| :---: | :---: |
| Glossary | List of Terms Used in this Request and their Detinitions |
| Table 1a | Counts of Transdermal Fentanyl Episodes and Proportions of Transdermal Fentanyl Episodes with Prior Tolerance with a 183-day Washout Period and a Primary Definition in the Mini-Sentinel Distributed Database (MSDD) from January 1, 2009 to December 31, 2013 |
| Table 1b | Counts of Transdermal Fentanyl Episodes and Proportions of Transdermal Fentanyl Episodes with Prior Tolerance with a 183-day Washout Period and a Secondary Definition in the Mini-Sentinel Distributed Database (MSDD) from January 1, 2009 to December 31, 2013 |
| Table 1c | Counts of Transdermal Fentanyl Episodes and Proportions of Transdermal Fentanyl Episodes with Prior Tolerance with a 183-day Washout Period and a Tertiary Definition in the Mini-Sentinel Distributed Database (MSDD) from January 1, 2009 to December 31, 2013 |
| Table 1d | Counts of Transdermal Fentanyl Episodes and Proportions of Transdermal Fentanyl Episodes with Prior Tolerance with a 183-day Washout Period and a Quaternary Definition in the Mini-Sentinel Distributed Database (MSDD) from January 1, 2009 to December 31, 2013 |
| Table 2a | Counts of Transdermal Fentanyl Episodes and Proportions of Transdermal Fentanyl Episodes with Prior Tolerance with a 91-day Washout Period and a Primary Definition in the Mini-Sentinel Distributed Database (MSDD) from January 1, 2009 to December 31, 2013 |
| Table 2b | Counts of Transdermal Fentanyl Episodes and Proportions of Transdermal Fentanyl Episodes with Prior Tolerance with a 91-day Washout Period and a Secondary Definition in the Mini-Sentinel Distributed Database (MSDD) from January 1, 2009 to December 31, 2013 |
| Table 2c | Counts of Transdermal Fentanyl Episodes and Proportions of Transdermal Fentanyl Episodes with Prior Tolerance with a 91-day Washout Period and a Tertiary Definition in the Mini-Sentinel Distributed Database (MSDD) from January 1, 2009 to December 31, 2013 |
| Table 2d | Counts of Transdermal Fentanyl Episodes and Proportions of Transdermal Fentanyl Episodes with Prior Tolerance with a 91-day Washout Period and a Quaternary Definition in the Mini-Sentinel Distributed Database (MSDD) from January 1, 2009 to December 31, 2013 |
| Appendix A | Latest Date of Available Data for Each Data Partner up to Request Send Date (April 20, 2016) |
| Appendix B | List of Drugs Used to Define Exposures in this Request |
| Appendix C | List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) Codes Used to Define Exclusion Criteria in this Request |

# Mini-Sentinel 

## Glossary of Terms for Analyses Using <br> Cohort Identification and Descriptive Analysis (CIDA) Tool*

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing. This is equivalent to the "RxAmt" Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.
Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency department (E), Home (H), Inpatient (I), Outbatient (O). or Unknown or Missing (U). Along with the Princibal Diagnosis Indicator. forms the Care Setting/PDX barameter. Cohort Definition (drug/exposure)- indicates how the cohort will be defined: (1) 01: Cohort includes only the first valid incident treatment episode during the query period; (2) 02: Cohort includes all valid incident treatment episodes during the query period; (3) 03: Cohort includes all valid incident treatment episodes during the query period until an event occurs.
Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.
Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the Event Deduplication - specifies how events are counted by the MP algorithm: (0) 0: Counts all occurrences of an HOI during an exposure episode; (1) 1: de-duplicates occurrences of the same HOl code and code type on the same day; (2) 2 : de-duplicates occurrences of the same HOI group on the same dav (e.g., de-duplicates at the group level).
Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode.
Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."
Lookback Period (pre-existing condition) - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).
Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.
Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered.
Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the
Query Period - period in which the modular program looks for exposures and outcomes of interest.
Treatment Episode Truncation Indicator - indicates whether observation of the incident query code during follow-up requires truncation of valid treatment episodes. A value of $Y$ indicates that the treatment episodes should be truncated at the first occurrence of an incident querv code. A value of $N$ indicates that the treatment episodes should not be truncated at the occurrence of the incident querv code. Users - number of members with exposure during the query period. Member must have no evidence of exposure(s) of interest (defined by incidence criteria) in the prior washout period. A user may only be counted once in a query period.
Washout Period (drug/exposure)** - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.
Washout Period (event/outcome)** - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.
Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.
*all terms may not be used in this report
**incident treatment episodes must be incident to both the exposure and the event

| Table 1a: Counts of Transdermal Fentanyl Episodes and Proportions of Transdermal Fentanyl Episodes with Prior Tolerance with a 183-day Washout Period and a Primary Definition in the Mini-Sentinel Distributed Database (MSDD) from January 1, 2009 to December 31, 2013 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Primary Tolerance Definition ( 230 mg per day in the prior 7 consecutive days) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | Dose $12 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $24 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $25 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $36 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $37 \mathrm{mcg} / \mathrm{hr}$ |  |  |
|  |  | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{array}{\|c\|} \hline \mathrm{N} \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ |  | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | $\begin{gathered} \text { \% with } \\ \text { Prior } \\ \text { Tolerance } \end{gathered}$ | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | $\%$ with Prior Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes |  | \% with Prior Tolerance | Total N of Transdermal <br> Fentanyl Episodes |  |  |
| Age (years) | Total | 16,379 | 4,699 | 28.7\% | ${ }^{3}$ | 1 | 33\% | 44,450 | 16,623 | 37.4\% | 1 | 0 | 0\% | 298 | 160 | 54\% |
|  | $0-11$ years | 2 | - | 0.0\% | - |  | 0\% | ${ }^{23}$ | 2 | 8.7\% | 0 | 0 | 0\% | 1 | - | 0\% |
|  | 12-17 years | 75 | ${ }^{6}$ | 8.0\% |  |  | 0\% | 79 | 15 | 19.0\% | 0 | 0 | 0\% | 2 |  | 0\% |
|  | $18-24$ years | 375 | 96 | 25.6\% |  |  | 0\% | 827 | 314 | 38.0\% | 0 | 0 | 0\% | 8 | 3 | 38\% |
|  | 25-34 years | 1,464 | 539 | 36.8\% | - |  | 0\% | 3,731 | 1,688 | 45.2\% | 1 | 0 | 0\% | 24 | 16 | 67\% |
|  | 35-44 years | 2,841 | 955 | 33.6\% | 2 | 1 | 50\% | 7,954 | 3,325 | 41.8\% | 0 | 0 | 0\% | 63 | 33 | 52\% |
|  | 45 - 54 years | 5,214 | 1,532 | 29.4\% | - |  | 0\% | 14,785 | 5,707 | 38.6\% | 0 | 0 | 0\% | 87 | 47 | 54\% |
|  | 55-64 years | 6,378 | 1,571 | 24.6\% | 1 | - | 0\% | 17,051 | 5,572 | 32.7\% | 0 | 0 | 0\% | 113 | 61 | 54\% |
| Gender | Male | 5,124 | 1,537 | 30.0\% | 1 | 1 | 100\% | 18,327 | 7,100 | 38.7\% | 0 | 0 | 0\% | 133 | 73 | 55\% |
|  | Female | 11,255 | 3,162 | 28.1\% | 2 | - | 0\% | 26,123 | 9,523 | 36.5\% | 1 | 0 | 0\% | 165 | 87 | 53\% |
|  | Ambiguous | - |  | 0.0\% | - |  | 0\% | . | - | 0.0\% | 0 | 0 | 0\% | - |  | 0\% |
|  | Unknown | 0 | 0 | 0 | 0 | - | 0\% | . | 0 | 0 | 0 | 0 | 0\% | - | - | 0\% |
| Month and Year of Episode Start Date | Jan 2009 | 220 | ${ }^{66}$ | 30.0\% | - |  | 0\% | 953 | 316 | 33.2\% | 0 | 0 | 0\% | 4 | 3 | 75\% |
|  | Feb 2009 | 206 | 51 | 24.8\% | - |  | 0\% | 890 | 312 | 35.1\% | 0 | 0 | 0\% | 8 | 3 | 38\% |
|  | Mar 2009 | 267 | 72 | 27.0\% | - |  | 0\% | 982 | 334 | 34.0\% | 0 | 0 | 0\% | 5 | 3 | 60\% |
|  | Apr 2009 | 220 | 52 | 23.6\% | - | - | 0\% | 969 | 334 | 34.5\% | 1 | 0 | 0\% | 4 | 1 | 25\% |
|  | May 2009 | 248 | 61 | 24.6\% | - |  | 0\% | 875 | 330 | 37.7\% | 0 | 0 | 0\% | 6 | 5 | 83\% |
|  | Jun 2009 | 258 | 65 | 25.2\% | - | - | 0\% | 909 | 312 | 34.3\% | 0 | 0 | 0\% | 5 | 4 | 80\% |
|  | Jul 2009 | 249 | 67 | 26.9\% | - | - | 0\% | 870 | 301 | 34.6\% | 0 | 0 | 0\% | 6 | 2 | 33\% |
|  | Aug 2009 | 268 | 71 | 26.5\% | - | - | 0\% | 881 | 289 | 32.8\% | 0 | 0 | 0\% | 2 | 1 | 50\% |
|  | Sep 2009 | 295 | 86 | 29.2\% | - | - | 0\% | 943 | 331 | 35.1\% | 0 | 0 | 0\% | 4 | 3 | 75\% |
|  | Oct 2009 | 261 | 69 | 26.4\% | - | - | 0\% | 857 | 292 | 34.1\% | 0 | 0 | 0\% | 1 | 1 | 100\% |
|  | Nov 2009 | 231 | 67 | 29.0\% | - | - | 0\% | 818 | 274 | 33.5\% | 0 | 0 | 0\% | 8 | 4 | 50\% |
|  | Dec 2009 | 244 | 74 | 30.3\% | - |  | 0\% | 900 | 337 | 37.4\% | 0 | 0 | 0\% | 7 | 3 | 43\% |
|  | Jan 2010 | 226 | 55 | 24.3\% | - | - | 0\% | 827 | 271 | 32.8\% | 0 | 0 | 0\% | 6 | - | 0\% |
|  | Feb 2010 | 238 | 79 | 33.2\% | - |  | 0\% | 753 | 270 | 35.9\% | 0 | 0 | 0\% | 8 | , | 75\% |
|  | Mar 2010 | 268 | 76 | 28.4\% | - | - | 0\% | 791 | 294 | 37.2\% | 0 | 0 | 0\% | 8 | 3 | 38\% |
|  | Apr 2010 | 257 | 71 | 27.6\% | - | - | 0\% | 833 | 277 | 33.3\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | May 2010 | 227 | 73 | 32.2\% | - | - | 0\% | 738 | 299 | 40.5\% | 0 | 0 | 0\% | 5 | 1 | 20\% |
|  | Jun 2010 | 246 | 68 | 27.6\% | - | - | 0\% | 746 | 281 | 37.7\% | 0 | 0 | 0\% | 4 | 1 | 25\% |
|  | Jul 2010 | 223 | 62 | 27.8\% | - |  | 0\% | 764 | 305 | 39.9\% | 0 | 0 | 0\% | 5 | 3 | 60\% |
|  | Aug 2010 | 260 | 73 | 28.1\% | - | - | 0\% | 810 | 281 | 34.7\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Sep 2010 | 301 | 91 | 30.2\% | - |  | 0\% | 833 | 323 | 38.8\% | 0 | 0 | 0\% | 2 | 2 | 100\% |
|  | Oct 2010 | 288 | 70 | 24.3\% | - | - | 0\% | 777 | 292 | 37.6\% | 0 | 0 | 0\% | 5 | 3 | 60\% |
|  | Nov 2010 | 290 | 87 | 30.0\% | - | - | 0\% | 824 | 306 | 37.1\% | 0 | 0 | 0\% | 9 | , | 44\% |
|  | Dec 2010 | 291 | 87 | 29.9\% | - | - | 0\% | 731 | 294 | 40.2\% | 0 | 0 | 0\% | 3 | 1 | 33\% |
|  | Jan 2011 | 252 | 67 | 26.6\% | - | - | 0\% | 724 | 272 | 37.6\% | 0 | 0 | 0\% | 1 | 1 | 100\% |
|  | Feb 2011 | 264 | 61 | 23.1\% | - | - | 0\% | 639 | 235 | 36.8\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Mar 2011 | 279 | 73 | 26.2\% | - | - | 0\% | 802 | 309 | 38.5\% | 0 | 0 | 0\% | 9 | 5 | 56\% |
|  | Apr 2011 | 269 | 80 | 29.7\% | - | - | 0\% | 710 | 281 | 39.6\% | 0 | 0 | 0\% | 10 | 9 | 90\% |
|  | May 2011 | 261 | 73 | 28.0\% | - | - | 0\% | 700 | 256 | 36.6\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Jun 2011 | 276 | 76 | 27.5\% | - | - | 0\% | 678 | 272 | 40.1\% | 0 | 0 | 0\% | 4 | 2 | 50\% |
|  | Jul 2011 | 282 | 81 | 28.7\% | - | - | 0\% | 679 | 249 | 36.7\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Aug 2011 | 314 | 106 | 33.8\% | - | - | 0\% | 758 | 265 | 35.0\% | 0 | 0 | 0\% | 4 | 2 | 50\% |
|  | Sep 2011 | 291 | 85 | 29.2\% | - |  | 0\% | 730 | 280 | 38.4\% | 0 | 0 | 0\% | 7 | 3 | 43\% |
|  | Oct 2011 | 263 | 79 | 30.0\% | - | - | 0\% | 711 | 283 | 39.8\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Nov 2011 | 288 | 96 | 33.3\% | - | - | 0\% | 659 | 275 | 41.7\% | 0 | 0 | 0\% | 8 | 2 | 25\% |
|  | Dec 2011 | 307 | 93 | 30.3\% | - | - | 0\% | 689 | 261 | 37.9\% | 0 | 0 | 0\% | 5 |  | 60\% |
|  | Jan 2012 | 279 | 80 | 28.7\% | - |  | 0\% | 720 | 278 | 38.6\% | 0 | 0 | 0\% | 2 | 2 | 100\% |
|  | Feb 2012 | 255 | 67 | 26.3\% | - | - | 0\% | 638 | 222 | 34.8\% | 0 | 0 | 0\% | 7 | 3 | 43\% |
|  | Mar 2012 | 294 | 83 | 28.2\% | - |  | 0\% | 683 | 252 | 36.9\% | 0 | 0 | 0\% | 6 | 4 | 67\% |
|  | Apr 2012 | 251 | 83 | 33.1\% | - | - | 0\% | 650 | 249 | 38.3\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | May 2012 | 324 | 88 | 27.2\% | - | - | 0\% | 631 | 249 | 39.5\% | 0 | 0 | 0\% | 8 | 5 | 63\% |
|  | Jun 2012 | 242 | 68 | 28.1\% | - | - | 0\% | 564 | 219 | 38.8\% | 0 | 0 | 0\% | 3 | , | 67\% |
|  | Jul 2012 | 295 | 90 | 30.5\% | - | - | 0\% | 617 | 244 | 39.5\% | 0 | 0 | 0\% | 5 | 2 | 40\% |
|  | Aug 2012 | 304 | 111 | 36.5\% | - | - | 0\% | 787 | 306 | 38.9\% | 0 | 0 | 0\% | 2 | 1 | 50\% |
|  | Sep 2012 | 279 | 75 | 26.9\% | - | - | 0\% | 645 | 239 | 37.1\% | 0 | 0 | 0\% | 5 | 4 | 80\% |
|  | Oct 2012 | 304 | 91 | 29.9\% | - | - | 0\% | 699 | 304 | 43.5\% | 0 | 0 | 0\% | 3 | 1 | 33\% |
|  | Nov 2012 | 313 | 82 | 26.2\% | - | - | 0\% | 712 | 241 | 33.8\% | 0 | 0 | 0\% | ${ }^{6}$ | 3 | 50\% |
|  | Dec 2012 | 293 | 78 | 26.6\% | - | - | 0\% | 631 | 251 | 39.8\% | 0 | 0 | 0\% | 8 | 3 | 38\% |
|  | Jan 2013 | 277 | 87 | 31.4\% | - | - | 0\% | 593 | 220 | 37.1\% | 0 | 0 | 0\% | 4 | 3 | 75\% |
|  | Feb 2013 | 254 | 76 | 29.9\% | - | - | 0\% | 638 | 270 | 42.3\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Mar 2013 | 253 | 85 | 33.6\% | - | - | 0\% | 585 | 246 | 42.1\% | 0 | 0 | 0\% | 4 | 3 | 75\% |
|  | Apr 2013 | 289 | 99 | 34.3\% | - | - | 0\% | 617 | 243 | 39.4\% | 0 | 0 | 0\% | 9 | 4 | 44\% |
|  | May 2013 | 261 | 80 | 30.7\% | - | - | 0\% | 640 | 261 | 40.8\% | 0 | 0 | 0\% | 8 | 4 | 50\% |
|  | Jun 2013 | 271 | 69 | 25.5\% | 1 | - | 0\% | 602 | 242 | 40.2\% | 0 | 0 | 0\% | 4 | 2 | 50\% |
|  | Jul 2013 | 331 | 95 | 28.7\% | - | - | 0\% | 663 | 264 | 39.8\% | 0 | 0 | 0\% | 8 | 5 | 63\% |
|  | Aug 2013 | 341 | 97 | 28.4\% | - | - | 0\% | 735 | 300 | 40.8\% | 0 | 0 | 0\% | ${ }^{3}$ | 1 | 33\% |
|  | Sep 2013 | 302 | 78 | 25.8\% | - | - | 0\% | 645 | 252 | 39.1\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Oct 2013 | 331 | 99 | 29.9\% | 1 | 1 | 100\% | 714 | 285 | 39.9\% | 0 | 0 | 0\% | 3 | 1 | 33\% |
|  | Nov 2013 | 310 | 89 | 28.7\% | 1 | - | 0\% | 651 | 255 | 39.2\% | 0 | 0 | 0\% | 5 | 1 | 20\% |
|  | Dec 2013 | 298 | 86 | 28.9\% | 0 |  | 0\% | 637 | 238 | 37.4\% | 0 | 0 | 0\% | 5 | 4 | 80\% |


| Table 1a: Counts of Transdermal Fentanyl Episodes and Proportions of Transdermal Fentanyl Episodes with Prior Tolerance with a 183-day Washout Period and a Primary Definition in the Mini-Sentinel Distributed Database (MSDD) from January 1, 2009 to December 31, 2013 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Primary Tolerance Definition ( 230 mg per day in the prior 7 consecutive days) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | Dose $50 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $62 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $75 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $87 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $100 \mathrm{mcg} / \mathrm{hr}$ |  |  |
|  |  | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with <br> Prior <br> Tolerance | $\begin{gathered} \text { \% with } \\ \text { Prior } \\ \text { Tolerance } \end{gathered}$ | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{array}{\|c\|} \mathrm{N} \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | $\begin{gathered} \text { \% with } \\ \text { Prior } \\ \text { Tolerance } \end{gathered}$ | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{array}{\|c\|} \hline N \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | $\begin{array}{\|c\|} \hline \% \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | $\begin{array}{\|c} \text { \% with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | Total N of <br> Transdermal <br> Fentanyl <br> Episodes |  | \% with Prior Tolerance |
| Age (years) | Total | 18,527 | 8,871 | 48\% | 22 | 6 | 27\% | 5,118 | 2,756 | 54\% | 8 | 2 | 25\% | 3,507 | 1,991 | 57\% |
|  | $0-11$ years | 7 | 2 | 29\% | 1 | - | 0\% | 2 | - | 0\% | - | - | 0\% | 4 | - | 0\% |
|  | $12-17$ years | 32 | 9 | 28\% | - | - | 0\% | 11 | 3 | 27\% | - | - | 0\% | ${ }^{8}$ | 2 | 25\% |
|  | $18-24$ years | 380 | 161 | 42\% | 1 | - | 0\% | 99 | 52 | 53\% | - | - | 0\% | 77 | 38 | 49\% |
|  | 25.34 years | 1,614 | 900 | 56\% | 2 | - | 0\% | 523 | 309 | 59\% | 1 | 1 | 100\% | 290 | 179 | 62\% |
|  | 35-44 years | 3,502 | 1,846 | 53\% | 4 | 1 | 25\% | 1,011 | 553 | 55\% | 1 | - | 0\% | 686 | 403 | 59\% |
|  | 45.54 years | 6,358 | 3,055 | 48\% | 11 | 3 | 27\% | 1,785 | 966 | 54\% | 4 | 1 | 25\% | 1,276 | 744 | 58\% |
|  | 55-64 years | 6,634 | 2,898 | 44\% | 3 | 2 | 67\% | 1,687 | 873 | 52\% | 2 | - | 0\% | 1,166 | 625 | 54\% |
| Gender | Male | 8,727 | 4,377 | 50\% | 11 | 5 | 45\% | 2,510 | 1,428 | 57\% | 4 | 1 | 25\% | 1,839 | 1,111 | 60\% |
|  | Female | 9,800 | 4,494 | 46\% | 11 | 1 | 9\% | 2,608 | 1,328 | 51\% | ${ }_{4}^{4}$ | 1 | 25\% | 1,668 | 880 | 53\% |
|  | Ambiguous | . | - | 0\% | - | - | 0\% | - | . | 0\% | - | - | 0\% | - | - | 0\% |
|  | Unknown | - | - | 0\% | - | . | 0\% | - | . | 0\% | - | - | 0\% | . | . | 0\% |
| Month and Year of Episode Start Date | Jan 2009 | 412 | 185 | 45\% | 2 | 2 | 100\% | 145 | 61 | 42\% | 1 | - | 0\% | 94 | ${ }^{42}$ | 45\% |
|  | Feb 2009 | 414 | 199 | 48\% | - | - | 0\% | 118 | 65 | 55\% | - | - | 0\% | 98 | 55 | 56\% |
|  | Mar 2009 | 424 | 208 | 49\% | - | - | 0\% | 112 | 55 | 49\% | - | - | 0\% | 79 | 38 | 48\% |
|  | Apr 2009 | 423 | 215 | 51\% | - | - | 0\% | 108 | 62 | 57\% | - | - | 0\% | 88 | 50 | 57\% |
|  | May 2009 | 368 | 166 | 45\% | - | - | 0\% | 101 | 50 | 50\% | - | - | 0\% | 84 | 42 | 50\% |
|  | Jun 2009 | 409 | 176 | 43\% | - | - | 0\% | 111 | 53 | 48\% | - | - | 0\% | 75 | 49 | 65\% |
|  | Jul 2009 | 376 | 170 | 45\% | 2 | - | 0\% | 89 | 41 | 46\% | - | - | 0\% | 86 | 48 | 56\% |
|  | Aug 2009 | 348 | 165 | 47\% | - | - | 0\% | 97 | 53 | 55\% | - | - | 0\% | 72 | 41 | 57\% |
|  | Sep 2009 | 396 | 180 | 45\% | - | - | 0\% | 95 | 63 | 66\% | 2 | - | 0\% | 72 | 37 | 51\% |
|  | Oct 2009 | 433 | 190 | 44\% | - | - | 0\% | 100 | 52 | 52\% | - | - | 0\% | 90 | 50 | 56\% |
|  | Nov 2009 | 366 | 172 | 47\% | 1 | 1 | 100\% | 94 | 51 | 54\% | - | - | 0\% | 77 | 46 | 60\% |
|  | Dec 2009 | 379 | 170 | 45\% | - | - | 0\% | 113 | 59 | 52\% | - | - | 0\% | 74 | 40 | 54\% |
|  | Jan 2010 | 359 | 158 | 44\% | - | - | 0\% | 101 | 52 | 51\% | - | - | 0\% | 89 | 55 | 62\% |
|  | Feb 2010 | 325 | 143 | 44\% | 1 | - | 0\% | 84 | 39 | 46\% | 1 | - | 0\% | 60 | 31 | 52\% |
|  | Mar 2010 | 331 | 142 | 43\% | - | - | 0\% | 113 | 63 | 56\% | - | - | 0\% | 62 | 35 | 56\% |
|  | Apr 2010 | 307 | 134 | 44\% | - | - | 0\% | 100 | 57 | 57\% | - | - | 0\% | 67 | 45 | 67\% |
|  | May 2010 | 326 | 147 | 45\% | - | - | 0\% | 84 | 38 | 45\% | - | - | 0\% | 60 | 39 | 65\% |
|  | Jun 2010 | 340 | 167 | 49\% | - | - | 0\% | 77 | 40 | 52\% | - | - | 0\% | 49 | 38 | 78\% |
|  | Jul 2010 | 342 | 180 | 53\% | - | - | 0\% | 92 | 45 | 49\% | - | - | 0\% | 55 | 37 | 67\% |
|  | Aug 2010 | 325 | 158 | 49\% | - | - | 0\% | 98 | 50 | 51\% | - | - | 0\% | 71 | 44 | 62\% |
|  | Sep 2010 | 343 | 165 | 48\% | 1 | 1 | 100\% | 93 | 57 | 61\% | - | - | 0\% | 70 | 41 | 59\% |
|  | Oct 2010 | 340 | 174 | 51\% | - | - | 0\% | 95 | 54 | 57\% | - | - | 0\% | 58 | 42 | 72\% |
|  | Nov 2010 | 326 | 163 | 50\% | - | - | 0\% | 93 | 56 | 60\% | - | - | 0\% | 63 | 37 | 59\% |
|  | Dec 2010 | 356 | 156 | 44\% | - | - | 0\% | 78 | 44 | 56\% | - | - | 0\% | 64 | 30 | 47\% |
|  | Jan 2011 | 306 | 130 | 42\% | - | - | 0\% | 112 | 54 | 48\% | - | - | 0\% | 90 | 52 | 58\% |
|  | Feb 2011 | 277 | 148 | 53\% | - | - | 0\% | 96 | 59 | 61\% | - | - | 0\% | 66 | 38 | 58\% |
|  | Mar 2011 | 338 | 174 | 51\% | 1 | - | 0\% | 94 | 61 | 65\% | - | - | 0\% | 79 | 43 | 54\% |
|  | Apr 2011 | 322 | 147 | 46\% | - | - | 0\% | 86 | 44 | 51\% | - | - | 0\% | 52 | 24 | 46\% |
|  | May 2011 | 280 | 126 | 45\% | - | - | 0\% | 86 | 47 | 55\% | - | - | 0\% | 52 | 28 | 54\% |
|  | Jun 2011 | 286 | 123 | 43\% | - | - | 0\% | 75 | 45 | 60\% | 1 | - | 0\% | 41 | 23 | 56\% |
|  | Jul 2011 | 309 | 146 | 47\% | - | - | 0\% | 70 | 48 | 69\% | - | - | 0\% | 48 | 26 | 54\% |
|  | Aug 2011 | 322 | 148 | 46\% | - | - | 0\% | 78 | 38 | 49\% | - | - | 0\% | 45 | 30 | 67\% |
|  | Sep 2011 | 310 | 153 | 49\% | - | - | 0\% | 78 | 44 | 56\% | - | - | 0\% | 42 | 23 | 55\% |
|  | Oct 2011 | 269 | 129 | 48\% | 2 | - | 0\% | 77 | 48 | 62\% | - | - | 0\% | 56 | 32 | 57\% |
|  | Nov 2011 | 274 | 140 | 51\% | - | - | 0\% | 77 | 43 | 56\% | - | - | 0\% | 47 | 26 | 55\% |
|  | Dec 2011 | 286 | 135 | 47\% | - | - | 0\% | 72 | 36 | 50\% | - | - | 0\% | 59 | 37 | 63\% |
|  | Jan 2012 | 273 | 132 | 48\% | - | - | 0\% | 88 | 48 | 55\% | - | - | 0\% | 53 | 27 | 51\% |
|  | Feb 2012 | 266 | 146 | 55\% | 1 | - | 0\% | 75 | 45 | 60\% | - | - | 0\% | 53 | 34 | 64\% |
|  | Mar 2012 | 282 | 141 | 50\% | - | - | 0\% | 76 | 43 | 57\% | - | - | 0\% | 48 | 28 | 58\% |
|  | Apr 2012 | 277 | 143 | 52\% | 1 | - | 0\% | 86 | 40 | 47\% | - | - | 0\% | 48 | 26 | 54\% |
|  | May 2012 | 287 | 149 | 52\% | 1 | - | 0\% | 71 | 40 | 56\% | - | - | 0\% | 52 | 36 | 69\% |
|  | Jun 2012 | 234 | 111 | 47\% | 1 | - | 0\% | 60 | 34 | 57\% | - | - | 0\% | 49 | 30 | 61\% |
|  | Jul 2012 | 307 | 156 | 51\% | - | - | 0\% | 87 | 43 | 49\% | - | - | 0\% | 37 | 17 | 46\% |
|  | Aug 2012 | 284 | 142 | 50\% | 1 | - | 0\% | 89 | 54 | 61\% | - | - | 0\% | 51 | 35 | 69\% |
|  | Sep 2012 | 254 | 131 | 52\% | 1 | - | 0\% | 77 | 49 | 64\% | 1 | 1 | 100\% | 38 | 20 | 53\% |
|  | Oct 2012 | 251 | 108 | 43\% | - | - | 0\% | 69 | 40 | 58\% | - | - | 0\% | 47 | 20 | 43\% |
|  | Nov 2012 | 296 | 137 | 46\% | - | - | 0\% | 90 | 39 | 43\% | 2 | 1 | 50\% | 62 | 32 | 52\% |
|  | Dec 2012 | 261 | 141 | 54\% | - | - | 0\% | 54 | 22 | 41\% | - | - | 0\% | 46 | 19 | $41 \%$ |
|  | Jan 2013 | 254 | 132 | 52\% | 2 | 1 | 50\% | 87 | 39 | 45\% | - | - | 0\% | 42 | 25 | 60\% |
|  | Feb 2013 | 212 | 117 | 55\% | 2 | - | 0\% | 56 | 31 | 55\% | - | - | 0\% | 44 | 27 | 61\% |
|  | Mar 2013 | 236 | 118 | 50\% | - | - | 0\% | 72 | 38 | 53\% | - | - | 0\% | 36 | 19 | 53\% |
|  | Apr 2013 | 226 | 108 | 48\% | - | - | 0\% | 68 | 33 | 49\% | - | - | 0\% | 37 | 23 | 62\% |
|  | May 2013 | 250 | 130 | 52\% | 1 | 1 | 100\% | 65 | 41 | 63\% | - | - | 0\% | 42 | 24 | 57\% |
|  | Jun 2013 | 244 | 116 | 48\% | - | - | 0\% | 69 | 36 | 52\% | - | - | 0\% | 34 | 17 | 50\% |
|  | Jul 2013 | 239 | 119 | 50\% | - | - | 0\% | 78 | 45 | 58\% | - | - | 0\% | 43 | 20 | 47\% |
|  | Aug 2013 | 272 | 130 | 48\% | - | - | 0\% | 61 | 26 | 43\% | - | - | 0\% | 31 | 14 | 45\% |
|  | Sep 2013 | 245 | 119 | 49\% | - | - | 0\% | 66 | 38 | 58\% | - | - | 0\% | 44 | 22 | 50\% |
|  | Oct 2013 | 242 | 130 | 54\% | - | - | 0\% | 67 | 41 | 61\% | - | - | 0\% | 47 | 32 | 68\% |
|  | Nov 2013 | 241 | 115 | 48\% |  | - | 0\% | 58 | 33 | 57\% | - | - | 0\% | 47 | 24 | 51\% |
|  | Dec 2013 | 247 | 118 | 48\% | 1 | - | 0\% | 57 | 31 | 54\% | - | - | 0\% | 42 | 26 | 62\% |


| Table 1a: Counts of Transdermal Fentanyl Episodes and Proportions of Transdermal Fentanyl Episodes with Prior Tolerance with a 183-day Washout Period and a Primary Definition in the Mini-Sentinel Distributed Database (MSDD) from January 1, 2009 to December 31, 2013 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Primary Tolerance Definition ( 230 mg per day in the prior 7 consecutive days) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | Dose $112 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $125 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $137 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $150 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $162 \mathrm{mcg} / \mathrm{hr}$ |  |  |
|  |  | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with <br> Prior <br> Tolerance | $\begin{gathered} \text { \% with } \\ \text { Prior } \\ \text { Tolerance } \end{gathered}$ | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{gathered} \mathrm{N} \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{gathered}$ | $\begin{array}{\|c\|} \hline \text { \% with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{gathered} \mathrm{N} \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{gathered}$ | $\begin{array}{\|c} \text { \% with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes |  | $\begin{array}{\|c\|} \hline \text { \% with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{gathered} \mathrm{N} \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{gathered}$ | $\begin{gathered} \text { \% with } \\ \text { Prior } \\ \text { Tolerance } \end{gathered}$ |
| Age (years) | Total | 3 | 3 | 100\% | 137 | 68 | 50\% | 2 | 1 | 50\% | 172 | 103 | 60\% | 2 | 1 | 50\% |
|  | $0-11$ years | - | - | 0\% | - | . | 0\% | - | - | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | 12-17 years | - | - | 0\% | 1 | - | 0\% | - | - | 0\% | 1 | 0 | 0\% | 0 | 0 | 0\% |
|  | 18.24 years | - | . | 0\% | 2 | 2 | 100\% | - | . | 0\% | 5 | 4 | 80\% | 1 | 0 | 0\% |
|  | 25.34 years | - | - | 0\% | 9 | 7 | 78\% | - | - | 0\% | 12 | 6 | 50\% | 0 | 0 | 0\% |
|  | $35-44$ years | - | - | 0\% | 20 | 8 | 40\% | - | - | 0\% | 30 | 21 | 70\% | 0 | 0 | 0\% |
|  | 45.54 years | 1 | 1 | 100\% | 57 | 29 | 51\% | 1 | - | 0\% | 60 | 36 | 60\% | 0 | 0 | 0\% |
|  | $55-64$ years | 2 | 2 | 100\% | 48 | 22 | 46\% | 1 | 1 | 100\% | 64 | 36 | 56\% | 1 |  | 100\% |
| Gender | Male | 1 | 1 | 100\% | 69 | 33 | 48\% | - | - | 0\% | 95 | 61 | 64\% | 2 | 1 | 50\% |
|  | Female | 2 | 2 | 100\% | 68 | 35 | 51\% | 2 | 1 | 50\% | 77 | 42 | 55\% | 0 | 0 | 0\% |
|  | Ambiguous | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | 0 | 0\% | 0 | 0 | 0\% |
|  | Unknown | . | . | 0\% | - | . | 0\% | . | . | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
| Month and Year of Episode Start Date | Jan 2009 | 1 | 1 | 100\% | 4 | 2 | 50\% | - | - | 0\% | 6 | 2 | 33\% | 0 | 0 | 0\% |
|  | Feb 2009 | - | - | 0\% | 3 | 1 | 33\% | - | - | 0\% | 2 | 1 | 50\% | 0 | 0 | 0\% |
|  | Mar 2009 | - | - | 0\% | 3 | - | 0\% | - | - | 0\% | 1 | 1 | 100\% | 0 | 0 | 0\% |
|  | Apr 2009 | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% | 1 | 1 | 100\% | 0 | 0 | 0\% |
|  | May 2009 | - | - | 0\% | 3 | 3 | 100\% | - | - | 0\% | 6 | 4 | 67\% | 0 | 0 | 0\% |
|  | Jun 2009 | - | - | 0\% | 2 | 2 | 100\% | - | - | 0\% | 7 | 6 | 86\% | 0 | 0 | 0\% |
|  | Jul 2009 | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% | 3 | 1 | 33\% | 0 | 0 | 0\% |
|  | Aug 2009 | - | - | 0\% | 1 | - | 0\% | - | - | 0\% | 4 | 0 | 0\% | 0 | 0 | 0\% |
|  | Sep 2009 | - | - | 0\% | - | - | 0\% | - | - | 0\% | 5 | 3 | 60\% | 0 | 0 | 0\% |
|  | Oct 2009 | - | - | 0\% | 1 | - | 0\% | - | - | 0\% | 4 | 2 | 50\% | 0 | 0 | 0\% |
|  | Nov 2009 | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% | 7 | 5 | 71\% | 0 | 0 | 0\% |
|  | Dec 2009 | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% | 7 | 5 | 71\% | 0 | 0 | 0\% |
|  | Jan 2010 | - | - | 0\% | 7 | 2 | 29\% | - | - | 0\% | 5 | 3 | 60\% | 0 | 0 | 0\% |
|  | Feb 2010 | - | - | 0\% | 6 | 1 | 17\% | - | - | 0\% | 5 | 3 | 60\% | 0 | 0 | 0\% |
|  | Mar 2010 | - | - | 0\% | 2 | - | 0\% | - | - | 0\% | 4 | 3 | 75\% | 0 | 0 | 0\% |
|  | Apr 2010 | - | - | 0\% | 4 | 1 | 25\% | - | - | 0\% | 4 | 3 | 75\% | 0 | 0 | 0\% |
|  | May 2010 | . | - | 0\% | 2 | 1 | 50\% | - | - | 0\% | 4 | 2 | 50\% | 0 | 0 | 0\% |
|  | Jun 2010 | - | - | 0\% | 5 | 2 | 40\% | - | - | 0\% | 2 | 1 | 50\% | 0 | 0 | 0\% |
|  | Jul 2010 | - | - | 0\% | 1 | - | 0\% | - | - | 0\% | 5 | 4 | 80\% | 0 | 0 | 0\% |
|  | Aug 2010 | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% | 2 | 0 | 0\% | 0 | 0 | - 0 |
|  | Sep 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% | 3 | 0 | 0\% | 0 | 0 | 0\% |
|  | Oct 2010 | . | - | 0\% | 3 | 3 | 100\% | 1 | 1 | 100\% | 3 | 3 | 100\% | 0 | 0 | 0\% |
|  | Nov 2010 | - | - | 0\% | 2 | 2 | 100\% | - | - | 0\% | 2 | 1 | 50\% | 0 | 0 | 0\% |
|  | Dec 2010 | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% | 4 | 2 | 50\% | 0 | 0 | 0\% |
|  | Jan 2011 | - | - | 0\% | 3 | 1 | 33\% | - | - | 0\% | 4 | 2 | 50\% | 1 | 0 | - 0 |
|  | Feb 2011 | 1 | 1 | 100\% | 3 | - | 0\% | - | - | 0\% | 3 | 1 | 33\% | 0 | 0 | 0\% |
|  | Mar 2011 | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% | 2 | 1 | 50\% | 0 | 0 | - 0\% |
|  | Apr 2011 | - | - | 0\% | 3 | 1 | 33\% | - | - | 0\% | 4 | 4 | 100\% | 0 | 0 | 0\% |
|  | May 2011 | - | - | 0\% | 5 | 1 | 20\% | - | - | 0\% | 2 | 1 | 50\% | 0 | 0 | 0\% |
|  | Jun 2011 | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Jul 2011 | - | - | 0\% | 2 | - | 0\% | - | - | 0\% | 4 | 4 | 100\% | 0 | 0 | 0\% |
|  | Aug 2011 | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% | 1 | 1 | 100\% | 0 | 0 | 0\% |
|  | Sep 2011 | - | - | 0\% | 4 | 2 | 50\% | 1 | - | 0\% | 3 | 3 | 100\% | 1 | 1 | 100\% |
|  | Oct 2011 | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% | 1 | 0 | 0\% | 0 | 0 | 0\% |
|  | Nov 2011 | - | - | 0\% | - | - | 0\% | - | - | 0\% | 1 | 1 | 100\% | 0 | 0 | 0\% |
|  | Dec 2011 | - | - | 0\% | 3 | 2 | 67\% | - | - | 0\% | 1 | 1 | 100\% | 0 | 0 | 0\% |
|  | Jan 2012 | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% | 2 | 2 | 100\% | 0 | 0 | 0\% |
|  | Feb 2012 | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% | 5 | 4 | 80\% | 0 | 0 | 0\% |
|  | Mar 2012 | - | - | 0\% | 3 | 3 | 100\% | - | - | 0\% | 2 | 1 | 50\% | 0 | 0 | 0\% |
|  | Apr 2012 | 1 | 1 | 100\% | 5 | 5 | 100\% | - | - | 0\% | 3 | 2 | 67\% | 0 | 0 | 0\% |
|  | May 2012 | - | - | 0\% | 4 | - | 0\% | - | - | 0\% | 0 | 0 | 0\% | 0 | 0 | - 0 |
|  | Jun 2012 | - | - | 0\% | - | - | 0\% | - | - | 0\% | 2 | 1 | 50\% | 0 | 0 | 0\% |
|  | Jul 2012 | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% | 0 | 0 | 0\% | 0 | 0 | - 0\% |
|  | Aug 2012 | - | - | 0\% | 4 | 3 | 75\% | - | - | 0\% | 1 | 1 | 100\% | 0 | 0 | 0\% |
|  | Sep 2012 | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% | 2 | 1 | 50\% | 0 | 0 | - 0 |
|  | Oct 2012 | - | - | 0\% | 2 | 2 | 100\% | - | - | 0\% | 2 | 2 | 100\% | 0 | 0 | 0\% |
|  | Nov 2012 | - | - | 0\% | 2 | 2 | 100\% | - | - | 0\% | 5 | 2 | 40\% | 0 | 0 | 0\% |
|  | Dec 2012 | - | - | 0\% | 3 | 1 | 33\% | - | - | 0\% | 0 | 0 | 0\% | 0 | 0 | - 0\% |
|  | Jan 2013 | - | - | 0\% | 2 | - | 0\% | - | - | 0\% | 4 | 0 | 0\% | 0 | 0 | 0\% |
|  | Feb 2013 | - | - | 0\% | 3 | 1 | 33\% | - | - | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Mar 2013 | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% | 3 | 1 | 33\% | 0 | 0 | - 0 |
|  | Apr 2013 | - | - | 0\% | - | - | 0\% | - | - | 0\% | 3 | 2 | 67\% | 0 | 0 | - 0\% |
|  | May 2013 | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Jun 2013 | - | - | 0\% | - | - | 0\% | - | - | 0\% | 3 | 1 | 33\% | 0 | 0 | - 0\% |
|  | Jul 2013 | - | - | 0\% | 3 | 3 | 100\% | - | - | 0\% | 2 | 2 | 100\% | 0 | 0 | 0\% |
|  | Aug 2013 | - | - | 0\% | 2 | 2 | 100\% | - | - | 0\% | 3 | 1 | 33\% | 0 | 0 | 0\% |
|  | Sep 2013 | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% | 2 | 1 | 50\% | 0 | 0 | - 0 |
|  | Oct 2013 | - | - | 0\% | 4 | 1 | 25\% | - | - | 0\% | 1 | 1 | 100\% | 0 | 0 | - $0 \%$ |
|  | Nov 2013 | - | - | 0\% | 1 | 1 | 100\% | - |  | 0\% | 3 | 2 | 67\% | 0 | 0 | - 0 |
|  | Dec 2013 | - | - | 0\% | 1 | . | 0\% | - | - | 0\% | 2 | 1 | 50\% | 0 | 0 | 0\% |


| Primary Tolerance Definition ( 230 mg per day in the prior 7 consecutive days) |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Dose $175 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $200 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $225 \mathrm{mcg} / \mathrm{hr}$ |  |  |
|  |  | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | $\begin{array}{\|c\|} \hline \text { \% with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | Total N of <br> Transdermal <br> Fentanyl <br> Episodes |  | $\begin{array}{\|c} \% \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{array}{\|c\|} \hline \mathrm{N} \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ |  |
| Age (years) | Total | 33 | 16 | 48\% | 4 | 3 | 75\% | 2 | 0 | 0\% |
|  | $0-11$ years | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | 12-17 years | 1 | 1 | 100\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | 18.24 years | 3 | 3 | 100\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | 25-34 years | 1 | 0 | 0\% | 0 | 0 | 0\% | 1 | 0 | 0\% |
|  | 35-44 years | 4 | 3 | 75\% | 3 | 2 | 67\% | 0 | 0 | 0\% |
|  | 45 - 54 years | 9 | 4 | 44\% | 1 | 1 | 100\% | 0 | 0 | 0\% |
|  | 55-64 years | 15 | 5 | $33 \%$ | 0 | 0 | 0\% | 1 | 0 | 0\% |
| Gender | Male | 11 | 9 | 82\% | 4 | 3 | 75\% | 2 | 0 | 0\% |
|  | Female | 22 | 7 | 32\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Ambiguous | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Unknown | 0 | 0 | 0\% | 0 | 0 | 0\% |  | 0 | 0\% |
| Month and Year of Episode Start Date | Jan 2009 | 1 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Feb 2009 | 1 | 1 | 100\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Mar 2009 | 1 | 1 | 100\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Apr 2009 | 3 | 3 | 100\% | 1 | 1 | 100\% | 0 | 0 | 0\% |
|  | May 2009 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Jun 2009 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Jul 2009 |  | 0 | 0\% | 0 | 0 | 0\% | 1 | 0 | 0\% |
|  | Aug 2009 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Sep 2009 | 1 | 1 | 100\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Oct 2009 | 1 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Nov 2009 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Dec 2009 | 1 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Jan 2010 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Feb 2010 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Mar 2010 | 1 | 1 | 100\% | 1 | 1 | 100\% | 0 | 0 | 0\% |
|  | Apr 2010 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | May 2010 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Jun 2010 | 1 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Jul 2010 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Aug 2010 | 1 | 1 | 100\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Sep 2010 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Oct 2010 | 1 | 1 | 100\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Nov 2010 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Dec 2010 | 1 | 1 | 100\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Jan 2011 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Feb 2011 | 2 | 1 | 50\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Mar 2011 | 1 | 1 | 100\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Apr 2011 | 1 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | May 2011 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Jun 2011 | 2 | 1 | 50\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Jul 2011 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Aug 2011 | 1 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Sep 2011 | 2 | 1 | 50\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Oct 2011 | 2 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Nov 2011 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Dec 2011 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Jan 2012 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Feb 2012 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Mar 2012 | 1 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Apr 2012 | 1 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | May 2012 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Jun 2012 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Jul 2012 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Aug 2012 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Sep 2012 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Oct 2012 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Nov 2012 | 0 | 0 | 0\% | 0 | 0 | 0\% | 1 | 0 | 0\% |
|  | Dec 2012 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Jan 2013 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Feb 2013 | 1 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Mar 2013 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Apr 2013 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | May 2013 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Jun 2013 | 1 | 0 | 0\% | 2 | 1 | 50\% | 0 | 0 | 0\% |
|  | Jul 2013 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Aug 2013 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Sep 2013 | 1 | 1 | 100\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Oct 2013 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Nov 2013 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Dec 2013 | 1 | 1 | 100\% | 0 | 0 | 0\% | 0 | 0 | 0\% |


| Table 1b: Counts of Transdermal Fentanyl Episodes and Proportions of Transdermal Fentanyl Episodes with Prior Tolerance with a 183-day Washout Period and a Secondary Definition in the Mini-Sentinel Distributed Database (MSDD) from January 1, 2009 to December 31, 2013 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Secondary Tolerance Definition ( 230 mg per day for seven days in the 30 days prior) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | Dose $12 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $24 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $25 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $36 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $37 \mathrm{mcg} / \mathrm{hr}$ |  |  |
|  |  | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | $N$ with <br> Prior <br> Tolerance | \% with <br> Prior <br> Tolerance | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | $N$ with <br> Prior <br> Tolerance | $\begin{aligned} & \text { \% with } \\ & \text { Prior } \\ & \text { Tolerance } \end{aligned}$ | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{aligned} & \mathrm{N} \text { with } \\ & \text { Prior } \\ & \text { Tolerance } \end{aligned}$ | \% with <br> Prior <br> Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | $N$ with <br> Prior Tolerance | \% with Prior Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with Prior Tolerance |
|  | Total | 16,379 | 7,855 | 48.0\% | 3 | 2 | 67\% | 44,450 | 26,009 | 58.5\% | 1 | 0 | 0\% | 298 | 210 | 70\% |
| Age (years) | $0-11$ years | 32 | 1 | 3.1\% | - | 0 | 0\% | 23 | 4 | 17.4\% | 0 | 0 | 0\% | 1 | 0 | 0\% |
|  | 12-17 years | 75 | 16 | 21.3\% | - |  | 0\% | 79 | 23 | 29.1\% | 0 | 0 | 0\% | 2 | 0 | 0\% |
|  | $18-24$ years | 375 | 151 | 40.3\% | - |  | 0\% | 827 | 440 | 53.2\% | 0 | 0 | 0\% | 8 | 5 | 63\% |
|  | 25.34 years | 1,464 | 822 | 56.1\% | - |  | 0\% | 3,731 | 2,488 | 66.7\% | 1 | 0 | 0\% | 24 | 20 | 83\% |
|  | 35-44 years | 2,841 | 1,500 | 52.8\% | 2 |  | 50\% | 7,954 | 4,989 | 62.7\% | 0 | 0 | 0\% | 63 | 43 | 68\% |
|  | 45.54 years | 5,214 | 2,529 | 48.5\% | - |  | 0\% | 14,785 | 8,764 | 59.3\% | 0 | 0 | 0\% | 87 | 64 | 74\% |
|  | 55-64 years | 6,378 | 2,836 | 44.5\% | 1 | 1 | 100\% | 17,051 | 9,301 | 54.5\% | 0 | 0 | 0\% | 113 | 78 | 69\% |
| Gender | Male | 5,124 | 2,569 | 50.1\% | 1 |  | 100\% | 18,327 | 11,006 | 60.1\% | 0 | 0 | 0\% | 133 | 96 | 72\% |
|  | Female | 11,255 | 5,286 | 47.0\% | 2 |  | 50\% | 26,123 | 15,003 | 57.4\% | 1 | 0 | 0\% | 165 | 114 | 69\% |
|  | Ambiguous | . | . | 0.0\% | - |  | 0\% | . | - | 0.0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Unknown | 0 | 0 | 0 | 0 | 0 | 0\% | - | 0 | 0 | 0 | 0 | 0\% | 0 | 0 | 0\% |
| Month and Year of Episode Start Date | Jan 2009 | 220 | 106 | 48.2\% | - |  | 0\% | 953 | 539 | 56.6\% | 0 | 0 | 0\% | 4 | 4 | 100\% |
|  | Feb 2009 | 206 | 95 | 46.1\% | - |  | 0\% | 890 | 519 | 58.3\% | 0 | 0 | 0\% | 8 | 4 | 50\% |
|  | Mar 2009 | 267 | 121 | 45.3\% | - |  | 0\% | 982 | 547 | 55.7\% | 0 | 0 | 0\% | 5 | 5 | 100\% |
|  | Apr 2009 | 220 | 100 | 45.5\% | - |  | 0\% | 969 | 526 | 54.3\% | 1 | 0 | 0\% | 4 | 2 | 50\% |
|  | May 2009 | 248 | 118 | 47.6\% | - |  | 0\% | 875 | 510 | 58.3\% | 0 | 0 | 0\% | 6 | 5 | 83\% |
|  | Jun 2009 | 258 | 106 | 41.1\% | - |  | 0\% | 909 | 521 | 57.3\% | 0 | 0 | 0\% | 5 | 4 | 80\% |
|  | Jul 2009 | 249 | 115 | 46.2\% | - |  | 0\% | 870 | 485 | 55.7\% | 0 | 0 | 0\% | 6 | 4 | 67\% |
|  | Aug 2009 | 268 | 129 | 48.1\% | - |  | 0\% | 881 | 472 | 53.6\% | 0 | 0 | 0\% | 2 | 1 | 50\% |
|  | Sep 2009 | 295 | 141 | 47.8\% | - |  | 0\% | 943 | 545 | 57.8\% | 0 | 0 | 0\% | 4 | 4 | 100\% |
|  | Oct 2009 | 261 | 127 | 48.7\% | - |  | 0\% | 857 | 494 | 57.6\% | 0 | 0 | 0\% | 1 | 1 | 100\% |
|  | Nov 2009 | 231 | 106 | 45.9\% | - |  | 0\% | 818 | 441 | 53.9\% | 0 | 0 | 0\% | 8 | 5 | 63\% |
|  | Dec 2009 | 244 | 118 | 48.4\% | - |  | 0\% | 900 | 523 | 58.1\% | 0 | 0 | 0\% | 7 | 4 | 57\% |
|  | Jan 2010 | 226 | 94 | 41.6\% | - | 0 | 0\% | 827 | 457 | 55.3\% | 0 | 0 | 0\% | 6 | 0 | 0\% |
|  | Feb 2010 | 238 | 119 | 50.0\% | - |  | 0\% | 753 | 432 | 57.4\% | 0 | 0 | 0\% | 8 | 6 | 75\% |
|  | Mar 2010 | 268 | 119 | 44.4\% | - |  | 0\% | 791 | 445 | 56.3\% | 0 | 0 | 0\% | 8 | 6 | 75\% |
|  | Apr 2010 | 257 | 129 | 50.2\% | - |  | 0\% | 833 | 467 | 56.1\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | May 2010 | 227 | 122 | 53.7\% | - |  | 0\% | 738 | 467 | 63.3\% | 0 | 0 | 0\% | 5 | 1 | 20\% |
|  | Jun 2010 | 246 | 116 | 47.2\% | - |  | 0\% | 746 | 434 | 58.2\% | 0 | 0 | 0\% | 4 | 1 | 25\% |
|  | Jul 2010 | 223 | 101 | 45.3\% | . |  | 0\% | 764 | 468 | 61.3\% | 0 | 0 | 0\% | 5 | 4 | 80\% |
|  | Aug 2010 | 260 | 119 | 45.8\% | - |  | 0\% | 810 | 459 | 56.7\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Sep 2010 | 301 | 153 | 50.8\% | - |  | 0\% | 833 | 506 | 60.7\% | 0 | 0 | 0\% | 2 | 2 | 100\% |
|  | Oct 2010 | 288 | 122 | 42.4\% | - |  | 0\% | 777 | 452 | 58.2\% | 0 | 0 | 0\% | 5 | 5 | 100\% |
|  | Nov 2010 | 290 | 147 | 50.7\% | - |  | 0\% | 824 | 497 | 60.3\% | 0 | 0 | 0\% | 9 | 7 | 78\% |
|  | Dec 2010 | 291 | 143 | 49.1\% | - |  | 0\% | 731 | 436 | 59.6\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Jan 2011 | 252 | 116 | 46.0\% | - | 0 | 0\% | 724 | 424 | 58.6\% | 0 | 0 | 0\% | 1 | 1 | 100\% |
|  | Feb 2011 | 264 | 114 | 43.2\% | . |  | 0\% | 639 | 376 | 58.8\% | 0 | 0 | 0\% | 3 | 3 | 100\% |
|  | Mar 2011 | 279 | 122 | 43.7\% | - |  | 0\% | 802 | 485 | 60.5\% | 0 | 0 | 0\% | 9 | 6 | 67\% |
|  | Apr 2011 | 269 | 134 | 49.8\% | - |  | 0\% | 710 | 422 | 59.4\% | 0 | 0 | 0\% | 10 | 9 | 90\% |
|  | May 2011 | 261 | 118 | 45.2\% | - |  | 0\% | 700 | 388 | 55.4\% | 0 | 0 | 0\% | 3 | 3 | 100\% |
|  | Jun 2011 | 276 | 137 | 49.6\% | - |  | 0\% | 678 | 398 | 58.7\% | 0 | 0 | 0\% | 4 | 2 | 50\% |
|  | Jul 2011 | 282 | 134 | 47.5\% | - |  | 0\% | 679 | 392 | 57.7\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Aug 2011 | 314 | 166 | 52.9\% | - |  | 0\% | 758 | 411 | 54.2\% | 0 | 0 | 0\% | 4 | 3 | 75\% |
|  | Sep 2011 | 291 | 140 | 48.1\% | . |  | 0\% | 730 | 446 | 61.1\% | 0 | 0 | 0\% | 7 | 5 | 71\% |
|  | Oct 2011 | 263 | 135 | 51.3\% | - |  | 0\% | 711 | 432 | 60.8\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Nov 2011 | 288 | 142 | 49.3\% | - | 0 | 0\% | 659 | 408 | 61.9\% | 0 | 0 | 0\% | 8 | 4 | 50\% |
|  | Dec 2011 | 307 | 152 | 49.5\% | - | 0 | 0\% | 689 | 400 | 58.1\% | 0 | 0 | 0\% | 5 | 4 | 80\% |
|  | Jan 2012 | 279 | 125 | 44.8\% | - |  | 0\% | 720 | 426 | 59.2\% | 0 | 0 | 0\% | 2 | 2 | 100\% |
|  | Feb 2012 | 255 | 124 | 48.6\% | - |  | 0\% | 638 | 356 | 55.8\% | 0 | 0 | 0\% | 7 | 5 | 71\% |
|  | Mar 2012 | 294 | 138 | 46.9\% | . |  | 0\% | 683 | 409 | 59.9\% | 0 | 0 | 0\% | 6 | 5 | 83\% |
|  | Apr 2012 | 251 | 125 | 49.8\% | - |  | 0\% | 650 | 381 | 58.6\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | May 2012 | 324 | 142 | 43.8\% | - |  | 0\% | 631 | 384 | 60.9\% | 0 | 0 | 0\% | 8 | 6 | 75\% |
|  | Jun 2012 | 242 | 114 | 47.1\% | - |  | 0\% | 564 | 337 | 59.8\% |  | 0 | 0\% | 3 | 3 | 100\% |
|  | Jul 2012 | 295 | 159 | 53.9\% | - |  | 0\% | 617 | 361 | 58.5\% | 0 | 0 | 0\% | 5 | 4 | 80\% |
|  | Aug 2012 | 304 | 161 | 53.0\% | - |  | 0\% | 787 | 474 | 60.2\% | 0 | 0 | 0\% | 2 | 2 | 100\% |
|  | Sep 2012 | 279 | 138 | 49.5\% | - |  | 0\% | 645 | 389 | 60.3\% | 0 | 0 | 0\% | 5 | 5 | 100\% |
|  | Oct 2012 | 304 | 147 | 48.4\% | - |  | 0\% | 699 | 438 | 62.7\% | 0 | 0 | 0\% | 3 | 1 | 33\% |
|  | Nov 2012 | 313 | 152 | 48.6\% | - |  | 0\% | 712 | 398 | 55.9\% | - | 0 | 0\% | 6 | 3 | 50\% |
|  | Dec 2012 | 293 | 143 | 48.8\% | - |  | 0\% | 631 | 373 | 59.1\% | 0 | 0 | 0\% | 8 | 5 | 63\% |
|  | Jan 2013 | 277 | 133 | 48.0\% | - |  | 0\% | 593 | 354 | 59.7\% |  | 0 | 0\% | 4 | 3 | 75\% |
|  | Feb 2013 | 254 | 126 | 49.6\% | - |  | 0\% | 638 | 393 | 61.6\% | 0 | 0 | 0\% | 3 | 3 | 100\% |
|  | Mar 2013 | 253 | 129 | 51.0\% | - |  | 0\% | 585 | 358 | 61.2\% |  | 0 | 0\% | 4 | 4 | 100\% |
|  | Apr 2013 | 289 | 159 | 55.0\% | - |  | 0\% | 617 | 375 | 60.8\% | 0 | 0 | 0\% | 9 | 6 | 67\% |
|  | May 2013 | 261 | 119 | 45.6\% | - |  | 0\% | 640 | 389 | 60.8\% |  | 0 | 0\% | 8 | 5 | 63\% |
|  | Jun 2013 | 271 | 121 | 44.6\% | 1 |  | 0\% | 602 | 375 | 62.3\% | 0 | 0 | 0\% | 4 | 3 | 75\% |
|  | Jul 2013 | 331 | 164 | 49.5\% | - |  | 0\% | 663 | 407 | 61.4\% | 0 | 0 | 0\% | 8 | 7 | 88\% |
|  | Aug 2013 | 341 | 157 | 46.0\% | - |  | 0\% | 735 | 439 | 59.7\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Sep 2013 | 302 | 142 | 47.0\% | - |  | 0\% | 645 | 375 | 58.1\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Oct 2013 | 331 | 165 | 49.8\% | 1 |  | 100\% | 714 | 437 | 61.2\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Nov 2013 | 310 | 148 | 47.7\% | 1 |  | 100\% | 651 | 391 | 60.1\% | 0 | 0 | 0\% | 5 | 1 | 20\% |
|  | Dec 2013 | 298 | 148 | 49.7\% | 0 | 0 | 0\% | 637 | 366 | 57.5\% | 0 | 0 | 0\% | 5 | 4 | 80\% |


| Table 1b: Counts of Transdermal Fentanyl Episodes and Proportions of Transdermal Fentanyl Episodes with Prior Tolerance with a 183-day Washout Period and a Secondary Definition in the MiniSentinel Distributed Database (MSDD) from January 1, 2009 to December 31, 2013 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Secondary Tolerance Definition ( 230 mg per day for seven days in the $\mathbf{3 0}$ days prior) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | Dose $50 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $62 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $75 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $87 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $100 \mathrm{mcg} / \mathrm{hr}$ |  |  |
|  |  | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | $\%$ with <br> Prior <br> Tolerance | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | N with <br> Prior Tolerance | \% with Prior Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | $N$ with Prior Tolerance | \% with Prior Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with Prior Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | $N$ with Prior Tolerance | \% with <br> Prior <br> Tolerance |
|  | Total | 18,527 | 12,461 | 67\% | 22 | 7 | 32\% | 5,118 | 3,578 | 70\% | 8 | 5 | 63\% | 3,507 | 2,447 | 70\% |
| Age (years) | 0.11 years | 7 | 2 | 29\% | 1 | 0 | 0\% | 2 | - | 0\% | 0 | 0 | 0\% | 4 | - | 0\% |
|  | $12 \cdot 17$ years | 32 | 15 | 47\% | 0 | 0 | 0\% | 11 | 3 | 27\% | 0 | 0 | 0\% | 8 | 3 | $38 \%$ |
|  | $18-24$ years | 380 | 228 | 60\% | 1 | 0 | 0\% | 99 | 63 | 64\% | 0 | 0 | 0\% | 77 | 45 | 58\% |
|  | 25-34 years | 1,614 | 1,187 | 74\% | 2 | 0 | 0\% | 523 | 384 | 73\% | 1 | 1 | 100\% | 290 | 223 | 77\% |
|  | 35-44 years | 3,502 | 2,528 | 72\% | 4 | 1 | 25\% | 1,011 | 719 | 71\% | 1 | 0 | 0\% | 686 | 493 | 72\% |
|  | 45-54 years | 6,358 | 4,270 | 67\% | 11 | 4 | 36\% | 1,785 | 1,265 | 71\% | 4 | 3 | 75\% | 1,276 | 908 | 71\% |
|  | 55-64 years | 6,634 | 4,231 | 64\% | 3 | 2 | 67\% | 1,687 | 1,144 | 68\% | 2 | 1 | 50\% | 1,166 | 775 | 66\% |
| Gender | Male | 8,727 | 6,009 | 69\% | 11 | 6 | 55\% | 2,510 | 1,812 | 72\% | 4 | 3 | 75\% | 1,839 | 1,331 | 72\% |
|  | Female | 9,800 | 6,452 | 66\% | 11 | 1 | 9\% | 2,608 | 1,766 | 68\% | 4 | 2 | 50\% | 1,668 | 1,116 | 67\% |
|  | Ambiguous | - | - | 0\% | 0 | 0 | 0\% | - | - | 0\% | 0 | 0 | 0\% | - | - | 0\% |
|  | Unknown | . | - | 0\% | 0 | 0 | 0\% | - | . | 0\% | 0 | 0 | 0\% | - | . | 0\% |
|  | Jan 2009 | 412 | 272 | 66\% | 2 | 2 | 100\% | 145 | 85 | 59\% | 1 | 0 | 0\% | 94 | 58 | 62\% |
| Month and Year of | Feb 2009 | 414 | 299 | 72\% | 0 | 0 | 0\% | 118 | 84 | 71\% | 0 | 0 | 0\% | 98 | 70 | 71\% |
| Episode Start Date | Mar 2009 | 424 | 291 | 69\% | 0 | 0 | 0\% | 112 | 69 | 62\% | 0 | 0 | 0\% | 79 | 46 | 58\% |
|  | Apr 2009 | 423 | 288 | 68\% | 0 | 0 | 0\% | 108 | 82 | 76\% | 0 | 0 | 0\% | 88 | 62 | 70\% |
|  | May 2009 | 368 | 226 | 61\% | 0 | 0 | 0\% | 101 | 67 | 66\% | 0 | 0 | 0\% | 84 | 56 | 67\% |
|  | Jun 2009 | 409 | 259 | 63\% | 0 | 0 | 0\% | 111 | 76 | 68\% | 0 | 0 | 0\% | 75 | 56 | 75\% |
|  | Jul 2009 | 376 | 245 | 65\% | 2 | 0 | 0\% | 89 | 59 | 66\% | 0 | 0 | 0\% | 86 | 58 | 67\% |
|  | Aug 2009 | 348 | 233 | 67\% | 0 | 0 | 0\% | 97 | 70 | 72\% | 0 | 0 | 0\% | 72 | 50 | 69\% |
|  | Sep 2009 | 396 | 263 | 66\% | 0 | 0 | 0\% | 95 | 74 | 78\% | 2 | 1 | 50\% | 72 | 47 | 65\% |
|  | Oct 2009 | 433 | 266 | 61\% | 0 | 0 | 0\% | 100 | 72 | 72\% | 0 | 0 | 0\% | 90 | 61 | 68\% |
|  | Nov 2009 | 366 | 238 | 65\% | 1 | 1 | 100\% | 94 | 70 | 74\% | 0 | 0 | 0\% | 77 | 52 | 68\% |
|  | Dec 2009 | 379 | 247 | 65\% | 0 | 0 | 0\% | 113 | 80 | 71\% | 0 | 0 | 0\% | 74 | 50 | 68\% |
|  | Jan 2010 | 359 | 228 | 64\% | 0 | 0 | 0\% | 101 | 65 | 64\% | 0 | 0 | 0\% | 89 | 65 | 73\% |
|  | Feb 2010 | 325 | 206 | 63\% | 1 | 0 | 0\% | 84 | 52 | 62\% | 1 | 1 | 100\% | 60 | 39 | 65\% |
|  | Mar 2010 | 331 | 215 | 65\% | 0 | 0 | 0\% | 113 | 77 | 68\% | 0 | 0 | 0\% | 62 | 40 | 65\% |
|  | Apr 2010 | 307 | 201 | 65\% | 0 | 0 | 0\% | 100 | 77 | 77\% | 0 | 0 | 0\% | 67 | 50 | 75\% |
|  | May 2010 | 326 | 212 | 65\% | 0 | 0 | 0\% | 84 | 52 | 62\% | 0 | 0 | 0\% | 60 | 45 | 75\% |
|  | Jun 2010 | 340 | 229 | 67\% | 0 | 0 | 0\% | 77 | 56 | 73\% | 0 | 0 | 0\% | 49 | 40 | 82\% |
|  | Jul 2010 | 342 | 235 | 69\% | 0 | 0 | 0\% | 92 | 63 | 68\% | 0 | 0 | 0\% | 55 | 44 | 80\% |
|  | Aug 2010 | 325 | 217 | 67\% | 0 | 0 | 0\% | 98 | 67 | 68\% | 0 | 0 | 0\% | 71 | 54 | 76\% |
|  | Sep 2010 | 343 | 229 | 67\% | 1 | 1 | 100\% | 93 | 72 | 77\% | 0 | 0 | 0\% | 70 | 49 | 70\% |
|  | Oct 2010 | 340 | 241 | 71\% | 0 | 0 | 0\% | 95 | 68 | 72\% | 0 | 0 | 0\% | 58 | 49 | 84\% |
|  | Nov 2010 | 326 | 228 | 70\% | 0 | 0 | 0\% | 93 | 73 | 78\% | 0 | 0 | 0\% | 63 | 47 | 75\% |
|  | Dec 2010 | 356 | 229 | 64\% | 0 | 0 | 0\% | 78 | 58 | 74\% | 0 | 0 | 0\% | 64 | 36 | 56\% |
|  | Jan 2011 | 306 | 198 | 65\% | 0 | 0 | 0\% | 112 | 71 | 63\% | 0 | 0 | 0\% | 90 | 62 | 69\% |
|  | Feb 2011 | 277 | 191 | 69\% | 0 | 0 | 0\% | 96 | 71 | 74\% | 0 | 0 | 0\% | 66 | 47 | 71\% |
|  | Mar 2011 | 338 | 231 | 68\% | 1 | 0 | 0\% | 94 | 73 | 78\% | 0 | 0 | 0\% | 79 | 55 | 70\% |
|  | Apr 2011 | 322 | 205 | 64\% | 0 | 0 | 0\% | 86 | 58 | 67\% | 0 | 0 | 0\% | 52 | 33 | 63\% |
|  | May 2011 | 280 | 175 | 63\% | 0 | 0 | 0\% | 86 | 59 | 69\% | 0 | 0 | 0\% | 52 | 32 | 62\% |
|  | Jun 2011 | 286 | 187 | 65\% | 0 | 0 | 0\% | 75 | 57 | 76\% | 1 | 1 | 100\% | 41 | 29 | 71\% |
|  | Jul 2011 | 309 | 201 | 65\% | 0 | 0 | 0\% | 70 | 54 | 77\% | 0 | 0 | 0\% | 48 | 36 | 75\% |
|  | Aug 2011 | 322 | 215 | 67\% | 0 | 0 | 0\% | 78 | 52 | 67\% | 0 | 0 | 0\% | 45 | 38 | 84\% |
|  | Sep 2011 | 310 | 223 | 72\% | 0 | 0 | 0\% | 78 | 56 | 72\% | 0 | 0 | 0\% | 42 | 26 | 62\% |
|  | Oct 2011 | 269 | 179 | 67\% | 2 | 0 | 0\% | 77 | 58 | 75\% | 0 | 0 | 0\% | 56 | 39 | 70\% |
|  | Nov 2011 | 274 | 194 | 71\% | 0 | 0 | 0\% | 77 | 55 | 71\% | 0 | 0 | 0\% | 47 | 32 | 68\% |
|  | Dec 2011 | 286 | 193 | 67\% | 0 | 0 | 0\% | 72 | 47 | 65\% | 0 | 0 | 0\% | 59 | 46 | 78\% |
|  | Jan 2012 | 273 | 198 | 73\% | 0 | 0 | 0\% | 88 | 65 | 74\% | 0 | 0 | 0\% | 53 | 34 | 64\% |
|  | Feb 2012 | 266 | 197 | 74\% | 1 | 0 | 0\% | 75 | 54 | 72\% | 0 | 0 | 0\% | 53 | 43 | 81\% |
|  | Mar 2012 | 282 | 201 | 71\% | 0 | 0 | 0\% | 76 | 58 | 76\% | 0 | 0 | 0\% | 48 | 39 | 81\% |
|  | Apr 2012 | 277 | 199 | 72\% | 1 | 0 | 0\% | 86 | 59 | 69\% | 0 | 0 | 0\% | 48 | 34 | 71\% |
|  | May 2012 | 287 | 185 | 64\% | 1 | 0 | 0\% | 71 | 49 | 69\% | 0 | 0 | 0\% | 52 | 39 | 75\% |
|  | Jun 2012 | 234 | 157 | 67\% | 1 | 0 | 0\% | 60 | 43 | 72\% | 0 | 0 | 0\% | 49 | 37 | 76\% |
|  | Jul 2012 | 307 | 208 | 68\% | 0 | 0 | 0\% | 87 | 56 | 64\% | 0 | 0 | 0\% | 37 | 22 | 59\% |
|  | Aug 2012 | 284 | 195 | 69\% | 1 | 1 | 100\% | 89 | 63 | 71\% | 0 | 0 | 0\% | 51 | 39 | 76\% |
|  | Sep 2012 | 254 | 184 | 72\% | 1 | 0 | 0\% | 77 | 57 | 74\% | 1 | 1 | 100\% | 38 | 30 | 79\% |
|  | Oct 2012 | 251 | 157 | 63\% | 0 | 0 | 0\% | 69 | 51 | 74\% | 0 | 0 | 0\% | 47 | 28 | 60\% |
|  | Nov 2012 | 296 | 186 | 63\% | 0 | 0 | 0\% | 90 | 52 | 58\% | 2 | 1 | 50\% | 62 | 40 | 65\% |
|  | Dec 2012 | 261 | 185 | 71\% | 0 | 0 | 0\% | 54 | 30 | 56\% | 0 | 0 | 0\% | 46 | 27 | 59\% |
|  | Jan 2013 | 254 | 177 | 70\% | 2 | 1 | 50\% | 87 | 54 | 62\% | 0 | 0 | 0\% | 42 | 30 | 71\% |
|  | Feb 2013 | 212 | 165 | 78\% | 2 | 0 | 0\% | 56 | 41 | 73\% | 0 | 0 | 0\% | 44 | 35 | 80\% |
|  | Mar 2013 | 236 | 154 | 65\% | 0 | 0 | 0\% | 72 | 46 | 64\% | 0 | 0 | 0\% | 36 | 27 | 75\% |
|  | Apr 2013 | 226 | 158 | 70\% | 0 | 0 | 0\% | 68 | 47 | 69\% | 0 | 0 | 0\% | 37 | 29 | 78\% |
|  | May 2013 | 250 | 173 | 69\% | 1 | 1 | 100\% | 65 | 53 | 82\% | 0 | 0 | 0\% | 42 | 26 | 62\% |
|  | Jun 2013 | 244 | 172 | 70\% | 0 | 0 | 0\% | 69 | 45 | 65\% | 0 | 0 | 0\% | 34 | 23 | 68\% |
|  | Jul 2013 | 239 | 168 | 70\% | 0 | 0 | 0\% | 78 | 62 | 79\% | 0 | 0 | 0\% | 43 | 29 | 67\% |
|  | Aug 2013 | 272 | 184 | 68\% | 0 | 0 | 0\% | 61 | 38 | 62\% | 0 | 0 | 0\% | 31 | 16 | 52\% |
|  | Sep 2013 | 245 | 174 | 71\% | 0 | 0 | 0\% | 66 | 47 | 71\% | 0 | 0 | 0\% | 44 | 28 | 64\% |
|  | Oct 2013 | 242 | 175 | 72\% | 0 | 0 | 0\% | 67 | 45 | 67\% | 0 | 0 | 0\% | 47 | 35 | 74\% |
|  | Nov 2013 | 241 | 153 | 63\% | 0 | 0 | 0\% | 58 | 43 | 74\% | 0 | 0 | 0\% | 47 | 30 | 64\% |
|  | Dec 2013 | 247 | 167 | 68\% | 1 | 0 | 0\% | 57 | 41 | 72\% | 0 | 0 | 0\% | 42 | 28 | 67\% |


| Secondary Tolerance Definition ( $\mathbf{3 0} \mathbf{~ m g ~ p e r ~ d a y ~ f o r ~ s e v e n ~ d a y s ~ i n ~ t h e ~} \mathbf{3 0}$ days prior) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Dose $112 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $125 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $137 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $150 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $162 \mathrm{mcg} / \mathrm{hr}$ |  |  |
|  |  | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with Prior Tolerance | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | $N$ with Prior Tolerance | \% with <br> Prior Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | $N$ with Prior Tolerance | $\begin{aligned} & \text { \% with } \\ & \text { Prior } \\ & \text { Tolerance } \end{aligned}$ | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with <br> Prior <br> Tolerance | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with Prior Tolerance |
| Age (years) | Total | 3 | 3 | 100\% | 137 | 83 | 61\% | 2 | 1 | 50\% | 172 | 119 | 69\% | 2 | 2 | 100\% |
|  | $0-11$ years | 0 | 0 | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | 12-17 years | 0 | 0 | 0\% | 1 | - | 0\% | - | - | 0\% | 1 | - | 0\% | - | - | 0\% |
|  | 18.24 years | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | 5 | 4 | 80\% | 1 | 1 | 100\% |
|  | $25-34$ years | 0 | 0 | 0\% | 9 | 7 | 78\% | - | - | 0\% | 12 | 8 | 67\% | - | - | 0\% |
|  | 35-44 years | 0 | 0 | 0\% | 20 | 13 | 65\% | - | - | 0\% | 30 | 24 | 80\% | - | - | 0\% |
|  | 45.54 years | 1 | 1 | 100\% | 57 | 34 | 60\% | 1 | - | 0\% | 60 | 41 | 68\% | - | - | 0\% |
|  | 55-64 years | 2 | 2 | 100\% | 48 | 27 | 56\% | 1 | 1 | 100\% | 64 | 42 | 66\% | 1 | 1 | 100\% |
| Gender | Male | 1 | 1 | 100\% | 69 | 39 | 57\% | - | - | 0\% | 95 | 74 | 78\% | 2 | 2 | 100\% |
|  | Female | 2 | 2 | 100\% | 68 | 44 | 65\% | 2 | 1 | 50\% | 77 | 45 | 58\% | - | - | 0\% |
|  | Ambiguous | 0 | 0 | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Unknown | 0 | 0 | 0\% | - | . | 0\% | - | . | 0\% | . | . | 0\% | - | . | 0\% |
| Month and Year of Episode Start Date | Jan 2009 | 1 | 1 | 100\% | 4 | 2 | 50\% | - | - | 0\% | 6 | 2 | 33\% | - | - | 0\% |
|  | Feb 2009 | 0 | 0 | 0\% | 3 | 2 | 67\% | - | - | 0\% | 2 | 2 | 100\% | - | - | 0\% |
|  | Mar 2009 | 0 | 0 | 0\% | 3 | 1 | 33\% | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% |
|  | Apr 2009 | 0 | 0 | 0\% | 2 | 1 | 50\% | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% |
|  | May 2009 | 0 | 0 | 0\% | 3 | 3 | 100\% | - | - | 0\% | 6 | 4 | 67\% | - | - | 0\% |
|  | Jun 2009 | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | 7 | 6 | 86\% | - | - | 0\% |
|  | Jul 2009 | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 3 | 1 | 33\% | - | - | 0\% |
|  | Aug 2009 | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 4 | 1 | 25\% | - | - | 0\% |
|  | Sep 2009 | 0 | 0 | 0\% | - | - | 0\% | - | - | 0\% | 5 | 4 | 80\% | - | - | 0\% |
|  | Oct 2009 | 0 | 0 | 0\% | 1 | - | 0\% | - | - | 0\% | 4 | 2 | 50\% | - | - | 0\% |
|  | Nov 2009 | 0 | 0 | 0\% | 2 | 1 | 50\% | - | - | 0\% | 7 | 5 | 71\% | - | - | 0\% |
|  | Dec 2009 | 0 | 0 | 0\% | 2 | 1 | 50\% | - | - | 0\% | 7 | 5 | 71\% | - | - | 0\% |
|  | Jan 2010 | 0 | 0 | 0\% | 7 | 3 | 43\% | $\cdot$ | - | 0\% | 5 | 3 | 60\% | - | - | 0\% |
|  | Feb 2010 | 0 | 0 | 0\% | 6 | 2 | 33\% | - | - | 0\% | 5 | 4 | 80\% | - | - | 0\% |
|  | Mar 2010 | 0 | 0 | 0\% | 2 | - | 0\% | ? | - | 0\% | 4 | 4 | 100\% | - | - | 0\% |
|  | Apr 2010 | 0 | 0 | 0\% | 4 | 1 | 25\% | - | - | 0\% | 4 | 3 | 75\% | - | - | 0\% |
|  | May 2010 | 0 | 0 | 0\% | 2 | 1 | 50\% | - | - | 0\% | 4 | 3 | 75\% | - | - | 0\% |
|  | Jun 2010 | 0 | 0 | 0\% | 5 | 4 | 80\% | - | - | 0\% | 2 | 2 | 100\% | - | - | 0\% |
|  | Jul 2010 | 0 | 0 | 0\% | 1 | - | 0\% | - | - | 0\% | 5 | 4 | 80\% | - | - | 0\% |
|  | Aug 2010 | 0 | 0 | 0\% | 2 | 1 | 50\% | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% |
|  | Sep 2010 | 0 | 0 | 0\% | - | - | 0\% | - | - | 0\% | 3 | 1 | 33\% | - | - | 0\% |
|  | Oct 2010 | 0 | 0 | 0\% | 3 | 3 | 100\% | 1 | 1 | 100\% | 3 | 3 | 100\% | - | - | 0\% |
|  | Nov 2010 | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% |
|  | Dec 2010 | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 4 | 2 | 50\% | - | - | 0\% |
|  | Jan 2011 | 0 | 0 | 0\% | 3 | 1 | 33\% | $\cdot$ | - | 0\% | 4 | 3 | 75\% | 1 | 1 | 100\% |
|  | Feb 2011 | 1 | 1 | 100\% | 3 | 1 | 33\% | - | - | 0\% | 3 | 1 | 33\% | - | - | 0\% |
|  | Mar 2011 | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | 2 | 1 | 50\% | $\cdot$ | - | 0\% |
|  | Apr 2011 | 0 | 0 | 0\% | 3 | 1 | 33\% | - | - | 0\% | 4 | 4 | 100\% | - | - | 0\% |
|  | May 2011 | 0 | 0 | 0\% | 5 | 3 | 60\% | - |  | 0\% | 2 | 2 | 100\% | $\cdot$ | - | 0\% |
|  | Jun 2011 | 0 | 0 | 0\% | 2 | 1 | 50\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jul 2011 | 0 | 0 | 0\% | 2 | - | 0\% | - | - | 0\% | 4 | 4 | 100\% | - | - | 0\% |
|  | Aug 2011 | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% |
|  | Sep 2011 | 0 | 0 | 0\% | 4 | 2 | 50\% | 1 | - | 0\% | 3 | 3 | 100\% | 1 | 1 | 100\% |
|  | Oct 2011 | 0 | 0 | 0\% | 1 | 1 | 100\% | - |  | 0\% | 1 | - | 0\% | - | - | 0\% |
|  | Nov 2011 | 0 | 0 | 0\% | - | - | 0\% | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% |
|  | Dec 2011 | 0 | 0 | 0\% | 3 | 2 | 67\% | - | * | 0\% | 1 | 1 | 100\% | - | - | 0\% |
|  | Jan 2012 | 0 | 0 | 0\% | 2 | 1 | 50\% | - | - | 0\% | 2 | 2 | 100\% | - | - | 0\% |
|  | Feb 2012 | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | 5 | 4 | 80\% | - | - | 0\% |
|  | Mar 2012 | 0 | 0 | 0\% | 3 | 3 | 100\% | - | - | 0\% | 2 | 2 | 100\% | - | - | 0\% |
|  | Apr 2012 | 1 | 1 | 100\% | 5 | 5 | 100\% | - | - | 0\% | 3 | 3 | 100\% | - | - | 0\% |
|  | May 2012 | 0 | 0 | 0\% | 4 | 1 | 25\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jun 2012 | 0 | 0 | 0\% | - | - | 0\% | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% |
|  | Jul 2012 | 0 | 0 | 0\% | 1 | 1 | 100\% | - |  | 0\% | - | - | 0\% | - | - | 0\% |
|  | Aug 2012 | 0 | 0 | 0\% | 4 | 4 | 100\% | - |  | 0\% | 1 | 1 | 100\% | - | - | 0\% |
|  | Sep 2012 | 0 | 0 | 0\% | 1 | 1 | 100\% | 5 | - | 0\% | 2 | 1 | 50\% | - | - | 0\% |
|  | Oct 2012 | 0 | 0 | 0\% | 2 | 2 | 100\% | - |  | 0\% | 2 | 2 | 100\% | - | - | 0\% |
|  | Nov 2012 | 0 | 0 | 0\% | 2 | 2 | 100\% | - |  | 0\% | 5 | 3 | 60\% | - | - | 0\% |
|  | Dec 2012 | 0 | 0 | 0\% | 3 | 1 | 33\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jan 2013 | 0 | 0 | 0\% | 2 | - | 0\% | - | - | 0\% | 4 | 1 | 25\% | - | - | 0\% |
|  | Feb 2013 | 0 | 0 | 0\% | 3 | 2 | 67\% | - |  | 0\% | - | - | 0\% | - | - | 0\% |
|  | Mar 2013 | 0 | 0 | 0\% | 2 | 1 | 50\% | - | - | 0\% | 3 | 1 | 33\% | - | - | 0\% |
|  | Apr 2013 | 0 | 0 | 0\% | - | - | 0\% | - | - | 0\% | 3 | 3 | 100\% | - | - | 0\% |
|  | May 2013 | 0 | 0 | 0\% | 1 | 1 | 100\% |  |  | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jun 2013 | 0 | 0 | 0\% | - | - | 0\% | - | - | 0\% | 3 | 1 | 33\% | - | - | 0\% |
|  | Jul 2013 | 0 | 0 | 0\% | 3 | 3 | 100\% | - | - | 0\% | 2 | 2 | 100\% | - | - | 0\% |
|  | Aug 2013 | 0 | 0 | 0\% | 2 | 2 | 100\% | . | - | 0\% | 3 | 1 | 33\% | - | - | 0\% |
|  | Sep 2013 | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% |
|  | Oct 2013 | 0 | 0 | 0\% | 4 | 1 | 25\% | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% |
|  | Nov 2013 | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 3 | 2 | 67\% | - | - | 0\% |
|  | Dec 2013 | 0 | 0 | 0\% | 1 | - | 0\% | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% |


| Secondary Tolerance Definition ( 30 mg per day for seven days in the $\mathbf{3 0}$ days prior) |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Dose $175 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $200 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $225 \mathrm{mcg} / \mathrm{hr}$ |  |  |
|  |  | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | $N$ with Prior Tolerance | \% with Prior Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with <br> Prior <br> Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with <br> Prior <br> Tolerance |
| Age (years) | Total | 33 | 18 | 55\% | 4 | 3 | 75\% |  | 1 | 50\% |
|  | $0-11$ years | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | 12-17 years | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | 18-24 years | 3 | 3 | 100\% | - | - | 0\% | - | - | 0\% |
|  | 25-34 years | 1 | - | 0\% | - | - | 0\% | 1 | 1 | 100\% |
|  | 35-44 years | 4 | 3 | 75\% | 3 | 2 | 67\% | - | - | 0\% |
|  | 45-54 years | 9 | 6 | 67\% | 1 | 1 | 100\% | - | - | 0\% |
|  | 55-64 years | 15 | 5 | 33\% | - | - | 0\% | 1 | . | 0\% |
| Gender | Male | 11 | 9 | 82\% | 4 | 3 | 75\% | 2 | 1 | 50\% |
|  | Female | 22 | 9 | 41\% | - | - | 0\% | - | - | 0\% |
|  | Ambiguous | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Unknown | . | - | 0\% | - | . | 0\% | - | - | 0\% |
| Month and Year of Episode Start Date | Jan 2009 | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Feb 2009 | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Mar 2009 | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Apr 2009 | 3 | 3 | 100\% | 1 | 1 | 100\% | - | - | 0\% |
|  | May 2009 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jun 2009 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jul 2009 | 2 | 2 | 100\% | - | - | 0\% | 1 | 1 | 100\% |
|  | Aug 2009 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Sep 2009 | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Oct 2009 | 1 | - | 0\% | - | - | 0\% | - | . | 0\% |
|  | Nov 2009 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Dec 2009 | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jan 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Feb 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Mar 2010 | 1 | 1 | 100\% | 1 | 1 | 100\% | - | - | 0\% |
|  | Apr 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | May 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jun 2010 | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jul 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Aug 2010 | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Sep 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Oct 2010 | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Nov 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Dec 2010 | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Jan 2011 | - | - | 0\% | - | - | 0\% |  | - | 0\% |
|  | Feb 2011 | 2 | 1 | 50\% | - | - | 0\% | - | - | 0\% |
|  | Mar 2011 | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Apr 2011 | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | May 2011 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jun 2011 | 2 | 1 | 50\% | - | - | 0\% | - | - | 0\% |
|  | Jul 2011 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Aug 2011 | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Sep 2011 | 2 | 1 | 50\% | - | - | 0\% | - | - | 0\% |
|  | Oct 2011 | 2 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Nov 2011 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Dec 2011 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jan 2012 | $\cdot$ | - | 0\% | - | . | 0\% | \% | . | 0\% |
|  | Feb 2012 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Mar 2012 | 1 | - | 0\% | \% | - | 0\% | $\cdot$ | - | 0\% |
|  | Apr 2012 | 1 | - | 0\% | - | - | 0\% |  | - | 0\% |
|  | May 2012 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jun 2012 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jul 2012 | - | - | 0\% |  | - | 0\% | - | - | 0\% |
|  | Aug 2012 |  | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Sep 2012 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Oct 2012 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Nov 2012 | - | - | 0\% | - | - | 0\% | 1 | - | 0\% |
|  | Dec 2012 |  | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jan 2013 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Feb 2013 | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Mar 2013 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Apr 2013 |  | - | 0\% |  | - | 0\% | - | - | 0\% |
|  | May 2013 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jun 2013 | 1 | - | 0\% | 2 | 1 | 50\% | - | - | 0\% |
|  | Jul 2013 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Aug 2013 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Sep 2013 | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Oct 2013 | - | - | 0\% | $\cdot$ | - | 0\% |  | - | 0\% |
|  | Nov 2013 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Dec 2013 | 1 | 1 | 100\% | - |  | 0\% | - |  | 0\% |


| Tertiary Tolerance Definition (>0 mg per day in the prior 7 consecutive days) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Dose $12 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $24 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $25 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $36 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $37 \mathrm{mcg} / \mathrm{hr}$ |  |  |
|  |  | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | $N$ with Prior Tolerance | \% with <br> Prior <br> Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | $N$ with Prior Tolerance |  | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with <br> Prior <br> Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with <br> Prior <br> Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | $\begin{aligned} & \text { \% with } \\ & \text { Prior } \\ & \text { Tolerance } \end{aligned}$ |
|  | Total | 16,379 | 8,076 | 49.3\% | 3 |  | 67\% | 44,450 | 23,730 | 53.4\% | 1 | 0 | 0\% | 298 | 181 | 61\% |
| Age (years) | $0-11$ years | 32 | 6 | 18.8\% | - |  | 0\% | 23 | 6 | 26.1\% | 0 | 0 | 0\% | 1 | 0 | 0\% |
|  | 12-17 years | 75 | 23 | 30.7\% | - |  | 0\% | 79 | 28 | 35.4\% | 0 | 0 | 0\% | 2 | 0 | 0\% |
|  | 18-24 years | 375 | 167 | 44.5\% | - |  | 0\% | 827 | 427 | 51.6\% | 0 | 0 | 0\% | 8 | 3 | 38\% |
|  | 25-34 years | 1,464 | 870 | 59.4\% | $\cdot$ |  | 0\% | 3,731 | 2,285 | 61.2\% | 1 | 0 | 0\% | 24 | 17 | 71\% |
|  | $35-44$ years | 2,841 | 1,561 | 54.9\% | 2 |  | 100\% | 7,954 | 4,564 | 57.4\% | 0 | 0 | 0\% | 63 | 37 | 59\% |
|  | $45-54$ years | 5,214 | 2,603 | 49.9\% | - |  | 0\% | 14,785 | 8,065 | 54.5\% | 0 | 0 | 0\% | 87 | 54 | 62\% |
|  | $55-64$ years | 6,378 | 2,846 | 44.6\% | 1 |  | 0\% | 17,051 | 8,355 | 49.0\% | 0 | 0 | 0\% | 113 | 70 | 62\% |
| Gender | Male | 5,124 | 2,585 | 50.4\% | 1 |  | 100\% | 18,327 | 9,822 | 53.6\% | 0 | 0 | 0\% | 133 | 85 | 64\% |
|  | Female | 11,255 | 5,491 | 48.8\% | 2 |  | 50\% | 26,123 | 13,908 | 53.2\% | 1 | 0 | 0\% | 165 | 96 | 58\% |
|  | Ambiguous | - | . | 0.0\% | - |  | 0\% | - | - | 0.0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Unknown | 0 | 0 | 0 | 0 |  | 0\% | - | 0 | 0 | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Jan 2009 | 220 | 117 | 53.2\% | - |  | 0\% | 953 | 470 | 49.3\% | 0 | 0 | 0\% | 4 | 3 | 75\% |
| Month and Year of | Feb 2009 | 206 | 97 | 47.1\% | - |  | 0\% | 890 | 438 | 49.2\% | 0 | 0 | 0\% | 8 | 3 | 38\% |
| Episode Start Date | Mar 2009 | 267 | 118 | 44.2\% | - |  | 0\% | 982 | 496 | 50.5\% | 0 | 0 | 0\% | 5 | 3 | 60\% |
|  | Apr 2009 | 220 | 105 | 47.7\% | - |  | 0\% | 969 | 503 | 51.9\% | 1 | 0 | 0\% | 4 | 2 | 50\% |
|  | May 2009 | 248 | 119 | 48.0\% | - |  | 0\% | 875 | 490 | 56.0\% | 0 | 0 | 0\% | 6 | 5 | 83\% |
|  | Jun 2009 | 258 | 115 | 44.6\% | - |  | 0\% | 909 | 443 | 48.7\% | 0 | 0 | 0\% | 5 | 5 | 100\% |
|  | Jul 2009 | 249 | 124 | 49.8\% | - |  | 0\% | 870 | 443 | 50.9\% | 0 | 0 | 0\% | 6 | 2 | 33\% |
|  | Aug 2009 | 268 | 122 | 45.5\% | - |  | 0\% | 881 | 432 | 49.0\% | 0 | 0 | 0\% | 2 | 1 | 50\% |
|  | Sep 2009 | 295 | 145 | 49.2\% | - |  | 0\% | 943 | 481 | 51.0\% | 0 | 0 | 0\% | 4 | ${ }^{4}$ | 100\% |
|  | Oct 2009 | 261 | 114 | 43.7\% | - |  | 0\% | 857 | 423 | 49.4\% | 0 | 0 | 0\% | 1 | 1 | 100\% |
|  | Nov 2009 | 231 | 109 | 47.2\% | - |  | 0\% | 818 | 412 | 50.4\% | 0 | 0 | 0\% | 8 | 4 | 50\% |
|  | Dec 2009 | 244 | 115 | 47.1\% | - |  | 0\% | 900 | 497 | 55.2\% | 0 | 0 | 0\% | 7 | 3 | 43\% |
|  | Jan 2010 | 226 | 109 | 48.2\% | - |  | 0\% | 827 | 414 | 50.1\% | 0 | 0 | 0\% | 6 | 0 | 0\% |
|  | Feb 2010 | 238 | 128 | 53.\% | - |  | 0\% | 753 | 400 | 53.1\% | 0 | 0 | 0\% | 8 | 8 | 100\% |
|  | Mar 2010 | 268 | 126 | 47.0\% | - |  | 0\% | 791 | 411 | 52.0\% | 0 | 0 | 0\% | 8 | 5 | 63\% |
|  | Apr 2010 | 257 | 119 | 46.3\% | - |  | 0\% | 833 | 418 | 50.2\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | May 2010 | 227 | 122 | 53.7\% | - |  | 0\% | 738 | 407 | 55.1\% | 0 | 0 | 0\% | 5 | 1 | 20\% |
|  | Jun 2010 | 246 | 117 | 47.6\% | - |  | 0\% | 746 | 391 | 52.4\% | 0 | 0 | 0\% | 4 | 1 | 25\% |
|  | Jul 2010 | 223 | 104 | 46.6\% | - |  | 0\% | 764 | 423 | 55.4\% | 0 | 0 | 0\% | 5 | ${ }^{1}$ | 60\% |
|  | Aug 2010 | 260 | 130 | 50.0\% | - |  | 0\% | 810 | 420 | 51.9\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Sep 2010 | 301 | 136 | 45.2\% | $\cdot$ |  | 0\% | 833 | 463 | 55.6\% | 0 | 0 | 0\% | 2 | 2 | 100\% |
|  | Oct 2010 | 288 | 134 | 46.5\% | - |  | 0\% | 777 | 410 | 52.8\% | 0 | 0 | 0\% | 5 | 3 | 60\% |
|  | Nov 2010 | 290 | 141 | 48.6\% | - |  | 0\% | 824 | 421 | 51.1\% | 0 | 0 | 0\% | 9 | 5 | 56\% |
|  | Dec 2010 | 291 | 138 | 47.4\% | - |  | 0\% | 731 | 398 | 54.4\% | 0 | 0 | 0\% | 3 | 1 | 33\% |
|  | Jan 2011 | 252 | 116 | 46.0\% | - |  | 0\% | 724 | 372 | 51.4\% | 0 | 0 | 0\% | 1 | 1 | 100\% |
|  | Feb 2011 | 264 | 121 | 45.8\% | - |  | 0\% | 639 | 329 | 51.5\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Mar 2011 | 279 | 144 | 51.6\% | - |  | 0\% | 802 | 433 | 54.0\% | 0 | 0 | 0\% | 9 | 5 | 56\% |
|  | Apr 2011 | 269 | 135 | 50.2\% | - |  | 0\% | 710 | 381 | 53.7\% | 0 | 0 | 0\% | 10 | 9 | 90\% |
|  | May 2011 | 261 | 120 | 46.0\% | - |  | 0\% | 700 | 371 | 53.0\% | 0 | 0 | 0\% | 3 | 3 | 100\% |
|  | Jun 2011 | 276 | 123 | 44.6\% | - |  | 0\% | 678 | 377 | 55.6\% | 0 | 0 | 0\% | 4 | 2 | 50\% |
|  | Jul 2011 | 282 | 145 | 51.4\% | - |  | 0\% | 679 | 355 | 52.3\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Aug 2011 | 314 | 162 | 51.6\% | - |  | 0\% | 758 | 389 | 51.3\% | 0 | 0 | 0\% | 4 | 2 | 50\% |
|  | Sep 2011 | 291 | 138 | 47.4\% | - |  | 0\% | 730 | 392 | 53.7\% | 0 | 0 | 0\% | 7 | 4 | 57\% |
|  | Oct 2011 | 263 | 133 | 50.6\% | - |  | 0\% | 711 | 404 | 56.8\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Nov 2011 | 288 | 147 | 51.0\% | - |  | 0\% | 659 | 383 | 58.1\% | 0 | 0 | 0\% | 8 | 2 | 25\% |
|  | Dec 2011 | 307 | 145 | 47.2\% | - |  | 0\% | 689 | 357 | 51.8\% | 0 | 0 | 0\% | 5 | 3 | 60\% |
|  | Jan 2012 | 279 | 125 | 44.8\% | - |  | 0\% | 720 | 394 | 54.7\% | 0 | 0 | 0\% | 2 | 2 | 100\% |
|  | Feb 2012 | 255 | 128 | 50.2\% | - |  | 0\% | 638 | 340 | 53.3\% | 0 | 0 | 0\% | 7 | 5 | 71\% |
|  | Mar 2012 | 294 | 145 | 49.3\% | - |  | 0\% | 683 | 358 | 52.4\% | 0 | 0 | 0\% | 6 | 5 | 83\% |
|  | Apr 2012 | 251 | 126 | 50.2\% | - |  | 0\% | 650 | 353 | 54.3\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | May 2012 | 324 | 159 | 49.1\% | - |  | 0\% | 631 | 341 | 54.0\% | 0 | 0 | 0\% | 8 | 6 | 75\% |
|  | Jun 2012 | 242 | 127 | 52.5\% | - |  | 0\% | 564 | 310 | 55.0\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Jul 2012 | 295 | 149 | 50.5\% | - |  | 0\% | 617 | 342 | 55.4\% | 0 | 0 | 0\% | 5 | 2 | 40\% |
|  | Aug 2012 | 304 | 169 | 55.6\% | - |  | 0\% | 787 | 437 | 55.5\% | 0 | 0 | 0\% | 2 | 1 | 50\% |
|  | Sep 2012 | 279 | 131 | 47.0\% | - |  | 0\% | 645 | 333 | 51.6\% | 0 | 0 | 0\% | 5 | 4 | 80\% |
|  | Oct 2012 | 304 | 160 | 52.6\% | - |  | 0\% | 699 | 426 | 60.9\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Nov 2012 | 313 | 161 | 51.4\% | - |  | 0\% | 712 | 373 | 52.4\% | 0 | 0 | 0\% | 6 | 4 | 67\% |
|  | Dec 2012 | 293 | 141 | 48.1\% | - |  | 0\% | 631 | 347 | 55.0\% | 0 | 0 | 0\% | 8 | 3 | 38\% |
|  | Jan 2013 | 277 | 143 | 51.6\% | - |  | 0\% | 593 | 320 | 54.0\% | 0 | 0 | 0\% | 4 | 3 | 75\% |
|  | Feb 2013 | 254 | 131 | 51.6\% | - |  | 0\% | 638 | 377 | 59.1\% | 0 | 0 | 0\% | 3 | 3 | 100\% |
|  | Mar 2013 | 253 | 137 | 54.2\% | - |  | 0\% | 585 | 346 | 59.1\% | 0 | 0 | 0\% | 4 | 3 | 75\% |
|  | Apr 2013 | 289 | 159 | 55.0\% | - |  | 0\% | 617 | 353 | 57.2\% | 0 | 0 | 0\% | 9 | 5 | 56\% |
|  | May 2013 | 261 | 135 | 51.7\% | - |  | 0\% | 640 | 362 | 56.6\% | 0 | 0 | 0\% | 8 | 5 | 63\% |
|  | Jun 2013 | 271 | 146 | 53.9\% | 1 |  | 100\% | 602 | 339 | 56.3\% | 0 | 0 | 0\% | 4 | 2 | 50\% |
|  | Jul 2013 | 331 | 162 | 48.9\% | - |  | 0\% | 663 | 386 | 58.2\% | 0 | 0 | 0\% | 8 | 7 | 88\% |
|  | Aug 2013 | 341 | 160 | 46.9\% | - |  | 0\% | 735 | 403 | 54.8\% | 0 | 0 | 0\% | 3 | 1 | 33\% |
|  | Sep 2013 | 302 | 149 | 49.3\% | - |  | 0\% | 645 | 348 | 54.0\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Oct 2013 | 331 | 173 | 52.3\% | 1 |  | 100\% | 714 | 397 | 55.6\% | 0 | 0 | 0\% | 3 | 1 | 33\% |
|  | Nov 2013 | 310 | 166 | 53.5\% | 1 |  | 0\% | 651 | 353 | 54.2\% | 0 | 0 | 0\% | 5 | 1 | 20\% |
|  | Dec 2013 | 298 | 161 | 54.0\% | 0 |  | 0\% | 637 | 345 | 54.2\% | 0 | 0 | 0\% | 5 | 4 | 80\% |


| Tertiary Tolerance Definition (>0 mg per day in the prior 7 consecutive days) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Dose $50 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $62 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $75 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $87 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $100 \mathrm{mcg} / \mathrm{hr}$ |  |  |
|  |  | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | $\begin{aligned} & \text { \% with } \\ & \text { Prior } \\ & \text { Tolerance } \end{aligned}$ | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | $\begin{array}{\|c\|} \hline \text { \% with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with Prior Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | $\begin{gathered} \% \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{gathered}$ | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes |  | $\begin{array}{\|c\|} \hline \text { \% with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ |
| Age (years) | Total | 18,527 | 11,000 | 59\% | 22 | 6 | 27\% | 5,118 | 3,122 | 61\% | 8 | 2 | 25\% | 3,507 | 2,125 | 61\% |
|  | $0-11$ years | 7 | 2 | 29\% | 1 | 0 | 0\% | 2 | - | 0\% | 0 | 0 | 0\% | 4 | - | 0\% |
|  | 12-17 years | 32 | 10 | 31\% | 0 | 0 | 0\% | 11 | 3 | 27\% | 0 | 0 | 0\% | 8 | 2 | 25\% |
|  | 18-24 years | 380 | 205 | 54\% | 1 | 0 | 0\% | 99 | 55 | 56\% | 0 | 0 | 0\% | 77 | 39 | 51\% |
|  | 25-34 years | 1,614 | 1,055 | 65\% | 2 | 0 | 0\% | 523 | 337 | 64\% | 1 | 1 | 100\% | 290 | 191 | 66\% |
|  | 35-44 years | 3,502 | 2,240 | 64\% | 4 | 1 | 25\% | 1,011 | 613 | 61\% | 1 | 0 | 0\% | 686 | 424 | 62\% |
|  | $45-54$ years | 6,358 | 3,779 | 59\% | 11 | 3 | 27\% | 1,785 | 1,110 | 62\% | 4 | 1 | 25\% | 1,276 | 790 | 62\% |
|  | 55-64 years | 6,634 | 3,709 | 56\% | 3 | 2 | 67\% | 1,687 | 1,004 | 60\% | 2 | 0 | 0\% | 1,166 | 679 | 58\% |
| Gender | Male | 8,727 | 5,343 | 61\% | 11 | 5 | 45\% | 2,510 | 1,590 | 63\% | ${ }_{4}^{4}$ | 1 | 25\% | 1,839 | 1,171 | 64\% |
|  | Female | 9,800 | 5,657 | 58\% | 11 | 1 | 9\% | 2,608 | 1,532 | 59\% | ${ }^{4}$ | 1 | 25\% | 1,668 | 954 | 57\% |
|  | Ambiguous | - | - | 0\% | 0 | 0 | 0\% | - | - | 0\% | 0 | 0 | 0\% | - | - | 0\% |
|  | Unknown | - | . | 0\% | 0 | 0 | 0\% | . | - | 0\% | 0 | 0 | 0\% | . | . | 0\% |
| Month and Year of Episode Start Date | Jan 2009 | 412 | 223 | 54\% | 2 | 2 | 100\% | 145 | 76 | 52\% | 1 | 0 | 0\% | 94 | 46 | 49\% |
|  | Feb 2009 | 414 | 251 | 61\% | 0 | 0 | 0\% | 118 | 68 | 58\% | 0 | 0 | 0\% | 98 | 59 | 60\% |
|  | Mar 2009 | 424 | 263 | 62\% | 0 | 0 | 0\% | 112 | 67 | 60\% | 0 | 0 | 0\% | 79 | 40 | 51\% |
|  | Apr 2009 | 423 | 262 | 62\% | 0 | 0 | 0\% | 108 | 68 | 63\% | 0 | 0 | 0\% | 88 | 56 | 64\% |
|  | May 2009 | 368 | 208 | 57\% | 0 | 0 | 0\% | 101 | 52 | 51\% | 0 | 0 | 0\% | 84 | 46 | 55\% |
|  | Jun 2009 | 409 | 227 | 56\% | 0 | 0 | 0\% | 111 | 58 | 52\% | 0 | 0 | 0\% | 75 | 56 | 75\% |
|  | Jul 2009 | 376 | 214 | 57\% | 2 | 0 | 0\% | 89 | 48 | 54\% | 0 | 0 | 0\% | 86 | 55 | 64\% |
|  | Aug 2009 | 348 | 212 | 61\% | 0 | 0 | 0\% | 97 | 58 | 60\% | 0 | 0 | 0\% | 72 | 43 | 60\% |
|  | Sep 2009 | 396 | 233 | 59\% | 0 | 0 | 0\% | 95 | 69 | 73\% | 2 | 0 | 0\% | 72 | 40 | 56\% |
|  | Oct 2009 | 433 | 241 | 56\% | 0 | 0 | 0\% | 100 | 59 | 59\% | 0 | 0 | 0\% | 90 | 54 | 60\% |
|  | Nov 2009 | 366 | 213 | 58\% | 1 | 1 | 100\% | 94 | 63 | 67\% | 0 | 0 | 0\% | 77 | 48 | 62\% |
|  | Dec 2009 | 379 | 216 | 57\% | 0 | 0 | 0\% | 113 | 67 | 59\% | 0 | 0 | 0\% | 74 | 44 | 59\% |
|  | Jan 2010 | 359 | 200 | 56\% | 0 | 0 | 0\% | 101 | 59 | 58\% | 0 | 0 | 0\% | 89 | 58 | 65\% |
|  | Feb 2010 | 325 | 176 | 54\% | 1 | 0 | 0\% | 84 | 44 | 52\% | 1 | 0 | 0\% | 60 | 35 | 58\% |
|  | Mar 2010 | 331 | 195 | 59\% | 0 | 0 | 0\% | 113 | 71 | 63\% | 0 | 0 | 0\% | 62 | 37 | 60\% |
|  | Apr 2010 | 307 | 172 | 56\% | 0 | 0 | 0\% | 100 | 67 | 67\% | 0 | 0 | 0\% | 67 | 48 | 72\% |
|  | May 2010 | 326 | 188 | 58\% | 0 | 0 | 0\% | 84 | 47 | 56\% | 0 | 0 | 0\% | 60 | 41 | 68\% |
|  | Jun 2010 | 340 | 206 | 61\% | 0 | 0 | 0\% | 77 | 42 | 55\% | 0 | 0 | 0\% | 49 | 39 | 80\% |
|  | Jul 2010 | 342 | 216 | 63\% | 0 | 0 | 0\% | 92 | 51 | 55\% | 0 | 0 | 0\% | 55 | 37 | 67\% |
|  | Aug 2010 | 325 | 191 | 59\% | 0 | 0 | 0\% | 98 | 58 | 59\% | 0 | 0 | 0\% | 71 | 47 | 66\% |
|  | Sep 2010 | 343 | 206 | 60\% | 1 | 1 | 100\% | 93 | 61 | 66\% | 0 | 0 | 0\% | 70 | 41 | 59\% |
|  | Oct 2010 | 340 | 215 | 63\% | 0 | 0 | 0\% | 95 | 64 | 67\% | 0 | 0 | 0\% | 58 | 43 | 74\% |
|  | Nov 2010 | 326 | 207 | 63\% | 0 | 0 | 0\% | 93 | 62 | 67\% | 0 | 0 | 0\% | 63 | 41 | 65\% |
|  | Dec 2010 | 356 | 203 | 57\% | 0 | 0 | 0\% | 78 | 46 | 59\% | 0 | 0 | 0\% | 64 | 30 | 47\% |
|  | Jan 2011 | 306 | 165 | 54\% | 0 | 0 | 0\% | 112 | 60 | 54\% | 0 | 0 | 0\% | 90 | 55 | 61\% |
|  | Feb 2011 | 277 | 171 | 62\% | 0 | 0 | 0\% | 96 | 64 | 67\% | 0 | 0 | 0\% | 66 | 39 | 59\% |
|  | Mar 2011 | 338 | 211 | 62\% | 1 | 0 | 0\% | 94 | 64 | 68\% | 0 | 0 | 0\% | 79 | 46 | 58\% |
|  | Apr 2011 | 322 | 173 | 54\% | 0 | 0 | 0\% | 86 | 56 | 65\% | 0 | 0 | 0\% | 52 | 30 | 58\% |
|  | May 2011 | 280 | 156 | 56\% | 0 | 0 | 0\% | 86 | 54 | 63\% | 0 | 0 | 0\% | 52 | 31 | 60\% |
|  | Jun 2011 | 286 | 157 | 55\% | 0 | 0 | 0\% | 75 | 53 | 71\% | 1 | 0 | 0\% | 41 | 27 | 66\% |
|  | Jul 2011 | 309 | 185 | 60\% | 0 | 0 | 0\% | 70 | 52 | 74\% | 0 | 0 | 0\% | 48 | 28 | 58\% |
|  | Aug 2011 | 322 | 185 | 57\% | 0 | 0 | 0\% | 78 | 44 | 56\% | 0 | 0 | 0\% | 45 | 31 | 69\% |
|  | Sep 2011 | 310 | 186 | 60\% | 0 | 0 | 0\% | 78 | 49 | 63\% | 0 | 0 | 0\% | 42 | 25 | 60\% |
|  | Oct 2011 | 269 | 156 | 58\% | 2 | 0 | 0\% | 77 | 56 | 73\% | 0 | 0 | 0\% | 56 | 33 | 59\% |
|  | Nov 2011 | 274 | 165 | 60\% | 0 | 0 | 0\% | 77 | 47 | 61\% | 0 | 0 | 0\% | 47 | 28 | 60\% |
|  | Dec 2011 | 286 | 167 | 58\% | 0 | 0 | 0\% | 72 | 41 | 57\% | 0 | 0 | 0\% | 59 | 38 | 64\% |
|  | Jan 2012 | 273 | 167 | 61\% | 0 | 0 | 0\% | 88 | 60 | 68\% | 0 | 0 | 0\% | 53 | 27 | 51\% |
|  | Feb 2012 | 266 | 168 | 63\% | 1 | 0 | 0\% | 75 | 49 | 65\% | 0 | 0 | 0\% | 53 | 36 | 68\% |
|  | Mar 2012 | 282 | 179 | 63\% | 0 | 0 | 0\% | 76 | 48 | 63\% | 0 | 0 | 0\% | 48 | 30 | 63\% |
|  | Apr 2012 | 277 | 175 | 63\% | 1 | 0 | 0\% | 86 | 50 | 58\% | 0 | 0 | 0\% | 48 | 29 | 60\% |
|  | May 2012 | 287 | 181 | 63\% | 1 | 0 | 0\% | 71 | 46 | 65\% | 0 | 0 | 0\% | 52 | 37 | 71\% |
|  | Jun 2012 | 234 | 144 | 62\% | 1 | 0 | 0\% | 60 | 38 | 63\% | 0 | 0 | 0\% | 49 | 32 | 65\% |
|  | Jul 2012 | 307 | 189 | 62\% | 0 | 0 | 0\% | 87 | 48 | 55\% | 0 | 0 | 0\% | 37 | 18 | 49\% |
|  | Aug 2012 | 284 | 170 | 60\% | 1 | 0 | 0\% | 89 | 59 | 66\% | 0 | 0 | 0\% | 51 | 35 | 69\% |
|  | Sep 2012 | 254 | 159 | 63\% | 1 | 0 | 0\% | 77 | 55 | 71\% | 1 | 1 | 100\% | 38 | 22 | 58\% |
|  | Oct 2012 | 251 | 145 | 58\% | 0 | 0 | 0\% | 69 | 47 | 68\% | 0 | 0 | 0\% | 47 | 21 | 45\% |
|  | Nov 2012 | 296 | 165 | 56\% | 0 | 0 | 0\% | 90 | 46 | 51\% | 2 | 1 | 50\% | 62 | 33 | 53\% |
|  | Dec 2012 | 261 | 171 | 66\% | 0 | 0 | 0\% | 54 | 26 | 48\% | 0 | 0 | 0\% | 46 | 20 | $43 \%$ |
|  | Jan 2013 | 254 | 156 | 61\% | 2 | 1 | 50\% | 87 | 45 | 52\% | 0 | 0 | 0\% | 42 | 26 | 62\% |
|  | Feb 2013 | 212 | 134 | 63\% | 2 | 0 | 0\% | 56 | 33 | 59\% | 0 | 0 | 0\% | 44 | 29 | 66\% |
|  | Mar 2013 | 236 | 148 | 63\% | 0 | 0 | 0\% | 72 | 45 | 63\% | 0 | 0 | 0\% | 36 | 19 | 53\% |
|  | Apr 2013 | 226 | 129 | 57\% | 0 | 0 | 0\% | 68 | 39 | 57\% | 0 | 0 | 0\% | 37 | 25 | 68\% |
|  | May 2013 | 250 | 160 | 64\% | 1 | 1 | 100\% | 65 | 43 | 66\% | 0 | 0 | 0\% | 42 | 26 | 62\% |
|  | Jun 2013 | 244 | 141 | 58\% | 0 | 0 | 0\% | 69 | 44 | 64\% | 0 | 0 | 0\% | 34 | 18 | 53\% |
|  | Jul 2013 | 239 | 141 | 59\% | 0 | 0 | 0\% | 78 | 49 | 63\% | 0 | 0 | 0\% | 43 | 22 | 51\% |
|  | Aug 2013 | 272 | 169 | 62\% | 0 | 0 | 0\% | 61 | 29 | 48\% | 0 | 0 | 0\% | 31 | 15 | 48\% |
|  | Sep 2013 | 245 | 152 | 62\% | 0 | 0 | 0\% | 66 | 41 | 62\% | 0 | 0 | 0\% | 44 | 25 | 57\% |
|  | Oct 2013 | 242 | 152 | 63\% | 0 | 0 | 0\% | 67 | 43 | 64\% | 0 | 0 | 0\% | 47 | 32 | 68\% |
|  | Nov 2013 | 241 | 142 | 59\% | 0 | 0 | 0\% | 58 | 37 | 64\% | 0 | 0 | 0\% | 47 | 26 | 55\% |
|  | Dec 2013 | 247 | 148 | 60\% | 1 | 0 | 0\% | 57 | 37 | 65\% | 0 | 0 | 0\% | 42 | 27 | 64\% |



| Tertiary Tolerance Definition (>0 mg per day in the prior 7 consecutive days) |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Dose $175 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $200 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $225 \mathrm{mcg} / \mathrm{hr}$ |  |  |
|  |  | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | $N$ with Prior Tolerance | \% with Prior Tolerance | Total N of Transsermal Fentanyl Episodes | N with Prior Tolerance | $\begin{aligned} & \text { \% with } \\ & \text { Prior } \\ & \text { Tolerance } \end{aligned}$ |  | $N$ with Prior Tolerance | \% with Prior Tolerance |
|  | Total | 33 | 16 | 48\% | 4 | 3 | 75\% | 2 | - | 0\% |
| Age (years) | 0.11 years | - | . | 0\% | - | - | 0\% | - | - | 0\% |
|  | 12-17 years | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | 18.24 years | 3 | 3 | 100\% | - | - | 0\% | - | - | 0\% |
|  | $25-34$ years | 1 | - | 0\% | - | - | 0\% | 1 | - | 0\% |
|  | $35-44$ years | 4 | 3 | 75\% | 3 | 2 | 67\% | - | - | 0\% |
|  | $45-54$ years | 9 | 4 | 44\% | 1 | 1 | 100\% | - | - | 0\% |
|  | $55-64$ years | 15 | 5 | 33\% | - | - | 0\% | 1 | . | 0\% |
| Gender | Male | 11 | 9 | 82\% | 4 | 3 | 75\% | ${ }^{2}$ | - | 0\% |
|  | Female | 22 | 7 | 32\% | - | - | 0\% | - | - | 0\% |
|  | Ambiguous | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Unknown | . | . | 0\% | . | . | 0\% | . | . | 0\% |
| Month and Year of Episode Start Date | Jan 2009 | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Feb 2009 | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Mar 2009 | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Apr 2009 | 3 | 3 | 100\% | 1 | 1 | 100\% | - | - | 0\% |
|  | May 2009 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jun 2009 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jul 2009 | 2 | - | 0\% | - | - | 0\% | 1 | - | 0\% |
|  | Aug 2009 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Sep 2009 | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Oct 2009 | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Nov 2009 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Dec 2009 | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jan 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Feb 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Mar 2010 | 1 | 1 | 100\% | 1 | 1 | 100\% | - | - | 0\% |
|  | Apr 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | May 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jun 2010 | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jul 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Aug 2010 | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Sep 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Oct 2010 | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Nov 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Dec 2010 | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Jan 2011 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Feb 2011 | 2 | 1 | 50\% | - | - | 0\% | - | - | 0\% |
|  | Mar 2011 | , | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Apr 2011 | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | May 2011 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jun 2011 | 2 | 1 | 50\% | - | - | 0\% | - | - | 0\% |
|  | Jul 2011 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Aug 2011 | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Sep 2011 | 2 | 1 | 50\% | - | - | 0\% | - | - | 0\% |
|  | Oct 2011 | 2 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Nov 2011 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Dec 2011 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jan 2012 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Feb 2012 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Mar 2012 | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Apr 2012 | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | May 2012 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jun 2012 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jul 2012 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Aug 2012 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Sep 2012 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Oct 2012 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Nov 2012 | - | - | 0\% | - | - | 0\% | 1 | - | 0\% |
|  | Dec 2012 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jan 2013 | $\cdot$ | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Feb 2013 | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Mar 2013 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Apr 2013 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | May 2013 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jun 2013 | 1 | - | 0\% | 2 | 1 | 50\% | - | - | 0\% |
|  | Jul 2013 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Aug 2013 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Sep 2013 | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Oct 2013 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Nov 2013 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Dee 2013 | 1 | $1$ | $100 \%$ |  | - | 0\% | - | . | 0\% |


| Quaternary Tolerance Definition ( $>0 \mathrm{mg}$ for seven days in the 30 days prior) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Dose $12 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $24 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $25 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $36 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $37 \mathrm{mcg} / \mathrm{hr}$ |  |  |
|  |  | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with Prior Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | $\begin{aligned} & \text { \% with } \\ & \text { Prior } \\ & \text { Tolerance } \end{aligned}$ | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | $N$ with Prior Tolerance | \% with Prior Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with Prior Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with Prior Tolerance |
| Age (years) | Total | 16,379 | 11,725 | 71.6\% | ${ }^{3}$ |  | 100\% | 44,450 | 34,055 | 76.6\% | 1 | 0 | 0\% | 298 | 226 | 76\% |
|  | 0.11 years | 32 | 13 | 40.6\% |  |  | 0\% | 23 | 9 | 39.1\% | 0 | 0 | 0\% | 1 | 0 | 0\% |
|  | 12-17 years | 75 | 34 | 45.3\% | - |  | 0\% | 79 | 35 | 44.3\% | 0 | 0 | 0\% | 2 | 0 | 0\% |
|  | 18.24 years | 375 | 244 | 65.1\% | - |  | 0\% | 827 | 573 | 69.3\% | 0 | 0 | 0\% | 8 | 5 | 63\% |
|  | 25-34 years | 1,464 | 1,149 | 78.5\% | - |  | 0\% | 3,731 | 3,036 | 81.4\% | 1 | 0 | 0\% | 24 | 20 | 83\% |
|  | 35. 44 years | 2,841 | 2,145 | 75.5\% | 2 |  | 100\% | 7,954 | 6,322 | 79.5\% | 0 | 0 | 0\% | 63 | 45 | 71\% |
|  | 45 - 54 years | 5,214 | 3,758 | 72.1\% | - |  | 0\% | 14,785 | 11,417 | 77.2\% | 0 | 0 | 0\% | 87 | 66 | 76\% |
|  | 55-64 years | 6,378 | 4,382 | 68.7\% | 1 |  | 100\% | 17,051 | 12,663 | 74.3\% | 0 | 0 | 0\% | 113 | 90 | 80\% |
| Gender | Male | 5,124 | 3,737 | 72.9\% | 1 |  | 100\% | 18,327 | 14,155 | 77.2\% | 0 | 0 | 0\% | 133 | 105 | 79\% |
|  | Female | 11,255 | 7,988 | 71.0\% | 2 |  | 100\% | 26,123 | 19,900 | 76.2\% | 1 | 0 | 0\% | 165 | 121 | 73\% |
|  | Ambiguous | - | . | 0.0\% | - |  | 0\% | . | - | 0.0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Unknown | 0 | 0 | 0 | 0 |  | 0\% | - | 0 | 0 | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Jan 2009 | 220 | 165 | 75.0\% | - |  | 0\% | 953 | 703 | 73.8\% | 0 | 0 | 0\% | 4 | 4 | 100\% |
| Month and Year of | Feb 2009 | 206 | 140 | 68.0\% | - |  | 0\% | 890 | 672 | 75.5\% | 0 | 0 | 0\% | 8 | 4 | 50\% |
| Episode Start Date | Mar 2009 | 267 | 174 | 65.2\% | - |  | 0\% | 982 | 739 | 75.3\% | 0 | 0 | 0\% | 5 | 5 | 100\% |
|  | Apr 2009 | 220 | 159 | 72.3\% | - |  | 0\% | 969 | 725 | 74.8\% | 1 | 0 | 0\% | ${ }^{4}$ | 2 | 50\% |
|  | May 2009 | 248 | 182 | 73.4\% | - |  | 0\% | 875 | 689 | 78.7\% | 0 | 0 | 0\% | 6 | 6 | 100\% |
|  | Jun 2009 | 258 | 172 | 66.7\% | - |  | 0\% | 909 | 689 | 75.8\% | 0 | 0 | 0\% | 5 | 5 | 100\% |
|  | Jul 2009 | 249 | 174 | 69.9\% | - |  | 0\% | 870 | 643 | 73.9\% | 0 | 0 | 0\% | 6 | 4 | 67\% |
|  | Aug 2009 | 268 | 191 | 71.3\% | - |  | 0\% | 881 | 641 | 72.8\% | 0 | 0 | 0\% | 2 | 1 | 50\% |
|  | Sep 2009 | 295 | 219 | 74.2\% | - |  | 0\% | 943 | 717 | 76.0\% | 0 | 0 | 0\% | 4 | 4 | 100\% |
|  | Oct 2009 | 261 | 172 | 65.9\% | - |  | 0\% | 857 | 631 | 73.6\% | 0 | 0 | 0\% | 1 | 1 | 100\% |
|  | Nov 2009 | 231 | 157 | 68.0\% | - |  | 0\% | 818 | 598 | 73.1\% | 0 | 0 | 0\% |  | 5 | 63\% |
|  | Dec 2009 | 244 | 167 | 68.4\% | - |  | 0\% | 900 | 687 | 76.3\% | 0 | 0 | 0\% | 7 | 5 | 71\% |
|  | Jan 2010 | 226 | 156 | 69.0\% | - |  | 0\% | 827 | 607 | 73.4\% | 0 | 0 | 0\% | 6 | 0 | 0\% |
|  | Feb 2010 | 238 | 171 | 71.8\% | - |  | 0\% | 753 | 562 | 74.6\% | 0 | 0 | 0\% | 8 | 8 | 100\% |
|  | Mar 2010 | 268 | 184 | 68.7\% | - |  | 0\% | 791 | 601 | 76.0\% | 0 | 0 | 0\% |  | 6 | 75\% |
|  | Apr 2010 | 257 | 179 | 69.6\% | - |  | 0\% | 833 | 621 | 74.5\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | May 2010 | 227 | 179 | 78.9\% | - |  | 0\% | 738 | 595 | 80.6\% | 0 | 0 | 0\% | 5 | 1 | 20\% |
|  | Jun 2010 | 246 | 171 | 69.5\% | - |  | 0\% | 746 | 557 | 74.7\% | 0 | 0 | 0\% | 4 | 1 | 25\% |
|  | Jul 2010 | 223 | 155 | 69.5\% | - |  | 0\% | 764 | 593 | 77.6\% | 0 | 0 | 0\% | 5 | 4 | 80\% |
|  | Aug 2010 | 260 | 186 | 71.5\% | - |  | 0\% | 810 | 623 | 76.9\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Sep 2010 | 301 | 213 | 70.8\% | - |  | 0\% | 833 | 643 | 77.2\% | 0 | 0 | 0\% | 2 | 2 | 100\% |
|  | Oct 2010 | 288 | 196 | 68.1\% | - |  | 0\% | 777 | 586 | 75.4\% | 0 | 0 | 0\% | 5 | 5 | 100\% |
|  | Nov 2010 | 290 | 210 | 72.4\% | - |  | 0\% | 824 | 621 | 75.4\% | 0 | 0 | 0\% | 9 | 7 | 78\% |
|  | Dec 2010 | 291 | 209 | 71.8\% | - |  | 0\% | 731 | 567 | 77.6\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Jan 2011 | 252 | 169 | 67.1\% | - |  | 0\% | 724 | 547 | 75.6\% | 0 | 0 | 0\% | , | 1 | 100\% |
|  | Feb 2011 | 264 | 177 | 67.0\% | - |  | 0\% | 639 | 490 | 76.7\% | 0 | 0 | 0\% | 3 | 3 | 100\% |
|  | Mar 2011 | 279 | 193 | 69.2\% | - |  | 0\% | 802 | 622 | 77.6\% | 0 | 0 | 0\% | 9 | 6 | 67\% |
|  | Apr 2011 | 269 | 199 | 74.0\% | - |  | 0\% | 710 | 553 | 77.9\% | 0 | 0 | 0\% | 10 | 10 | 100\% |
|  | May 2011 | 261 | 184 | 70.5\% | - |  | 0\% | 700 | 527 | 75.3\% | 0 | 0 | 0\% | 3 | 3 | 100\% |
|  | Jun 2011 | 276 | 192 | 69.6\% | - |  | 0\% | 678 | 521 | 76.8\% | 0 | 0 | 0\% | ${ }^{4}$ | 3 | 75\% |
|  | Jul 2011 | 282 | 193 | 68.4\% | - |  | 0\% | 679 | 515 | 75.8\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Aug 2011 | 314 | 237 | 75.5\% | - |  | 0\% | 758 | 559 | 73.7\% | 0 | 0 | 0\% | 4 | 3 | 75\% |
|  | Sep 2011 | 291 | 208 | 71.5\% | - |  | 0\% | 730 | 565 | 77.4\% | 0 | 0 | 0\% | 7 | 5 | 71\% |
|  | Oct 2011 | 263 | 194 | 73.\% | - |  | 0\% | 711 | 555 | 78.1\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Nov 2011 | 288 | 204 | 70.8\% | - |  | 0\% | 659 | 529 | 80.3\% | 0 | 0 | 0\% | 8 | 4 | 50\% |
|  | Dec 2011 | 307 | 215 | 70.0\% | - |  | 0\% | 689 | 517 | 75.0\% | 0 | 0 | 0\% | 5 | 5 | 100\% |
|  | Jan 2012 | 279 | 190 | 68.1\% | - |  | 0\% | 720 | 562 | 78.1\% | 0 | 0 | 0\% | 2 | 2 | 100\% |
|  | Feb 2012 | 255 | 189 | 74.1\% | - |  | 0\% | 638 | 492 | 77.1\% | 0 | 0 | 0\% | 7 | 6 | 86\% |
|  | Mar 2012 | 294 | 218 | 74.1\% | - |  | 0\% | 683 | 538 | 78.8\% | 0 | 0 | 0\% | 6 | 5 | 83\% |
|  | Apr 2012 | 251 | 180 | 71.7\% | - |  | 0\% | 650 | 494 | 76.0\% | 0 | 0 | 0\% | 3 | 3 | 100\% |
|  | May 2012 | 324 | 225 | 69.4\% | - |  | 0\% | 631 | 486 | 77.0\% | 0 | 0 | 0\% | 8 | 7 | 88\% |
|  | Jun 2012 | 242 | 179 | 74.0\% | - |  | 0\% | 564 | 443 | 78.5\% | 0 | 0 | 0\% | 3 | 3 | 100\% |
|  | Jul 2012 | 295 | 225 | 76.3\% | - |  | 0\% | 617 | 464 | 75.2\% | 0 | 0 | 0\% | 5 | 4 | 80\% |
|  | Aug 2012 | 304 | 230 | 75.7\% | - |  | 0\% | 787 | 625 | 79.4\% | 0 | 0 | 0\% | 2 | 2 | 100\% |
|  | Sep 2012 | 279 | 199 | 71.3\% | - |  | 0\% | 645 | 496 | 76.9\% | 0 | 0 | 0\% | 5 | 5 | 100\% |
|  | Oct 2012 | 304 | 223 | 73.4\% | - |  | 0\% | 699 | 565 | 80.8\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Nov 2012 | 313 | 227 | 72.5\% | - |  | 0\% | 712 | 553 | 77.7\% | 0 | 0 | 0\% | 6 | 4 | 67\% |
|  | Dec 2012 | 293 | 214 | 73.0\% | - |  | 0\% | 631 | 478 | 75.8\% | 0 | 0 | 0\% | 8 | 5 | 63\% |
|  | Jan 2013 | 277 | 200 | 72.2\% | - |  | 0\% | 593 | 452 | 76.2\% | 0 | 0 | 0\% | 4 | 3 | 75\% |
|  | Feb 2013 | 254 | 182 | 71.7\% | - |  | 0\% | 638 | 516 | 80.9\% | 0 | 0 | 0\% | 3 | 3 | 100\% |
|  | Mar 2013 | 253 | 185 | 73.1\% | - |  | 0\% | 585 | 470 | 80.3\% | 0 | 0 | 0\% | 4 | 4 | 100\% |
|  | Apr 2013 | 289 | 219 | 75.8\% | - |  | 0\% | 617 | 486 | 78.8\% | 0 | 0 | 0\% | 9 | 7 | 78\% |
|  | May 2013 | 261 | 185 | 70.9\% | - |  | 0\% | 640 | 500 | 78.1\% | 0 | 0 | 0\% | 8 | 6 | 75\% |
|  | Jun 2013 | 271 | 197 | 72.7\% | 1 |  | 100\% | 602 | 482 | 80.1\% | 0 | 0 | 0\% | 4 | 3 | 75\% |
|  | Jul 2013 | 331 | 241 | 72.8\% | - |  | 0\% | 663 | 530 | 79.9\% | 0 | 0 | 0\% | 8 | 7 | 88\% |
|  | Aug 2013 | 341 | 244 | 71.6\% | - |  | 0\% | 735 | 582 | 79.2\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Sep 2013 | 302 | 221 | 73.2\% | - |  | 0\% | 645 | 489 | 75.8\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Oct 2013 | 331 | 248 | 74.9\% | 1 |  | 100\% | 714 | 550 | 77.0\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Nov 2013 | 310 | 236 | 76.1\% | 1 |  | 100\% | 651 | 501 | 77.0\% | 0 | 0 | 0\% | 5 | 2 | 40\% |
|  | Dec 2013 | 298 | 222 | 74.5\% | 0 |  | 0\% | 637 | 491 | 77.1\% | 0 | 0 | 0\% | 5 | 4 | 80\% |


| Quaternary Tolerance Definition ( $>0 \mathrm{mg}$ for seven days in the 30 days prior) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Dose $50 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $62 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $75 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $87 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $100 \mathrm{mcg} / \mathrm{hr}$ |  |  |
|  |  | Total $\mathbf{N}$ of <br> Transdermal <br> Fentanyl <br> Episodes | $N$ with Prior Tolerance | \% with Prior Tolerance | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | $\begin{gathered} \% \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{gathered}$ | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | $\begin{array}{\|c\|} \hline \text { \% with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | $\begin{array}{\|c\|} \hline \text { \% with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with Prior Tolerance |
| Age (years) | Total | 18,527 | 14,686 | 79\% | 22 | 8 | 36\% | 5,118 | 3,944 | 77\% | 8 | 5 | 63\% | 3,507 | 2,603 | 74\% |
|  | 0.11 years | 7 | 3 | 43\% | 1 | 0 | 0\% | 2 | 1 | 50\% | 0 | 0 | 0\% | 4 | - | 0\% |
|  | 12-17 years | 32 | 17 | 53\% | 0 | 0 | 0\% | 11 | 4 | 36\% | 0 | 0 | 0\% | ${ }^{8}$ | 3 | 38\% |
|  | 18.24 years | 380 | 277 | 73\% | 1 | 0 | 0\% | 99 | 70 | 71\% | 0 | 0 | 0\% | 77 | 48 | 62\% |
|  | 25.34 years | 1,614 | 1,331 | 82\% | 2 | 0 | 0\% | 523 | 409 | 78\% | 1 | 1 | 100\% | 290 | 231 | 80\% |
|  | $35-44$ years | 3,502 | 2,886 | 82\% | 4 | 2 | 50\% | 1,011 | 771 | 76\% | 1 | 0 | 0\% | 686 | 518 | 76\% |
|  | 45.54 years | 6,358 | 5,038 | 79\% | 11 | 4 | 36\% | 1,785 | 1,396 | 78\% | 4 | 3 | 75\% | 1,276 | 960 | 75\% |
|  | 55-64 years | 6,634 | 5,134 | 77\% | 3 | 2 | 67\% | 1,687 | 1,293 | 77\% | 2 | 1 | 50\% | 1,166 | 843 | 72\% |
| Gender | Male | 8,727 | 7,004 | 80\% | 11 | 6 | 55\% | 2,510 | 1,966 | 78\% | 4 | 3 | 75\% | 1,839 | 1,404 | 76\% |
|  | Female | 9,800 | 7,682 | 78\% | 11 | 2 | 18\% | 2,608 | 1,978 | 76\% | 4 | 2 | 50\% | 1,668 | 1,199 | 72\% |
|  | Ambiguous | - | - | 0\% | 0 | 0 | 0\% | - | - | 0\% | 0 | 0 | 0\% | - | - | 0\% |
|  | Unknown | . | . | 0\% | 0 | 0 | 0\% | . | . | 0\% | 0 | 0 | 0\% | . | . | 0\% |
|  | Jan 2009 | 412 | 313 | 76\% | 2 | 2 | 100\% | 145 | 98 | 68\% | 1 | 0 | 0\% | 94 | 65 | 69\% |
| Month and Year of Episode Start Date | Feb 2009 | 414 | 346 | 84\% | 0 | 0 | 0\% | 118 | 90 | 76\% | 0 | 0 | 0\% | 98 | 75 | 77\% |
|  | Mar 2009 | 424 | 348 | 82\% | 0 | 0 | 0\% | 112 | 80 | 71\% | 0 | 0 | 0\% | 79 | 52 | 66\% |
|  | Apr 2009 | 423 | 337 | 80\% | 0 | 0 | 0\% | 108 | 88 | 81\% | 0 | 0 | 0\% | 88 | 68 | 77\% |
|  | May 2009 | 368 | 269 | 73\% | 0 | 0 | 0\% | 101 | 74 | 73\% | 0 | 0 | 0\% | 84 | 62 | 74\% |
|  | Jun 2009 | 409 | 311 | 76\% | 0 | 0 | 0\% | 111 | 83 | 75\% | 0 | 0 | 0\% | 75 | 66 | 88\% |
|  | Jul 2009 | 376 | 294 | 78\% | 2 | 0 | 0\% | 89 | 62 | 70\% | 0 | 0 | 0\% | 86 | 63 | 73\% |
|  | Aug 2009 | 348 | 285 | 82\% | 0 | 0 | 0\% | 97 | 75 | 77\% | 0 | 0 | 0\% | 72 | 52 | 72\% |
|  | Sep 2009 | 396 | 312 | 79\% | 0 | 0 | 0\% | 95 | 81 | 85\% | 2 | 1 | 50\% | 72 | 49 | 68\% |
|  | Oct 2009 | 433 | 322 | 74\% | 0 | 0 | 0\% | 100 | 77 | 77\% | 0 | 0 | 0\% | 90 | 64 | 71\% |
|  | Nov 2009 | 366 | 287 | 78\% | 1 | 1 | 100\% | 94 | 78 | 83\% | 0 | 0 | 0\% | 77 | 57 | 74\% |
|  | Dec 2009 | 379 | 295 | 78\% | 0 | 0 | 0\% | 113 | 86 | 76\% | 0 | 0 | 0\% | 74 | 55 | 74\% |
|  | Jan 2010 | 359 | 269 | 75\% | 0 | 0 | 0\% | 101 | 70 | 69\% | 0 | 0 | 0\% | 89 | 67 | 75\% |
|  | Feb 2010 | 325 | 241 | 74\% | 1 | 0 | 0\% | 84 | 60 | 71\% | 1 | 1 | 100\% | 60 | 43 | 72\% |
|  | Mar 2010 | 331 | 260 | 79\% | 0 | 0 | 0\% | 113 | 86 | 76\% | 0 | 0 | 0\% | 62 | 43 | 69\% |
|  | Apr 2010 | 307 | 240 | 78\% | 0 | 0 | 0\% | 100 | 84 | 84\% | 0 | 0 | 0\% | 67 | 53 | 79\% |
|  | May 2010 | 326 | 250 | 77\% | 0 | 0 | 0\% | 84 | 60 | 71\% | 0 | 0 | 0\% | 60 | 46 | 77\% |
|  | Jun 2010 | 340 | 272 | 80\% | 0 | 0 | 0\% | 77 | 61 | 79\% | 0 | 0 | 0\% | 49 | 42 | 86\% |
|  | Jul 2010 | 342 | 276 | 81\% | 0 | 0 | 0\% | 92 | 69 | 75\% | 0 | 0 | 0\% | 55 | 44 | 80\% |
|  | Aug 2010 | 325 | 258 | 79\% | 0 | 0 | 0\% | 98 | 72 | 73\% | 0 | 0 | 0\% | 71 | 57 | 80\% |
|  | Sep 2010 | 343 | 271 | 79\% | 1 | 1 | 100\% | 93 | 78 | 84\% | 0 | 0 | 0\% | 70 | 51 | 73\% |
|  | Oct 2010 | 340 | 278 | 82\% | 0 | 0 | 0\% | 95 | 77 | 81\% | 0 | 0 | 0\% | 58 | 50 | 86\% |
|  | Nov 2010 | 326 | 269 | 83\% | 0 | 0 | 0\% | 93 | 77 | 83\% | 0 | 0 | 0\% | 63 | 49 | 78\% |
|  | Dec 2010 | 356 | 281 | 79\% | 0 | 0 | 0\% | 78 | 61 | 78\% | 0 | 0 | 0\% | 64 | 38 | 59\% |
|  | Jan 2011 | 306 | 232 | 76\% | 0 | 0 | 0\% | 112 | 78 | 70\% | 0 | 0 | 0\% | 90 | 67 | 74\% |
|  | Feb 2011 | 277 | 217 | 78\% | 0 | 0 | 0\% | 96 | 76 | 79\% | 0 | 0 | 0\% | 66 | 49 | 74\% |
|  | Mar 2011 | 338 | 270 | 80\% | 1 | 0 | 0\% | 94 | 78 | 83\% | 0 | 0 | 0\% | 79 | 57 | 72\% |
|  | Apr 2011 | 322 | 244 | 76\% | 0 | 0 | 0\% | 86 | 67 | 78\% | 0 | 0 | 0\% | 52 | 38 | 73\% |
|  | May 2011 | 280 | 211 | 75\% | 0 | 0 | 0\% | 86 | 67 | 78\% | 0 | 0 | 0\% | 52 | 34 | 65\% |
|  | Jun 2011 | 286 | 220 | 77\% | 0 | 0 | 0\% | 75 | 65 | 87\% | 1 | 1 | 100\% | 41 | 31 | 76\% |
|  | Jul 2011 | 309 | 244 | 79\% | 0 | 0 | 0\% | 70 | 59 | 84\% | 0 | 0 | 0\% | 48 | 39 | 81\% |
|  | Aug 2011 | 322 | 256 | 80\% | 0 | 0 | 0\% | 78 | 58 | 74\% | 0 | 0 | 0\% | 45 | 39 | 87\% |
|  | Sep 2011 | 310 | 253 | 82\% | 0 | 0 | 0\% | 78 | 63 | 81\% | 0 | 0 | 0\% | 42 | 31 | 74\% |
|  | Oct 2011 | 269 | 210 | 78\% | 2 | 0 | - 0\% | 77 | 64 | 83\% | 0 | 0 | 0\% | 56 | 41 | 73\% |
|  | Nov 2011 | 274 | 221 | 81\% | 0 | 0 | 0\% | 77 | 59 | 77\% | 0 | 0 | 0\% | 47 | 34 | 72\% |
|  | Dec 2011 | 286 | 236 | 83\% | 0 | 0 | 0\% | 72 | 52 | 72\% | 0 | 0 | 0\% | 59 | 48 | 81\% |
|  | Jan 2012 | 273 | 226 | 83\% | 0 | 0 | 0\% | 88 | 74 | 84\% | 0 | 0 | 0\% | 53 | 35 | 66\% |
|  | Feb 2012 | 266 | 219 | 82\% | 1 | 0 | 0\% | 75 | 56 | 75\% | 0 | 0 | 0\% | 53 | 45 | 85\% |
|  | Mar 2012 | 282 | 237 | 84\% | 0 | 0 | 0\% | 76 | 64 | 84\% | 0 | 0 | 0\% | 48 | 40 | 83\% |
|  | Apr 2012 | 277 | 221 | 80\% | 1 |  | 0 0\% | 86 | 66 | 77\% | 0 | 0 | 0\% | 48 | 37 | 77\% |
|  | May 2012 | 287 | 222 | 77\% | 1 |  | 0 0\% | 71 | 56 | 79\% | 0 | 0 | 0\% | 52 | 39 | 75\% |
|  | Jun 2012 | 234 | 193 | 82\% | 1 |  | 0 0\% | 60 | 49 | 82\% | 0 | 0 | 0\% | 49 | 39 | 80\% |
|  | Jul 2012 | 307 | 245 | 80\% | 0 |  | - 0\% | 87 | 64 | 74\% | 0 | 0 | 0\% | 37 | 22 | 59\% |
|  | Aug 2012 | 284 | 225 | 79\% | 1 |  | 1 100\% | 89 | 68 | 76\% | 0 | 0 | 0\% | 51 | 39 | 76\% |
|  | Sep 2012 | 254 | 213 | 84\% | 1 |  | 0 0\% | 77 | 64 | 83\% | 1 | 1 | 100\% | 38 | 31 | 82\% |
|  | Oct 2012 | 251 | 202 | 80\% | 0 |  | 0 0\% | 69 | 57 | 83\% | 0 | 0 | 0\% | 47 | 32 | 68\% |
|  | Nov 2012 | 296 | 211 | 71\% | 0 |  | 0 0\% | 90 | 60 | 67\% | 2 | 1 | 50\% | 62 | 43 | 69\% |
|  | Dec 2012 | 261 | 209 | 80\% | 0 |  | - 0\% | 54 | 34 | 63\% | 0 | 0 | 0\% | 46 | 31 | 67\% |
|  | Jan 2013 | 254 | 202 | 80\% | 2 |  | 1 50\% | 87 | 62 | 71\% | 0 | 0 | 0\% | 42 | 31 | 74\% |
|  | Feb 2013 | 212 | 180 | 85\% | 2 |  | 0 0\% | 56 | 46 | 82\% | 0 | 0 | 0\% | 44 | 36 | 82\% |
|  | Mar 2013 | 236 | 187 | 79\% | 0 |  | 0 0\% | 72 | 52 | 72\% | 0 | 0 | 0\% | 36 | 27 | 75\% |
|  | Apr 2013 | 226 | 183 | 81\% | 0 |  | - 0\% | 68 | 54 | 79\% | 0 | 0 | 0\% | 37 | 29 | 78\% |
|  | May 2013 | 250 | 205 | 82\% | 1 |  | 1 100\% | 65 | 56 | 86\% | 0 | 0 | 0\% | 42 | 27 | 64\% |
|  | Jun 2013 | 244 | 203 | 83\% | 0 | 0 | 0 0\% | 69 | 51 | 74\% | 0 | 0 | 0\% | 34 | 24 | 71\% |
|  | Jul 2013 | 239 | 192 | 80\% | 0 |  | 0 0\% | 78 | 67 | 86\% | 0 | 0 | 0\% | 43 | 30 | 70\% |
|  | Aug 2013 | 272 | 229 | 84\% | 0 |  | 0 0\% | 61 | 41 | 67\% | 0 | 0 | 0\% | 31 | 17 | 55\% |
|  | Sep 2013 | 245 | 204 | 83\% | 0 |  | 0 0\% | 66 | 50 | 76\% | 0 | 0 | 0\% | 44 | 33 | 75\% |
|  | Oct 2013 | 242 | 197 | 81\% | 0 |  | 0 0\% | 67 | 50 | 75\% | 0 | 0 | 0\% | 47 | 35 | 74\% |
|  | Nov 2013 | 241 | 189 | 78\% | 0 |  | - 0\% | 58 | 47 | 81\% | 0 | 0 | 0\% | 47 | 31 | 66\% |
|  | Dec 2013 | 247 | 194 | 79\% | 1 | 1 | 1 100\% | 57 | 43 | 75\% | 0 | 0 | 0\% | 42 | 31 | 74\% |


| Quaternary Tolerance Definition (>0 mg for seven days in the $\mathbf{3 0}$ days prior) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Dose $112 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $125 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $137 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $150 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $162 \mathrm{mcg} / \mathrm{hr}$ |  |  |
|  |  | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{gathered} \mathrm{N} \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{gathered}$ | $\begin{aligned} & \text { \% with } \\ & \text { Prior } \\ & \text { Tolerance } \end{aligned}$ | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{aligned} & \text { N with } \\ & \text { Prior } \\ & \text { Tolerance } \end{aligned}$ | $\begin{gathered} \text { \% with } \\ \text { Prior } \\ \text { Tolerance } \end{gathered}$ | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{array}{\|c\|} \hline N \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | $\begin{array}{\|c\|} \hline \% \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{array}{\|c\|} \hline N \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | $\begin{array}{\|c\|} \hline \% \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{gathered} N \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{gathered}$ | $\begin{gathered} \text { \% with } \\ \text { Prior } \\ \text { Tolerance } \end{gathered}$ |
| Age (years) | Total | 3 | 3 | 100\% | 137 | 94 | 69\% | 2 | 1 | 50\% | 172 | 124 | 72\% | 2 | 2 | 100\% |
|  | $0-11$ years | 0 | 0 | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | 12-17 years | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 1 | - | 0\% | - | - | 0\% |
|  | 18.24 years | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | 5 | 4 | 80\% | 1 | 1 | 100\% |
|  | 25-34 years | 0 | 0 | 0\% | 9 | 7 | 78\% | - | - | 0\% | 12 | 8 | 67\% | - | - | 0\% |
|  | 35-44 years | 0 | 0 | 0\% | 20 | 15 | 75\% | - | - | 0\% | 30 | 24 | 80\% | - | - | 0\% |
|  | 45-54 years | 1 | 1 | 100\% | 57 | 38 | 67\% | 1 | - | 0\% | 60 | 44 | 73\% | - | - | 0\% |
|  | 55-64 years | 2 | 2 | 100\% | 48 | 31 | 65\% | 1 | 1 | 100\% | 64 | 44 | 69\% | 1 | 1 | 100\% |
| Gender | Male | 1 | 1 | 100\% | 69 | 46 | 67\% | - | - | 0\% | 95 | 75 | 79\% | 2 | 2 | 100\% |
|  | Female | 2 | 2 | 100\% | 68 | 48 | 71\% | 2 | 1 | 50\% | 77 | 49 | 64\% | - | - | 0\% |
|  | Ambiguous | 0 | 0 | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Unknown | 0 | 0 | 0\% | . | . | 0\% | . | . | 0\% | . | . | 0\% | . | . | 0\% |
| Month and Year of Episode Start Date | Jan 2009 | 1 | 1 | 100\% | 4 | 3 | 75\% | - | - | 0\% | 6 | 2 | 33\% | - | - | 0\% |
|  | Feb 2009 | 0 | 0 | 0\% | 3 | 2 | 67\% | - | - | 0\% | 2 | 2 | 100\% | - | - | 0\% |
|  | Mar 2009 | 0 | 0 | 0\% | ${ }^{3}$ | 1 | 33\% | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% |
|  | Apr 2009 | 0 | 0 | 0\% | 2 | 1 | 50\% | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% |
|  | May 2009 | 0 | 0 | 0\% | 3 | 3 | 100\% | - | - | 0\% | 6 | 4 | 67\% | - | - | 0\% |
|  | Jun 2009 | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | 7 | 6 | 86\% | - | - | 0\% |
|  | Jul 2009 | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 3 | 1 | 33\% | - | - | 0\% |
|  | Aug 2009 | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 4 | 1 | 25\% | , | - | 0\% |
|  | Sep 2009 | 0 | 0 | 0\% | - | - | 0\% | - | - | 0\% | 5 | 4 | 80\% | - | - | 0\% |
|  | Oct 2009 | 0 | 0 | 0\% | 1 | - | 0\% | - | - | 0\% | 4 | 2 | 50\% | - | - | 0\% |
|  | Nov 2009 | 0 | 0 | 0\% | 2 | 1 | 50\% | - | - | 0\% | 7 | 5 | 71\% | 4 |  | 0\% |
|  | Dec 2009 | 0 | 0 | 0\% | 2 | 1 | 50\% | - | - | 0\% | 7 | 6 | 86\% | - | - | 0\% |
|  | Jan 2010 | 0 | 0 | 0\% | 7 | 4 | 57\% | - | - | 0\% | 5 | 3 | 60\% | - | - | 0\% |
|  | Feb 2010 | 0 | 0 | 0\% | 6 | 3 | 50\% | - | - | 0\% | 5 | 4 | 80\% | - |  | 0\% |
|  | Mar 2010 | 0 | 0 | 0\% | 2 | - | 0\% | - | - | 0\% | 4 | 4 | 100\% | - | - | 0\% |
|  | Apr 2010 | 0 | 0 | 0\% | 4 | 2 | 50\% | - | - | 0\% | 4 | 3 | 75\% | - | - | 0\% |
|  | May 2010 | 0 | 0 | 0\% | 2 | 1 | 50\% | - | - | 0\% | 4 | 3 | 75\% | - | - | 0\% |
|  | Jun 2010 | 0 | 0 | 0\% | 5 | 4 | 80\% | - |  | 0\% | 2 | 2 | 100\% | - | - | 0\% |
|  | Jul 2010 | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 5 | 4 | 80\% | - | - | 0\% |
|  | Aug 2010 | 0 | 0 | 0\% | 2 | 1 | 50\% | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% |
|  | Sep 2010 | 0 | 0 | 0\% | - | - | 0\% | - | , | 0\% | 3 | 1 | 33\% | - | - | 0\% |
|  | Oct 2010 | 0 | 0 | 0\% | 3 | 3 | 100\% | 1 | 1 | 100\% | 3 | 3 | 100\% | - | - | 0\% |
|  | Nov 2010 | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% |
|  | Dec 2010 | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 4 | 2 | 50\% | - |  | 0\% |
|  | Jan 2011 | 0 | 0 | 0\% | 3 | 1 | $33 \%$ | - | - | 0\% | 4 | 3 | 75\% | 1 | 1 | 100\% |
|  | Feb 2011 | 1 | 1 | 100\% | 3 | 2 | 67\% | - | - | 0\% | 3 | 2 | 67\% | - |  | 0\% |
|  | Mar 2011 | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% |
|  | Apr 2011 | 0 | 0 | 0\% | 3 | 2 | 67\% | - | - | 0\% | 4 | 4 | 100\% | - | - | 0\% |
|  | May 2011 | 0 | 0 | 0\% | 5 | 3 | 60\% | - | - | 0\% | 2 | 2 | 100\% | - | - | 0\% |
|  | Jun 2011 | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jul 2011 | 0 | 0 | 0\% | 2 | - | 0\% | - | - | 0\% | 4 | 4 | 100\% | - | - | 0\% |
|  | Aug 2011 | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% |
|  | Sep 2011 | 0 | 0 | 0\% | 4 | 3 | 75\% | 1 | - | 0\% | 3 | 3 | 100\% | 1 | 1 | 100\% |
|  | Oct 2011 | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 1 | - | 0\% | - | \% | 0\% |
|  | Nov 2011 | 0 | 0 | 0\% | - | - | 0\% | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% |
|  | Dec 2011 | 0 | 0 | 0\% | 3 | 2 | 67\% | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% |
|  | Jan 2012 | 0 | 0 | 0\% | 2 | 1 | 50\% | - | . | 0\% | 2 | 2 | 100\% | - | - | 0\% |
|  | Feb 2012 | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | 5 | 4 | 80\% | - | - | 0\% |
|  | Mar 2012 | 0 | 0 | 0\% | 3 | 3 | 100\% | - | - | 0\% | 2 | 2 | 100\% | - | - | 0\% |
|  | Apr 2012 | 1 | 1 | 100\% | 5 | 5 | 100\% | - | - | 0\% | 3 | 3 | 100\% | - | - | 0\% |
|  | May 2012 | 0 | 0 | 0\% | 4 | 2 | 50\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jun 2012 | 0 | 0 | 0\% | $\cdots$ | - | 0\% | - | - | 0\% | 2 | 1 | 50\% | - | * | 0\% |
|  | Jul 2012 | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Aug 2012 | 0 | 0 | 0\% | 4 | 4 | 100\% | - | , | 0\% | 1 | 1 | 100\% | - | \% | 0\% |
|  | Sep 2012 | 0 | 0 | 0\% | 1 | 1 | 100\% | - |  | 0\% | 2 | 1 | 50\% | - | - | 0\% |
|  | Oct 2012 | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | 2 | 2 | 100\% | - | - | 0\% |
|  | Nov 2012 | 0 | 0 | 0\% | 2 | 2 | 100\% | - |  | 0\% | 5 | 4 | 80\% | - | - | 0\% |
|  | Dec 2012 | 0 | 0 | 0\% | 3 | 1 | 33\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jan 2013 | 0 | 0 | 0\% | 2 | - | 0\% | - |  | 0\% | 4 | 1 | 25\% | - | - | 0\% |
|  | Feb 2013 | 0 | 0 | 0\% | 3 | 2 | 67\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Mar 2013 | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | 3 | 1 | 33\% | - | - | 0\% |
|  | Apr 2013 | 0 | 0 | 0\% | - | - | 0\% | - |  | 0\% | 3 | 3 | 100\% | - | - | 0\% |
|  | May 2013 | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jun 2013 | 0 | 0 | 0\% | - | - | 0\% | - | - | 0\% | 3 | 3 | 100\% | - | - | 0\% |
|  | Jul 2013 | 0 | 0 | 0\% | 3 | 3 | 100\% | - | - | 0\% | 2 | 2 | 100\% | - | - | 0\% |
|  | Aug 2013 | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | 3 | 1 | 33\% | - | - | 0\% |
|  | Sep 2013 | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% |
|  | Oct 2013 | 0 | 0 | 0\% | 4 | 1 | 25\% | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% |
|  | Nov 2013 | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 3 | 2 | 67\% | - | - | 0\% |
|  | Dec 2013 |  |  | 0\% | 1 | - |  | - | - |  | 2 | 1 | 50\% | - |  | 0\% |



| Primary Tolerance Definition ( 230 mg per day in the prior 7 consecutive days) |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Dose $12 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $24 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $25 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $36 \mathrm{mcg} / \mathrm{hr}$ |  |  |
|  |  | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with <br> Prior <br> Tolerance | \% with <br> Prior <br> Tolerance | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with Prior Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with <br> Prior <br> Tolerance | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with Prior Tolerance |
|  | Total | 17,812 | 5,093 | 28.6\% | 3 |  | 33\% | 49,148 | 18,322 | 37.3\% | 1 | 0 | 0\% |
| Age (years) | 0.11 years | 34 | 1 | 2.9\% | - |  | 0\% | 25 | 2 | 8.0\% | 0 | 0 | 0\% |
|  | 12-17 years | 81 | 6 | 7.4\% |  |  | 0\% | 85 | 16 | 18.\% | 0 | 0 | 0\% |
|  | 18.24 years | 412 | 104 | 25.2\% | - |  | 0\% | 925 | 345 | 37.3\% | 0 | 0 | 0\% |
|  | 25-34 years | 1,605 | 582 | 36.3\% | - |  | 0\% | 4,297 | 1,931 | 44.9\% | 1 | 0 | 0\% |
|  | 35-44 years | 3,153 | 1,065 | 33.\% | 2 |  | 50\% | 8,915 | 3,696 | 41.5\% | 0 | 0 | 0\% |
|  | 45.54 years | 5,672 | 1,650 | 29.1\% | - |  | 0\% | 16,409 | 6,277 | 38.3\% | 0 | 0 | 0\% |
|  | 55-64 years | 6,855 | 1,685 | 24.6\% | 1 |  | 0\% | 18,492 | 6,055 | 32.7\% | 0 | 0 | 0\% |
| Gender | Male | 5,595 | 1,675 | 29.9\% | ${ }^{1}$ |  | 100\% | 20,233 | 7,836 | 38.7\% | 0 | 0 | 0\% |
|  | Female | 12,217 | 3,418 | 28.0\% | ${ }^{2}$ |  | 0\% | 28,915 | 10,486 | 36.3\% | 1 | 0 | 0\% |
|  | Ambiguous |  | - | 0.0\% | - |  | 0\% |  |  | 0.0\% | 0 | 0 | 0\% |
|  | Unknown | 0 | 0 | 0 | 0 |  | 0\% | - | 0 | 0 | 0 | 0 | 0\% |
| Month and Year of Episode Start Date | Jan 2009 | 238 | 72 | 30.3\% |  |  | 0\% | 1,070 | 365 | 34.1\% | 0 | 0 | 0\% |
|  | Feb 2009 | 227 | 53 | 23.3\% | - |  | 0\% | 992 | 346 | 34.9\% | 0 | 0 | 0\% |
|  | Mar 2009 | 284 | 76 | 26.8\% | - |  | 0\% | 1,072 | 369 | 34.4\% | 0 | 0 | 0\% |
|  | Apr 2009 | 251 | 57 | 22.7\% | - |  | 0\% | 1,147 | 388 | 33.8\% | 1 | 0 | 0\% |
|  | May 2009 | 283 | 73 | 25.8\% | - |  | 0\% | 1,039 | 386 | 37.2\% | 0 | 0 | 0\% |
|  | Jun 2009 | 300 | 72 | 24.0\% | - |  | 0\% | 1,080 | 368 | 34.1\% | 0 | 0 | 0\% |
|  | Jul 2009 | 267 | 73 | 27.3\% | - |  | 0\% | 966 | 335 | 34.7\% | 0 | 0 | 0\% |
|  | Aug 2009 | 284 | 74 | 26.1\% | - |  | 0\% | 946 | 307 | 32.5\% | 0 | 0 | 0\% |
|  | Sep 2009 | 318 | 89 | 28.0\% | - |  | 0\% | 1,007 | 357 | 35.5\% | 0 | 0 | 0\% |
|  | Oct 2009 | 278 | 78 | 28.1\% | - |  | 0\% | 948 | 328 | 34.6\% | 0 | 0 | 0\% |
|  | Nov 2009 | 244 | 71 | 29.1\% | - |  | 0\% | 898 | 294 | 32.7\% | 0 | 0 | 0\% |
|  | Dec 2009 | 261 | 74 | 28.4\% | - |  | 0\% | 970 | 363 | 37.4\% | 0 | 0 | 0\% |
|  | Jan 2010 | 245 | 59 | 24.1\% | - |  | 0\% | 881 | 292 | 33.1\% | 0 | 0 | 0\% |
|  | Feb 2010 | 254 | 84 | 33.1\% | - |  | 0\% | 790 | 282 | 35.7\% | 0 | 0 | 0\% |
|  | Mar 2010 | 283 | 79 | 27.9\% | - |  | 0\% | 853 | 317 | 37.2\% | 0 | 0 | 0\% |
|  | Apr 2010 | 289 | 78 | 27.0\% | - |  | 0\% | 958 | 331 | 34.6\% | 0 | 0 | 0\% |
|  | May 2010 | 261 | 84 | 32.2\% | - |  | 0\% | 845 | 342 | 40.5\% | 0 | 0 | 0\% |
|  | Jun 2010 | 285 | 81 | 28.4\% | - |  | 0\% | 884 | 341 | 38.6\% | 0 | 0 | 0\% |
|  | Jul 2010 | 239 | 68 | 28.5\% | - |  | 0\% | 837 | 333 | 39.8\% | 0 | 0 | 0\% |
|  | Aug 2010 | 270 | 77 | 28.5\% | - |  | 0\% | 871 | 310 | 35.6\% | 0 | 0 | 0\% |
|  | Sep 2010 | 320 | 96 | 30.\% | - |  | 0\% | 908 | 348 | 38.3\% | 0 | 0 | 0\% |
|  | Oct 2010 | 313 | 74 | 23.6\% | - |  | 0\% | 843 | 312 | 37.0\% | 0 | 0 | 0\% |
|  | Nov 2010 | 306 | 91 | 29.7\% | - |  | 0\% | 889 | 334 | 37.6\% | 0 | 0 | 0\% |
|  | Dec 2010 | 307 | 90 | 29.3\% | - |  | 0\% | 796 | 321 | 40.3\% | 0 | 0 | 0\% |
|  | Jan 2011 | 264 | 69 | 26.1\% | - |  | 0\% | 774 | 284 | 36.7\% | 0 | 0 | 0\% |
|  | Feb 2011 | 279 | 66 | 23.7\% | - |  | 0\% | 674 | 246 | 36.5\% | 0 | 0 | 0\% |
|  | Mar 2011 | 292 | 82 | 28.1\% | - |  | 0\% | 845 | 331 | 39.2\% | 0 | 0 | 0\% |
|  | Apr 2011 | 307 | 97 | 31.6\% | - |  | 0\% | 812 | 324 | 39.9\% | 0 | 0 | 0\% |
|  | May 2011 | 299 | 84 | 28.1\% | - |  | 0\% | 795 | 286 | 36.0\% | 0 | 0 | 0\% |
|  | Jun 2011 | 316 | 85 | 26.9\% | - |  | 0\% | 777 | 311 | 40.0\% | 0 | 0 | 0\% |
|  | Jul 2011 | 294 | 82 | 27.9\% | - |  | 0\% | 728 | 263 | 36.1\% | 0 | 0 | 0\% |
|  | Aug 2011 | 328 | 112 | 34.1\% | - |  | 0\% | 820 | 290 | 35.4\% | 0 | 0 | 0\% |
|  | Sep 2011 | 307 | 90 | 29.3\% | - |  | 0\% | 795 | 300 | 37.7\% | 0 | 0 | 0\% |
|  | Oct 2011 | 279 | 87 | 31.2\% | - |  | 0\% | 768 | 308 | 40.1\% | 0 | 0 | 0\% |
|  | Nov 2011 | 306 | 100 | 32.7\% | - |  | 0\% | 718 | 293 | 40.8\% | 0 | 0 | 0\% |
|  | Dec 2011 | 323 | 96 | 29.7\% | - |  | 0\% | 747 | 283 | 37.9\% | 0 | 0 | 0\% |
|  | Jan 2012 | 298 | 87 | 29.2\% | - |  | 0\% | 776 | 301 | 38.\% | 0 | 0 | 0\% |
|  | Feb 2012 | 269 | 68 | 25.3\% | - |  | 0\% | 696 | 236 | 33.9\% | 0 | 0 | 0\% |
|  | Mar 2012 | 307 | 88 | 28.7\% | - |  | 0\% | 738 | 271 | 36.7\% | 0 | 0 | 0\% |
|  | Apr 2012 | 316 | 96 | 30.4\% | - |  | 0\% | 803 | 302 | 37.6\% | 0 | 0 | 0\% |
|  | May 2012 | 389 | 107 | 27.5\% | - |  | 0\% | 786 | 313 | 39.8\% | 0 | 0 | 0\% |
|  | Jun 2012 | 293 | 82 | 28.0\% | - |  | 0\% | 683 | 263 | 38.5\% | 0 | 0 | 0\% |
|  | Jul 2012 | 315 | 96 | 30.5\% | . |  | 0\% | 672 | 264 | 39.3\% | 0 | 0 | 0\% |
|  | Aug 2012 | 324 | 116 | 35.8\% | - |  | 0\% | 857 | 328 | 38.3\% | 0 | 0 | 0\% |
|  | Sep 2012 | 290 | 76 | 26.2\% | - |  | 0\% | 705 | 264 | 37.4\% | 0 | 0 | 0\% |
|  | Oct 2012 | 330 | 100 | 30.3\% | - |  | 0\% | 754 | 325 | 43.1\% | 0 | 0 | 0\% |
|  | Nov 2012 | 332 | 85 | 25.6\% | - |  | 0\% | 775 | 261 | 33.7\% | 0 | 0 | 0\% |
|  | Dec 2012 | 316 | 84 | 26.6\% | - |  | 0\% | 666 | 266 | 39.9\% | 0 | 0 | 0\% |
|  | Jan 2013 | 296 | 93 | 31.4\% | - |  | 0\% | 650 | 242 | 37.2\% | 0 | 0 | 0\% |
|  | Feb 2013 | 275 | 81 | 29.5\% | - |  | 0\% | 675 | 281 | 41.6\% | 0 | 0 | 0\% |
|  | Mar 2013 | 274 | 95 | 34.7\% | - |  | 0\% | 632 | 256 | 40.5\% | 0 | 0 | 0\% |
|  | Apr 2013 | 327 | 112 | 34.3\% | - |  | 0\% | 724 | 284 | 39.2\% | 0 | 0 | 0\% |
|  | May 2013 | 293 | 85 | 29.0\% | - |  | 0\% | 754 | 303 | 40.2\% | 0 | 0 | 0\% |
|  | Jun 2013 | 306 | 83 | 27.1\% | 1 |  | 0\% | 701 | 278 | 39.7\% | 0 | 0 | 0\% |
|  | Jul 2013 | 345 | 99 | 28.7\% | - |  | 0\% | 719 | 282 | 39.2\% | 0 | 0 | 0\% |
|  | Aug 2013 | 358 | 108 | 30.2\% | - |  | 0\% | 780 | 314 | 40.3\% | 0 | 0 | 0\% |
|  | Sep 2013 | 323 | 85 | 26.3\% | - |  | 0\% | 687 | 269 | 39.2\% | 0 | 0 | 0\% |
|  | Oct 2013 | 366 | 107 | 29.2\% | 1 |  | 100\% | 784 | 307 | 39.2\% | 0 | 0 | 0\% |
|  | Nov 2013 | 344 | 96 | 27.9\% | 1 |  | 0\% | 702 | 272 | 38.7\% | 0 | 0 | 0\% |
|  | Dec 2013 | 325 | 91 | 28.0\% | 0 | - | 0\% | 686 | 252 | 36.7\% | 0 | 0 | 0\% |


| Table 2a: Counts of Transdermal Fentanyl Episodes and Proportions of Transdermal Fentanyl Episodes with Prior Tolerance with a 91-day Washout Period and a Primary Definition in the MiniSentinel Distributed Database (MSDD) from January 1, 2009 to December 31, 2013 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Primary Tolerance Definition ( 300 mg per day in the prior 7 consecutive days) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | Dose $37 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $50 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $62 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $75 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $87 \mathrm{mcg} / \mathrm{hr}$ |  |  |
|  |  | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{array}{\|c\|} \hline N \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | $\%$ with Prior Tolerance | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{array}{\|c\|} \hline \mathrm{N} \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | $\begin{array}{\|c\|} \hline \text { \% with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{array}{\|c\|} \hline N \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | $\begin{array}{\|c\|} \hline \% \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{array}{\|c\|} \hline N \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | $\begin{array}{\|c\|} \hline \text { \% with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{array}{\|c\|} \hline \mathrm{N} \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | $\begin{gathered} \text { \% with } \\ \text { Prior } \\ \text { Tolerance } \end{gathered}$ |
| Age (years) | Total | 339 | 174 | 51\% | 21,245 | 10,088 | 47\% | 26 | 7 | 27\% | 6,215 | 3,197 | 51\% | 14 | 4 | 29\% |
|  | $0-11$ years | 1 | - | 0\% | 8 | 3 | 38\% | 1 | - | 0\% | 3 | - | 0\% | - | - | 0\% |
|  | 12-17 years | 2 | - | 0\% | 37 | 11 | 30\% | - | - | 0\% | 14 | 4 | 29\% | - | - | 0\% |
|  | 18.24 years | 9 | 3 | 33\% | 423 | 182 | 43\% | 2 |  | 0\% | 121 | 61 | 50\% | - | - | 0\% |
|  | $25-34$ years | 27 | 16 | 59\% | 1,911 | 1,051 | 55\% | 2 | - | 0\% | 614 | 355 | 58\% | 2 | 2 | 100\% |
|  | 35-44 years | 71 | 35 | 49\% | 4,031 | 2,108 | 52\% | ${ }^{6}$ | 2 | 33\% | 1,229 | 649 | 53\% | 1 | - | 0\% |
|  | 45. 54 years | 99 | 51 | 52\% | 7,320 | 3,506 | 48\% | 11 | 3 | 27\% | 2,201 | 1,141 | 52\% | ${ }^{6}$ | 2 | 33\% |
|  | 55-64 years | 130 | 69 | 53\% | 7,515 | 3,227 | 43\% | 4 | 2 | 50\% | 2,033 | 987 | 49\% | 5 | - | 0\% |
| Gender | Male | 145 | 77 | 53\% | 9,916 | 4,945 | 50\% | 13 | 6 | 46\% | 2,974 | 1,629 | 55\% | 6 | 2 | 33\% |
|  | Female | 194 | 97 | 50\% | 11,329 | 5,143 | 45\% | 13 | 1 | 8\% | 3,241 | 1,568 | 48\% | ${ }^{8}$ | 2 | 25\% |
|  | Ambiguous | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Unknown | - | . | 0\% | - | . | 0\% | - | . | 0\% | . | . | 0\% | - |  | 0\% |
| Month and Year of Episode Start Date | Jan 2009 | 6 | 3 | 50\% | 490 | 217 | 44\% | 2 | 2 | 100\% | 189 | 79 | 42\% | 1 | - | 0\% |
|  | Feb 2009 | 9 | 4 | 44\% | 484 | 231 | 48\% | - | - | 0\% | 152 | 73 | 48\% | - | - | 0\% |
|  | Mar 2009 | 5 | 3 | 60\% | 492 | 236 | 48\% | - | - | 0\% | 140 | 67 | 48\% | - | - | 0\% |
|  | Apr 2009 | 4 | 1 | 25\% | 532 | 265 | 50\% | - | - | 0\% | 147 | 80 | 54\% | - | - | 0\% |
|  | May 2009 | 6 | 5 | 83\% | 470 | 213 | 45\% | - | - | 0\% | 146 | 69 | 47\% | - | - | 0\% |
|  | Jun 2009 | 8 | 6 | 75\% | 496 | 215 | 43\% | - | - | 0\% | 138 | 64 | 46\% | 1 | - | 0\% |
|  | Jul 2009 | 8 | 2 | 25\% | 440 | 196 | 45\% | 2 | - | 0\% | 112 | 53 | 47\% | 1 | 1 | 100\% |
|  | Aug 2009 | 3 | 1 | 33\% | 398 | 182 | 46\% | - | - | 0\% | 129 | 66 | 51\% | - | - | 0\% |
|  | Sep 2009 | 5 | 3 | 60\% | 457 | 210 | 46\% | - | - | 0\% | 108 | 69 | 64\% | 2 | - | 0\% |
|  | Oct 2009 | 1 | 1 | 100\% | 486 | 215 | 44\% | 1 | - | 0\% | 123 | 60 | 49\% | - | - | 0\% |
|  | Nov 2009 | 8 | 4 | 50\% | 402 | 185 | 46\% | 1 | 1 | 100\% | 108 | 56 | 52\% | - | - | 0\% |
|  | Dec 2009 | 8 | 4 | 50\% | 429 | 191 | 45\% | - | - | 0\% | 135 | 67 | 50\% | 1 | - | 0\% |
|  | Jan 2010 | 6 | - | 0\% | 406 | 177 | 44\% | - | - | 0\% | 120 | 54 | 45\% | - | - | 0\% |
|  | Feb 2010 | 9 | 7 | 78\% | 362 | 159 | 44\% | 1 | - | 0\% | 100 | 46 | 46\% | 1 | - | 0\% |
|  | Mar 2010 | 8 | 3 | 38\% | 354 | 153 | 43\% | - | - | 0\% | 132 | 67 | 51\% | - | - | 0\% |
|  | Apr 2010 | 4 | 2 | 50\% | 368 | 166 | 45\% | - | - | 0\% | 122 | 66 | 54\% | - | - | 0\% |
|  | May 2010 | 6 | 2 | 33\% | 388 | 172 | 44\% | - | - | 0\% | 109 | 49 | 45\% | 1 | - | 0\% |
|  | Jun 2010 | 7 | 3 | 43\% | 402 | 195 | 49\% | 1 | - | 0\% | 103 | 55 | 53\% | - | - | 0\% |
|  | Jul 2010 | 5 | 3 | 60\% | 371 | 196 | 53\% | - | - | 0\% | 98 | 45 | 46\% | - | - | 0\% |
|  | Aug 2010 | 3 | 2 | 67\% | 363 | 170 | 47\% | - | - | 0\% | 116 | 58 | 50\% | - | - | 0\% |
|  | Sep 2010 | 2 | 2 | 100\% | 373 | 176 | 47\% | 1 | 1 | 100\% | 105 | 62 | 59\% | - | - | 0\% |
|  | Oct 2010 | 5 | 3 | 60\% | 383 | 193 | 50\% | - | - | 0\% | 115 | 60 | 52\% | - | - | 0\% |
|  | Nov 2010 | 8 | 4 | 50\% | 353 | 175 | 50\% | - | - | 0\% | 102 | 61 | 60\% | 1 | - | 0\% |
|  | Dec 2010 | 3 | 1 | 33\% | 404 | 178 | 44\% | - | - | 0\% | 90 | 50 | 56\% | - | - | 0\% |
|  | Jan 2011 | 1 | 1 | 100\% | 346 | 148 | 43\% | 1 | 1 | 100\% | 138 | 63 | 46\% | - | - | 0\% |
|  | Feb 2011 | 3 | 2 | 67\% | 305 | 166 | 54\% | - | - | 0\% | 109 | 64 | 59\% | - | - | 0\% |
|  | Mar 2011 | 9 | 5 | 56\% | 371 | 192 | 52\% | - | - | 0\% | 103 | 65 | 63\% | - | - | 0\% |
|  | Apr 2011 | 10 | 9 | 90\% | 386 | 175 | 45\% | - | - | 0\% | 124 | 67 | 54\% | - | - | 0\% |
|  | May 2011 | 4 |  | 50\% | 346 | 158 | 46\% | - | - | 0\% | 98 | 53 | 54\% | - | - | 0\% |
|  | Jun 2011 | 4 | 2 | 50\% | 344 | 144 | 42\% | 1 | - | 0\% | 96 | 54 | 56\% | 1 | - | 0\% |
|  | Jul 2011 | 4 | 2 | 50\% | 350 | 170 | 49\% | - | - | 0\% | 80 | 51 | 64\% | - | - | 0\% |
|  | Aug 2011 | 5 | 2 | 40\% | 342 | 157 | 46\% | - | - | 0\% | 94 | 41 | 44\% | - | - | 0\% |
|  | Sep 2011 | 6 | 3 | 50\% | 337 | 161 | 48\% | - | - | 0\% | 87 | 47 | 54\% | - | - | 0\% |
|  | Oct 2011 | 3 | 2 | 67\% | 306 | 143 | 47\% | 2 | - | 0\% | 86 | 51 | 59\% | - | - | 0\% |
|  | Nov 2011 | 7 | 2 | 29\% | 300 | 155 | 52\% | - | - | 0\% | 85 | 46 | 54\% | - | - | 0\% |
|  | Dec 2011 | 5 | 4 | 80\% | 312 | 146 | 47\% | - | - | 0\% | 88 | 42 | 48\% | - | - | 0\% |
|  | Jan 2012 | 3 | 2 | 67\% | 310 | 148 | 48\% | - | - | 0\% | 108 | 54 | 50\% | - | - | 0\% |
|  | Feb 2012 | 7 | , | 43\% | 300 | 161 | 54\% | 1 | - | 0\% | 86 | 51 | 59\% | - | - | 0\% |
|  | Mar 2012 | 7 | 4 | 57\% | 314 | 157 | 50\% | - | - | 0\% | 84 | 47 | 56\% | - | - | 0\% |
|  | Apr 2012 | 7 | 3 | 43\% | 359 | 184 | 51\% | 1 | - | 0\% | 118 | 56 | 47\% | 1 | 1 | 100\% |
|  | May 2012 | 8 | 5 | 63\% | 363 | 189 | 52\% | 1 | - | 0\% | 98 | 52 | 53\% | - | - | 0\% |
|  | Jun 2012 | 4 | 2 | 50\% | 299 | 141 | 47\% | 1 | - | 0\% | 82 | 45 | 55\% | - | - | 0\% |
|  | Jul 2012 | 5 | 2 | 40\% | 331 | 170 | 51\% | - | - | 0\% | 103 | 52 | 50\% | - | - | 0\% |
|  | Aug 2012 | 2 | 1 | 50\% | 297 | 147 | 49\% | 1 | - | 0\% | 102 | 59 | 58\% | - | - | 0\% |
|  | Sep 2012 | 5 | 4 | 80\% | 283 | 135 | 48\% | 1 | - | 0\% | 89 | 47 | 53\% | 1 | 1 | 100\% |
|  | Oct 2012 | 3 | 1 | 33\% | 285 | 127 | 45\% | - | - | 0\% | 83 | 45 | 54\% | - | - | 0\% |
|  | Nov 2012 | 6 | 3 | 50\% | 336 | 157 | 47\% | - | - | 0\% | 105 | 48 | 46\% | 2 | 1 | 50\% |
|  | Dec 2012 | 9 | 3 | 33\% | 286 | 156 | 55\% | - | - | 0\% | 64 | 26 | 41\% | - | - | 0\% |
|  | Jan 2013 | 5 | , | 60\% | 302 | 146 | 48\% | 2 | 1 | 50\% | 103 | 43 | 42\% | - | - | 0\% |
|  | Feb 2013 | 3 | 2 | 67\% | 246 | 131 | 53\% | 2 | - | 0\% | 64 | 35 | 55\% | - | - | 0\% |
|  | Mar 2013 | 4 | 3 | 75\% | 248 | 123 | 50\% | - | - | 0\% | 80 | 40 | 50\% | - | - | 0\% |
|  | Apr 2013 | 11 | 4 | 36\% | 280 | 137 | 49\% | - | - | 0\% | 93 | 43 | 46\% | - | - | 0\% |
|  | May 2013 | 9 | 5 | 56\% | 307 | 152 | 50\% | 1 | 1 | 100\% | 83 | 46 | 55\% | - | - | 0\% |
|  | Jun 2013 | 5 | 3 | 60\% | 288 | 135 | 47\% | - | - | 0\% | 89 | 49 | 55\% | - | - | 0\% |
|  | Jul 2013 | 9 | 5 | 56\% | 272 | 134 | 49\% | $\cdots$ | - | 0\% | 88 | 48 | 55\% | - | - | 0\% |
|  | Aug 2013 | 7 | 2 | 29\% | 300 | 146 | 49\% | - | - | 0\% | 75 | 29 | 39\% | - | - | 0\% |
|  | Sep 2013 | 5 | 3 | 60\% | 276 | 131 | 47\% | 1 | - | 0\% | 75 | 38 | 51\% | - | - | 0\% |
|  | Oct 2013 | 4 | 1 | 25\% | 274 | 145 | 53\% | - | - | 0\% | 78 | 45 | 58\% | - | - | 0\% |
|  | Nov 2013 | 7 | 1 | 14\% | 265 | 125 | 47\% | - | - | 0\% | 71 | 42 | 59\% | - | - | 0\% |
|  | Dec 2013 | 6 | 4 | 67\% | 276 | 130 | 47\% | 1 | - | 0\% | 67 | 37 | 55\% | - |  | 0\% |


| Primary Tolerance Definition ( 230 mg per day in the prior 7 consecutive days) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Dose $100 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $112 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $125 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $137 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $150 \mathrm{mcg} / \mathrm{hr}$ |  |  |
|  |  | Total $\mathbf{N}$ of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{array}{\|c\|} \hline \mathrm{N} \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | \% with Prior Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with Prior Tolerance | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with <br> Prior <br> Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with Prior Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with <br> Prior Tolerance |
| Age (years) | Total | 4,524 | 2,410 | 53\% | 5 | 4 | 80\% | 179 | 88 | 49\% | 2 | 1 | 50\% | 233 | 119 | 51\% |
|  | $0-11$ years | 6 | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% | 0 | 0 | 0\% |
|  | 12-17 years | 9 | 2 | 22\% | - | - | 0\% | 1 | - | 0\% | - | - | 0\% | 2 | 0 | 0\% |
|  | 18-24 years | 91 | 43 | 47\% | - | - | 0\% | 2 | 2 | 100\% | - | - | 0\% | ${ }^{5}$ | 4 | 80\% |
|  | 25-34 years | 375 | 226 | 60\% | - | - | 0\% | 10 | 8 | 80\% | - | - | 0\% | 13 | 6 | 46\% |
|  | 35-44 years | 870 | 492 | 57\% | 1 | 1 | 100\% | 30 | 15 | 50\% | - | - | 0\% | 37 | 22 | 59\% |
|  | 45.54 years | 1,644 | 892 | 54\% | 1 | 1 | 100\% | 72 | 33 | 46\% | 1 | - | 0\% | 88 | 45 | 51\% |
|  | $55-64$ years | 1,529 | 755 | 49\% | 3 | , | 67\% | 64 | 30 | 47\% | 1 | 1 | 100\% | 88 | 42 | 48\% |
| Gender | Male | 2,316 | 1,323 | 57\% | 2 | 2 | 100\% | 83 | 43 | 52\% | - |  | 0\% | 125 | 70 | 56\% |
|  | Female | 2,208 | 1,087 | 49\% | 3 | , | 67\% | 96 | 45 | 47\% | 2 | 1 | 50\% | 108 | 49 | 45\% |
|  | Ambiguous | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% | 0 | 0 | 0\% |
|  | Unknown | . | . | 0\% | . | . | 0\% | . | . | 0\% | . | . | 0\% | 0 | 0 | 0\% |
|  | Jan 2009 | 131 | 56 | 43\% | 1 | 1 | 100\% | 5 | 3 | 60\% | - | - | 0\% | 7 | 3 | 43\% |
| Month and Year of | Feb 2009 | 132 | 69 | 52\% | - | - | 0\% | 5 | 1 | 20\% | - | - | 0\% | 3 | 2 | 67\% |
| Episode Start Date | Mar 2009 | 101 | 48 | 48\% | - | - | 0\% | 4 | 1 | 25\% | - | - | 0\% | 2 | 1 | 50\% |
|  | Apr 2009 | 120 | 66 | 55\% | - | - | 0\% | 5 | 3 | 60\% | - | - | 0\% | 7 | 3 | 43\% |
|  | May 2009 | 122 | 57 | 47\% | - | - | 0\% | 4 | 3 | 75\% | - | - | 0\% | 8 | 5 | 63\% |
|  | Jun 2009 | 107 | 64 | 60\% | - | - | 0\% | 4 | 3 | 75\% | - | - | 0\% | 9 | 6 | 67\% |
|  | Jul 2009 | 114 | 57 | 50\% | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% | 3 | 1 | 33\% |
|  | Aug 2009 | 98 | 49 | 50\% | - | - | 0\% | ${ }^{3}$ | 1 | 33\% | - | - | 0\% | 5 | 0 | 0\% |
|  | Sep 2009 | 89 | 42 | 47\% | - | - | 0\% | 1 | - | 0\% | - | - | 0\% | 5 | 3 | 60\% |
|  | Oct 2009 | 108 | 58 | 54\% | - | - | 0\% | 2 | - | 0\% | - | - | 0\% | 6 | 2 | 33\% |
|  | Nov 2009 | 93 | 50 | 54\% | - | - | 0\% | 3 | 2 | 67\% | - | - | 0\% | 7 | 5 | 71\% |
|  | Dec 2009 | 96 | 52 | 54\% | - | - | 0\% | 5 | 2 | 40\% | - | - | 0\% | 7 | 5 | 71\% |
|  | Jan 2010 | 115 | 63 | 55\% | - | - | 0\% | 10 | 2 | 20\% | - | - | 0\% | 7 | 3 | 43\% |
|  | Feb 2010 | 74 | 35 | 47\% | - | - | 0\% | 6 | 1 | 17\% | - | - | 0\% | 5 | 3 | 60\% |
|  | Mar 2010 | 71 | 38 | 54\% | - | - | 0\% | 3 | - | 0\% | - | - | 0\% | 5 | 3 | 60\% |
|  | Apr 2010 | 98 | 64 | 65\% | - | - | 0\% | 3 | 1 | 33\% | - | - | 0\% | 6 | 5 | 83\% |
|  | May 2010 | 75 | 44 | 59\% | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% | 5 | 3 | 60\% |
|  | Jun 2010 | 71 | 47 | 66\% | - | - | 0\% | 6 | 3 | 50\% | - | - | 0\% | 5 | 2 | 40\% |
|  | Jul 2010 | 66 | 41 | 62\% | - | - | 0\% | 4 | 3 | 75\% | - | - | 0\% | 6 | 4 | 67\% |
|  | Aug 2010 | 86 | 52 | 60\% | 1 | - | 0\% | 3 | 1 | 33\% | - | - | 0\% | ${ }^{3}$ | 0 | 0\% |
|  | Sep 2010 | 84 | 47 | 56\% | - | - | 0\% | 1 | - | 0\% | - | - | 0\% | 3 | 0 | 0\% |
|  | Oct 2010 | 75 | 53 | 71\% | - | - | 0\% | 7 | 6 | 86\% | 1 | 1 | 100\% | 5 | 4 | 80\% |
|  | Nov 2010 | 70 | 37 | 53\% | - | - | 0\% | 2 | 2 | 100\% | - | - | 0\% | ${ }^{3}$ | 2 | 67\% |
|  | Dec 2010 | 77 | 35 | 45\% | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% | 4 | 2 | 50\% |
|  | Jan 2011 | 115 | 59 | 51\% | - | - | 0\% | 3 | 1 | 33\% | - | - | 0\% | 5 | 2 | 40\% |
|  | Feb 2011 | 77 | 45 | 58\% | 1 | 1 | 100\% | 2 | - | 0\% | - | - | 0\% | 3 | 1 | 33\% |
|  | Mar 2011 | 101 | 56 | 55\% | - | - | 0\% | 3 | 1 | 33\% | - | - | 0\% | 4 | 1 | 25\% |
|  | Apr 2011 | 70 | 31 | 44\% | - | - | 0\% | 5 | 2 | 40\% | - | - | 0\% | 7 | 4 | 57\% |
|  | May 2011 | 69 | 38 | 55\% | - |  | 0\% | 5 | 1 | 20\% |  | - | 0\% | 4 | 1 | 25\% |
|  | Jun 2011 | 59 | 31 | 53\% | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% | 0 | 0 | 0\% |
|  | Jul 2011 | 53 | 28 | 53\% | - | - | 0\% | 2 | - | 0\% | - | - | 0\% | 4 | 4 | 100\% |
|  | Aug 2011 | 52 | 34 | 65\% | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% | 1 | 1 | 100\% |
|  | Sep 2011 | 55 | 31 | 56\% | - | - | 0\% | 4 | 2 | 50\% | 1 | - | 0\% | 5 | 4 | 80\% |
|  | Oct 2011 | 68 | 37 | 54\% | - |  | 0\% | 2 | 2 | 100\% | - | - | 0\% | 1 | 0 | 0\% |
|  | Nov 2011 | 62 | 29 | 47\% | - | - | 0\% | 1 | 1 | 100\% | - | . | 0\% | 2 | 1 | 50\% |
|  | Dec 2011 | 73 | 41 | 56\% | - | - | 0\% | 4 | 2 | 50\% | \% | - | 0\% | 2 | 2 | 100\% |
|  | Jan 2012 | 69 | 35 | 51\% | - | - | 0\% | 3 | 2 | 67\% | - | - | 0\% | 3 | 2 | 67\% |
|  | Feb 2012 | 60 | 37 | 62\% | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% | 6 | 4 | 67\% |
|  | Mar 2012 | 61 | 35 | 57\% | - |  | 0\% | 3 | 3 | 100\% | - | - | 0\% | 2 | 1 | 50\% |
|  | Apr 2012 | 74 | 37 | 50\% | 1 | 1 | 100\% | 5 | 5 | 100\% | - | - | 0\% | 6 | 3 | 50\% |
|  | May 2012 | 77 | 43 | 56\% | - | - | 0\% | 4 | - | 0\% | - | - | 0\% | 0 | 0 | 0\% |
|  | Jun 2012 | 64 | 37 | 58\% | - | - | 0\% | 2 | 2 | 100\% | - | - | 0\% | 6 | 1 | 17\% |
|  | Jul 2012 | 52 | 22 | 42\% | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% | 0 | 0 | 0\% |
|  | Aug 2012 | 61 | 39 | 64\% | - | - | 0\% | 4 | 3 | 75\% | - | - | 0\% | 1 | 1 | 100\% |
|  | Sep 2012 | 48 | 26 | 54\% | - | - | 0\% | 2 | 2 | 100\% | - | - | 0\% | 2 | 1 | 50\% |
|  | Oct 2012 | 60 | 23 | 38\% | - | - | 0\% | 4 | 2 | 50\% | - | - | 0\% | 2 | 2 | 100\% |
|  | Nov 2012 | 77 | 39 | 51\% | - | - | 0\% | 2 | 2 | 100\% | - | - | 0\% | 5 | 2 | 40\% |
|  | Dec 2012 | 54 | 23 | 43\% | - | - | 0\% | 3 | 1 | 33\% | + | - | 0\% | 1 | 0 | 0\% |
|  | Jan 2013 | 64 | 30 | 47\% |  | - | 0\% | 4 | - | 0\% | - | - | 0\% | 4 | 0 | 0\% |
|  | Feb 2013 | 52 | 27 | 52\% | 1 | 1 | 100\% | 3 | 1 | 33\% |  | - | 0\% | 0 | 0 | 0\% |
|  | Mar 2013 | 40 | 21 | 53\% | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% | 3 | 1 | 33\% |
|  | Apr 2013 | 59 | 30 | 51\% | - | - | 0\% | - | - | 0\% | - | - | 0\% | 5 | 2 | 40\% |
|  | May 2013 | 54 | 30 | 56\% | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% | 3 | 1 | 33\% |
|  | Jun 2013 | 55 | 28 | 51\% |  | - | 0\% | - |  | 0\% | - | - | 0\% | 5 | 1 | 20\% |
|  | Jul 2013 | 60 | 25 | 42\% | - | - | 0\% | 2 | 2 | 100\% | + | - | 0\% | 3 | 2 | 67\% |
|  | Aug 2013 | 39 | 17 | 44\% |  |  | 0\% | 2 | 2 | 100\% | - | - | 0\% | 2 | 1 | 50\% |
|  | Sep 2013 | 52 | 25 | 48\% | - | - | 0\% | 1 | - | 0\% | - | - | 0\% | 3 | 1 | 33\% |
|  | Oct 2013 | 56 | 35 | 63\% | - | - | 0\% | 3 | 1 | 33\% | - | - | 0\% | 1 | 1 | 100\% |
|  | Nov 2013 | 57 | 30 | 53\% | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% | 3 | 2 | 67\% |
|  | Dec 2013 | 52 | 32 | 62\% | - | - | 0\% | 1 | - | 0\% | - | - | 0\% | 3 | 2 | 67\% |


| Primary Tolerance Definition ( 230 mg per day in the prior 7 consecutive days) |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Dose $162 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $175 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $200 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $225 \mathrm{mcg} / \mathrm{hr}$ |  |  |
|  |  | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with <br> Prior <br> Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with <br> Prior <br> Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with <br> Prior Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with <br> Prior <br> Tolerance |
| Age (years) | Total | 2 | 1 | 50\% | 52 | 25 | 48\% | 5 | 3 | 60\% | 4 | 0 | 0\% |
|  | $0 \cdot 11$ years | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | 12-17 years | 0 | 0 | 0\% | 1 | 1 | 100\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | 18-24 years | 1 | 0 | 0\% | 3 | 3 | 100\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | 25-34 years | 0 |  | 0\% | ${ }^{3}$ | 2 | 67\% | 0 | 0 | 0\% | 1 | 0 | 0\% |
|  | 35-44 years | 0 |  | 0\% | 7 | 4 | 57\% | 3 | 2 | 67\% | 1 | 0 | 0\% |
|  | $45-54$ years | 0 | 0 | 0\% | 17 | 7 | 41\% | 2 | 1 | 50\% | 0 | 0 | 0\% |
|  | $55-64$ years | 1 | , | 100\% | 21 | 8 | 38\% | 0 | 0 | 0\% | 2 | 0 | 0\% |
| Gender | Male | 2 | 1 | 50\% | 17 | 11 | 65\% | 5 | 3 | 60\% | 2 | 0 | 0\% |
|  | Female | 0 | 0 | 0\% | 35 | 14 | 40\% | 0 | 0 | 0\% | 2 | 0 | 0\% |
|  | Ambiguous | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Unknown | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
| Month and Year of Episode Start Date | Jan 2009 | 0 | 0 | 0\% | ${ }^{2}$ | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Feb 2009 | 0 | 0 | 0\% | 2 | 1 | 50\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Mar 2009 | 0 | 0 | 0\% | 2 | 2 | 100\% | 1 | 0 | 0\% | 1 | 0 | 0\% |
|  | Apr 2009 | 0 |  | 0\% | ${ }^{4}$ | 4 | 100\% | 1 | 1 | 100\% | 0 | 0 | 0\% |
|  | May 2009 | 0 | 0 | 0\% | 1 | 1 | 100\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Jun 2009 | 0 | 0 | 0\% | 1 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Jul 2009 | 0 | 0 | 0\% | 2 | 0 | 0\% | 0 | 0 | 0\% | 1 | 0 | 0\% |
|  | Aug 2009 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Sep 2009 | 0 | 0 | 0\% | 2 | 1 | 50\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Oct 2009 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Nov 2009 | 0 | 0 | 0\% | 1 | 1 | 100\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Dec 2009 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Jan 2010 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Feb 2010 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Mar 2010 | 0 | 0 | 0\% | 1 | 1 | 100\% | 1 | 1 | 100\% | 0 | 0 | 0\% |
|  | Apr 2010 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | May 2010 | 0 | 0 | 0\% | 1 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Jun 2010 | 0 | 0 | 0\% | 1 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Jul 2010 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Aug 2010 | 0 | 0 | 0\% | 2 | 2 | 100\% | 0 | 0 | 0\% | 1 | 0 | 0\% |
|  | Sep 2010 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Oct 2010 | 0 | 0 | 0\% | 1 | 1 | 100\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Nov 2010 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Dec 2010 | 0 | 0 | 0\% | 1 | 1 | 100\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Jan 2011 | 1 | 0 | 0\% | 1 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Feb 2011 | 0 | 0 | 0\% | 2 | 1 | 50\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Mar 2011 | 0 | 0 | 0\% | 2 | 1 | 50\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Apr 2011 | 0 | 0 | 0\% | 2 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | May 2011 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Jun 2011 | 0 | 0 | 0\% | 2 | 1 | 50\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Jul 2011 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Aug 2011 | 0 | 0 | 0\% | 1 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Sep 2011 | 1 | 1 | 100\% | 3 | 1 | 33\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Oct 2011 | 0 | 0 | 0\% | 2 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Nov 2011 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Dec 2011 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Jan 2012 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Feb 2012 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Mar 2012 | 0 | 0 | 0\% | 1 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Apr 2012 | 0 | 0 | 0\% | 2 | 1 | 50\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | May 2012 | 0 | 0 | 0\% | 1 | 1 | 100\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Jun 2012 | 0 | 0 | 0\% | 1 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Jul 2012 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Aug 2012 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Sep 2012 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Oct 2012 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Nov 2012 | 0 | 0 | 0\% | 1 | 0 | 0\% | 0 | 0 | 0\% | 1 | 0 | 0\% |
|  | Dec 2012 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Jan 2013 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Feb 2013 | 0 | 0 | 0\% | 1 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Mar 2013 | 0 | 0 | 0\% | 1 | 1 | 100\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Apr 2013 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | May 2013 | 0 | 0 | 0\% | 1 | 1 | 100\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Jun 2013 | 0 | 0 | 0\% | 1 | 0 | 0\% | 2 | 1 | 50\% | 0 | 0 | 0\% |
|  | Jul 2013 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Aug 2013 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Sep 2013 | 0 | 0 | 0\% | 1 | 1 | 100\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Oct 2013 | 0 | 0 | 0\% | 1 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Nov 2013 | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Dec 2013 | 0 | 0 | 0\% | 1 | 1 | 100\% | 0 | 0 | 0\% | 0 | 0 | 0\% |


| Secondary Tolerance Definition ( 230 mg per day for seven days in the 30 days prior) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Dose $12 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $24 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $25 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $36 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $37 \mathrm{mcg} / \mathrm{hr}$ |  |  |
|  |  | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | $N$ with <br> Prior <br> Tolerance | \% with <br> Prior <br> Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | $\begin{aligned} & \text { \% with } \\ & \text { Prior } \\ & \text { Tolerance } \end{aligned}$ | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with <br> Prior <br> Tolerance | \% with <br> Prior <br> Tolerance | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with <br> Prior <br> Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with <br> Prior Tolerance |
| Age (years) | Total | 17,812 | 8,518 | 47.8\% | 3 |  | $267 \%$ | 49,148 | 28,665 | 58.3\% | 1 | 0 | 0\% | 339 | 233 | 69\% |
|  | $0-11$ years | 34 | 2 | 5.9\% | . |  | 0 0\% | 25 | 4 | 16.0\% | 0 | 0 | 0\% | 1 | 0 | 0\% |
|  | 12-17 years | 81 | 18 | 22.2\% | - |  | 0 0\% | 85 | 25 | 29.4\% | 0 | 0 | 0\% | 2 | 0 | 0\% |
|  | 18.24 years | 412 | 164 | 39.8\% | - |  | 0 0\% | 925 | 494 | 53.4\% | 0 | 0 | 0\% | 9 | 6 | 67\% |
|  | 25-34 years | 1,605 | 898 | 56.0\% | - |  | 0 0\% | 4,297 | 2,845 | 66.2\% | 1 | 0 | 0\% | 27 | 22 | 81\% |
|  | 35-44 years | 3,153 | 1,661 | 52.7\% | 2 |  | 1 50\% | 8,915 | 5,544 | 62.2\% | 0 | 0 | 0\% | 71 | 45 | 63\% |
|  | 45 - 54 years | 5,672 | 2,741 | 48.3\% | - |  | 0 0\% | 16,409 | 9,658 | 58.9\% | 0 | 0 | 0\% | 99 | 72 | 73\% |
|  | 55-64 years | 6,855 | 3,034 | 44.3\% | 1 |  | 1 100\% | 18,492 | 10,095 | 54.6\% | 0 | 0 | 0\% | 130 | 88 | 68\% |
| Gender | Male | 5,595 | 2,786 | 49.8\% | 1 |  | 1 100\% | 20,233 | 12,138 | 60.\% | 0 | 0 | 0\% | 145 | 104 | 72\% |
|  | Female | 12,217 | 5,732 | 46.9\% | 2 |  | 1 50\% | 28,915 | 16,527 | 57.2\% | 1 | 0 | 0\% | 194 | 129 | 66\% |
|  | Ambiguous | - | - | 0.0\% | - |  | 0 0\% | - | - | 0.0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Unknown | 0 | 0 | 0 | 0 |  | 0 0\% | $\cdot$ | 0 | 0 | 0 | 0 | 0\% | 0 | 0 | 0\% |
| Month and Year of Episode Start Date | Jan 2009 | 238 | 115 | 48.3\% | - |  | 0 0\% | 1,070 | 609 | 56.9\% | 0 | 0 | 0\% | 6 | 6 | 100\% |
|  | Feb 2009 | 227 | 107 | 47.1\% | - |  | 0 0\% | 992 | 576 | 58.1\% | 0 | 0 | 0\% | 9 | 5 | 56\% |
|  | Mar 2009 | 284 | 128 | 45.1\% | - |  | 0 0\% | 1,072 | 596 | 55.6\% | 0 | 0 | 0\% | 5 | 5 | 100\% |
|  | Apr 2009 | 251 | 108 | 43.0\% | - |  | 0 0\% | 1,147 | 618 | 53.9\% | 1 | 0 | 0\% | 4 | 2 | 50\% |
|  | May 2009 | 283 | 136 | 48.1\% | - |  | 0 0\% | 1,039 | 603 | 58.0\% | 0 | 0 | 0\% | 6 | 5 | 83\% |
|  | Jun 2009 | 300 | 120 | 40.0\% | - |  | 0 0\% | 1,080 | 624 | 57.8\% | 0 | 0 | 0\% | 8 | 6 | 75\% |
|  | Jul 2009 | 267 | 124 | 46.4\% | - |  | 0 0\% | 966 | 539 | 55.8\% | 0 | 0 | 0\% | 8 | 5 | 63\% |
|  | Aug 2009 | 284 | 135 | 47.5\% | - |  | 0 0\% | 946 | 503 | 53.2\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Sep 2009 | 318 | 149 | 46.9\% | - |  | 0 0\% | 1,007 | 585 | 58.1\% | 0 | 0 | 0\% | 5 | 5 | 100\% |
|  | Oct 2009 | 278 | 136 | 48.9\% | - |  | 0 0\% | 948 | 549 | 57.9\% | 0 | 0 | 0\% | 1 | 1 | 100\% |
|  | Nov 2009 | 244 | 112 | 45.9\% | - |  | 0 0\% | 898 | 471 | 52.4\% | 0 | 0 | 0\% | 8 | 5 | 63\% |
|  | Dec 2009 | 261 | 125 | 47.9\% | - |  | 0 0\% | 970 | 562 | 57.9\% | 0 | 0 | 0\% | 8 | 5 | 63\% |
|  | Jan 2010 | 245 | 100 | 40.8\% | - |  | 0 0\% | 881 | 487 | 55.3\% | 0 | 0 | 0\% | 6 | 0 | 0\% |
|  | Feb 2010 | 254 | 125 | 49.2\% | $\cdot$ |  | 0 0\% | 790 | 458 | 58.0\% | 0 | 0 | 0\% | 9 | 7 | 78\% |
|  | Mar 2010 | 283 | 123 | 43.5\% | - |  | 0 0\% | 853 | 479 | 56.2\% | 0 | 0 | 0\% | 8 | 6 | 75\% |
|  | Apr 2010 | 289 | 139 | 48.1\% | - |  | 0 0\% | 958 | 549 | 57.3\% | 0 | 0 | 0\% | 4 | 2 | 50\% |
|  | May 2010 | 261 | 141 | 54.0\% | - |  | 0 0\% | 845 | 528 | 62.5\% | 0 | 0 | 0\% | 6 | 2 | 33\% |
|  | Jun 2010 | 285 | 136 | 47.7\% | - |  | 0 0\% | 884 | 511 | 57.8\% | 0 | 0 | 0\% | 7 | 4 | 57\% |
|  | Jul 2010 | 239 | 110 | 46.0\% | - |  | 0 0\% | 837 | 507 | 60.6\% | 0 | 0 | 0\% | 5 | 4 | 80\% |
|  | Aug 2010 | 270 | 124 | 45.9\% | - |  | 0 0\% | 871 | 502 | 57.6\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Sep 2010 | 320 | 162 | 50.6\% | - |  | 0 0\% | 908 | 557 | 61.3\% | 0 | 0 | 0\% | 2 | 2 | 100\% |
|  | Oct 2010 | 313 | 130 | 41.5\% | - |  | 0 0\% | 843 | 483 | 57.3\% | 0 | 0 | 0\% | 5 | 5 | 100\% |
|  | Nov 2010 | 306 | 154 | 50.3\% | - |  | 0 0\% | 889 | 538 | 60.5\% | 0 | 0 | 0\% | 8 | 6 | 75\% |
|  | Dec 2010 | 307 | 147 | 47.9\% | - |  | 0 0\% | 796 | 474 | 59.5\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Jan 2011 | 264 | 122 | 46.2\% | - |  | 0 0\% | 774 | 447 | 57.8\% | 0 | 0 | 0\% | 1 | 1 | 100\% |
|  | Feb 2011 | 279 | 122 | 43.7\% | - |  | 0 0\% | 674 | 398 | 59.1\% | 0 | 0 | 0\% | 3 | 3 | 100\% |
|  | Mar 2011 | 292 | 132 | 45.2\% | - |  | 0 0\% | 845 | 516 | 61.1\% | 0 | 0 | 0\% | 9 | 6 | 67\% |
|  | Apr 2011 | 307 | 156 | 50.8\% | - |  | 0 0\% | 812 | 473 | 58.3\% | 0 | 0 | 0\% | 10 | 9 | 90\% |
|  | May 2011 | 299 | 140 | 46.8\% | - |  | 0 0\% | 795 | 438 | 55.1\% | 0 | 0 | 0\% | 4 | 3 | 75\% |
|  | Jun 2011 | 316 | 154 | 48.7\% | - |  | 0 0\% | 777 | 458 | 58.9\% | 0 | 0 | 0\% | 4 | 2 | 50\% |
|  | Jul 2011 | 294 | 136 | 46.3\% | - |  | 0 0\% | 728 | 419 | 57.6\% | 0 | 0 | 0\% | 4 | 2 | 50\% |
|  | Aug 2011 | 328 | 176 | 53.7\% | - |  | 0 0\% | 820 | 450 | 54.9\% | 0 | 0 | 0\% | 5 | 3 | 60\% |
|  | Sep 2011 | 307 | 149 | 48.5\% | - |  | 0 0\% | 795 | 480 | 60.4\% | 0 | 0 | 0\% | 6 | 5 | 83\% |
|  | Oct 2011 | 279 | 145 | 52.0\% | - |  | 0 0\% | 768 | 469 | 61.1\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Nov 2011 | 306 | 147 | 48.0\% | - |  | 0 0\% | 718 | 437 | 60.9\% | 0 | 0 | 0\% | 7 | 4 | 57\% |
|  | Dec 2011 | 323 | 159 | 49.2\% | - |  | 0 0\% | 747 | 436 | 58.4\% | 0 | 0 | 0\% | 5 | 5 | 100\% |
|  | Jan 2012 | 298 | 136 | 45.6\% | - |  | 0 0\% | 776 | 464 | 59.8\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Feb 2012 | 269 | 127 | 47.2\% | - |  | 0 0\% | 696 | 384 | 55.2\% | 0 | 0 | 0\% | 7 | 5 | 71\% |
|  | Mar 2012 | 307 | 146 | 47.6\% | - |  | 0 0\% | 738 | 441 | 59.8\% | 0 | 0 | 0\% | 7 | 5 | 71\% |
|  | Apr 2012 | 316 | 152 | 48.1\% | - |  | 0 0\% | 803 | 465 | 57.9\% | 0 | 0 | 0\% | 7 | 3 | 43\% |
|  | May 2012 | 389 | 174 | 44.7\% | - |  | 0 0\% | 786 | 476 | 60.6\% | 0 | 0 | 0\% | 8 | 6 | 75\% |
|  | Jun 2012 | 293 | 140 | 47.8\% | - |  | 0 0\% | 683 | 404 | 59.2\% | 0 | 0 | 0\% | 4 | 3 | 75\% |
|  | Jul 2012 | 315 | 168 | 53.3\% | - |  | 0 0\% | 672 | 394 | 58.6\% | 0 | 0 | 0\% | 5 | 4 | 80\% |
|  | Aug 2012 | 324 | 172 | 53.1\% | - |  | 0 0\% | 857 | 508 | 59.3\% | 0 | 0 | 0\% | 2 | 2 | 100\% |
|  | Sep 2012 | 290 | 144 | 49.7\% | - |  | 0 0\% | 705 | 424 | 60.1\% | 0 | 0 | 0\% | 5 | 5 | 100\% |
|  | Oct 2012 | 330 | 161 | 48.8\% | - |  | 0 0\% | 754 | 468 | 62.1\% | 0 | 0 | 0\% | 3 | 1 | 33\% |
|  | Nov 2012 | 332 | 160 | 48.2\% | - |  | 0 0\% | 775 | 435 | 56.1\% | 0 | 0 | 0\% | 6 | 3 | 50\% |
|  | Dec 2012 | 316 | 156 | 49.4\% | - |  | 0 0\% | 666 | 394 | 59.2\% | 0 | 0 | 0\% | 9 | 5 | 56\% |
|  | Jan 2013 | 296 | 143 | 48.3\% | - |  | 0 0\% | 650 | 383 | 58.9\% | 0 | 0 | 0\% | 5 | 3 | 60\% |
|  | Feb 2013 | 275 | 136 | 49.5\% | - |  | 0 0\% | 675 | 419 | 62.1\% | 0 | 0 | 0\% | 3 | 3 | 100\% |
|  | Mar 2013 | 274 | 142 | 51.8\% | - |  | 0 0\% | 632 | 382 | 60.4\% | 0 | 0 | 0\% | 4 | 4 | 100\% |
|  | Apr 2013 | 327 | 179 | 54.7\% | - |  | 0 0\% | 724 | 440 | 60.8\% | 0 | 0 | 0\% | 11 | 7 | 64\% |
|  | May 2013 | 293 | 131 | 44.7\% | - |  | 0 0\% | 754 | 448 | 59.4\% | 0 | 0 | 0\% | 9 | 6 | 67\% |
|  | Jun 2013 | 306 | 140 | 45.8\% | 1 |  | 0 0\% | 701 | 428 | 61.1\% | 0 | 0 | 0\% | 5 | 4 | 80\% |
|  | Jul 2013 | 345 | 170 | 49.3\% | - |  | 0 0\% | 719 | 434 | 60.4\% | 0 | 0 | 0\% | 9 | 7 | 78\% |
|  | Aug 2013 | 358 | 169 | 47.2\% | - |  | 0 0\% | 780 | 460 | 59.0\% | 0 | 0 | 0\% | 7 | 4 | 57\% |
|  | Sep 2013 | 323 | 152 | 47.1\% | - |  | 0 0\% | 687 | 402 | 58.5\% | 0 | 0 | 0\% | 5 | 3 | 60\% |
|  | Oct 2013 | 366 | 178 | 48.6\% | 1 |  | 1 100\% | 784 | 475 | 60.6\% | 0 | 0 | 0\% | 4 | 2 | 50\% |
|  | Nov 2013 | 344 | 162 | 47.1\% | 1 |  | 1 100\% | 702 | 418 | 59.5\% | 0 | 0 | 0\% | 7 | 2 | 29\% |
|  | Dec 2013 | 325 | 156 | 48.0\% | 0 | - | 0 0\% | 686 | 390 | 56.9\% | 0 | 0 | 0\% | 6 | 5 | 83\% |


| Secondary Tolerance Definition ( 230 mg per day for seven days in the $\mathbf{3 0}$ days prior) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Dose $50 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $62 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $75 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $87 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $100 \mathrm{mcg} / \mathrm{hr}$ |  |  |
|  |  | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with Prior Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | $\qquad$ | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | $N$ with Prior Tolerance | $\%$ with Prior Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | $\%$ with <br> Prior <br> Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with Prior Tolerance |
| Age (years) | Total | 21,245 | 14,126 | 66\% | 26 | 8 | 31\% | 6,215 | 4,211 | 68\% | 14 | 7 | 50\% | 4,524 | 3,032 | 67\% |
|  | 0.11 years | 8 | 3 | 38\% | 1 | 0 | 0\% | 3 | - | 0\% | 0 | 0 | 0\% | 6 | 1 | 17\% |
|  | $12 \cdot 17$ years | 37 | 17 | 46\% | 0 | 0 | 0\% | 14 | 4 | 29\% | 0 | 0 | 0\% | 9 | 3 | 33\% |
|  | 18.24 years | 423 | 254 | 60\% | 2 | 0 | 0\% | 121 | 76 | 63\% | 0 | 0 | 0\% | 91 | 52 | 57\% |
|  | $25-34$ years | 1,911 | 1,387 | 73\% | 2 | 0 | 0\% | 614 | 443 | 72\% | 2 | 2 | 100\% | 375 | 284 | 76\% |
|  | 35-44 years | 4,031 | 2,875 | 71\% | 6 | 2 | 33\% | 1,229 | 857 | 70\% | 1 | 0 | 0\% | 870 | 607 | 70\% |
|  | 45.54 years | 7,320 | 4,882 | 67\% | 11 | 4 | 36\% | 2,201 | 1,507 | 68\% | 6 | 4 | 67\% | 1,644 | 1,121 | 68\% |
|  | 55-64 years | 7,515 | 4,708 | 63\% | ${ }^{4}$ | 2 | 50\% | 2,033 | 1,324 | 65\% | 5 | 1 | 20\% | 1,529 | 964 | 63\% |
| Gender | Male | 9,916 | 6,779 | 68\% | 13 | 7 | 54\% | 2,974 | 2,091 | 70\% | 6 | 4 | 67\% | 2,316 | 1,621 | 70\% |
|  | Female | 11,329 | 7,347 | 65\% | 13 | 1 | 8\% | 3,241 | 2,120 | 65\% | 8 | 3 | 38\% | 2,208 | 1,411 | 64\% |
|  | Ambiguous | - | - | 0\% | 0 | 0 | 0\% | - | - | 0\% | 0 | 0 | 0\% | - | - | 0\% |
|  | Unknown | . | . | 0\% | 0 | 0 | 0\% | . | . | 0\% | 0 | 0 | 0\% | . | - | 0\% |
| Month and Year of Episode Start Date | Jan 2009 | 490 | 318 | 65\% | 2 | 2 | 100\% | 189 | 112 | 59\% | 1 | 0 | 0\% | 131 | 79 | 60\% |
|  | Feb 2009 | 484 | 338 | 70\% | 0 | 0 | 0\% | 152 | 99 | 65\% | 0 | 0 | 0\% | 132 | 92 | 70\% |
|  | Mar 2009 | 492 | 332 | 67\% | 0 | 0 | 0\% | 140 | 85 | 61\% | 0 | 0 | 0\% | 101 | 60 | 59\% |
|  | Apr 2009 | 532 | 355 | 67\% | 0 | 0 | 0\% | 147 | 104 | 71\% | 0 | 0 | 0\% | 120 | 85 | 71\% |
|  | May 2009 | 470 | 290 | 62\% | 0 | 0 | 0\% | 146 | 91 | 62\% | 0 | 0 | 0\% | 122 | 76 | 62\% |
|  | Jun 2009 | 496 | 317 | 64\% | 0 | 0 | 0\% | 138 | 93 | 67\% | 1 | 0 | 0\% | 107 | 72 | 67\% |
|  | Jul 2009 | 440 | 280 | 64\% | 2 | 0 | 0\% | 112 | 75 | 67\% | 1 | 1 | 100\% | 114 | 70 | 61\% |
|  | Aug 2009 | 398 | 259 | 65\% | 0 | 0 | 0\% | 129 | 89 | 69\% | 0 | 0 | 0\% | 98 | 61 | 62\% |
|  | Sep 2009 | 457 | 302 | 66\% | 0 | 0 | 0\% | 108 | 82 | 76\% | 2 | 1 | 50\% | 89 | 55 | 62\% |
|  | Oct 2009 | 486 | 297 | 61\% | 1 | 0 | 0\% | 123 | 83 | 67\% | 0 | 0 | 0\% | 108 | 73 | 68\% |
|  | Nov 2009 | 402 | 257 | 64\% | 1 | 1 | 100\% | 108 | 79 | 73\% | 0 | 0 | 0\% | 93 | 60 | 65\% |
|  | Dec 2009 | 429 | 278 | 65\% | 0 | 0 | 0\% | 135 | 90 | 67\% | 1 | 0 | 0\% | 96 | 67 | 70\% |
|  | Jan 2010 | 406 | 255 | 63\% | 0 | 0 | 0\% | 120 | 72 | 60\% | 0 | 0 | 0\% | 115 | 76 | 66\% |
|  | Feb 2010 | 362 | 226 | 62\% | 1 | 0 | 0\% | 100 | 61 | 61\% | 1 | 1 | 100\% | 74 | 46 | 62\% |
|  | Mar 2010 | 354 | 229 | 65\% | 0 | 0 | 0\% | 132 | 87 | 66\% | 0 | 0 | 0\% | 71 | 44 | 62\% |
|  | Apr 2010 | 368 | 244 | 66\% | 0 | 0 | 0\% | 122 | 91 | 75\% | 0 | 0 | 0\% | 98 | 74 | 76\% |
|  | May 2010 | 388 | 250 | 64\% | 0 | 0 | 0\% | 109 | 66 | 61\% | 1 | 0 | 0\% | 75 | 54 | 72\% |
|  | Jun 2010 | 402 | 267 | 66\% | 1 | 0 | 0\% | 103 | 77 | 75\% | 0 | 0 | 0\% | 71 | 53 | 75\% |
|  | Jul 2010 | 371 | 255 | 69\% | 0 | 0 | 0\% | 98 | 64 | 65\% | 0 | 0 | 0\% | 66 | 51 | 77\% |
|  | Aug 2010 | 363 | 239 | 66\% | 0 | 0 | 0\% | 116 | 76 | 66\% | 0 | 0 | 0\% | 86 | 62 | 72\% |
|  | Sep 2010 | 373 | 249 | 67\% | 1 | 1 | 100\% | 105 | 78 | 74\% | 0 | 0 | 0\% | 84 | 59 | 70\% |
|  | Oct 2010 | 383 | 268 | 70\% | 0 | 0 | 0\% | 115 | 78 | 68\% | 0 | 0 | 0\% | 75 | 61 | 81\% |
|  | Nov 2010 | 353 | 243 | 69\% | 0 | 0 | 0\% | 102 | 79 | 77\% | 1 | 0 | 0\% | 70 | 50 | 71\% |
|  | Dec 2010 | 404 | 256 | 63\% | 0 | 0 | 0\% | 90 | 67 | 74\% | 0 | 0 | 0\% | 77 | 42 | 55\% |
|  | Jan 2011 | 346 | 220 | 64\% | 1 | 1 | 100\% | 138 | 88 | 64\% | 0 | 0 | 0\% | 115 | 77 | 67\% |
|  | Feb 2011 | 305 | 213 | 70\% | 0 | 0 | 0\% | 109 | 78 | 72\% | 0 | 0 | 0\% | 77 | 53 | 69\% |
|  | Mar 2011 | 371 | 252 | 68\% | 0 | 0 | 0\% | 103 | 79 | 77\% | 0 | 0 | 0\% | 101 | 70 | 69\% |
|  | Apr 2011 | 386 | 245 | 63\% | 0 | 0 | 0\% | 124 | 83 | 67\% | 0 | 0 | 0\% | 70 | 44 | 63\% |
|  | May 2011 | 346 | 215 | 62\% | 0 | 0 | 0\% | 98 | 65 | 66\% | 0 | 0 | 0\% | 69 | 44 | 64\% |
|  | Jun 2011 | 344 | 224 | 65\% | 1 | 0 | 0\% | 96 | 69 | 72\% | 1 | 1 | 100\% | 59 | 38 | 64\% |
|  | Jul 2011 | 350 | 229 | 65\% | 0 | 0 | 0\% | 80 | 63 | 79\% | 0 | 0 | 0\% | 53 | 38 | 72\% |
|  | Aug 2011 | 342 | 228 | 67\% | 0 | 0 | 0\% | 94 | 59 | 63\% | 0 | 0 | 0\% | 52 | 44 | 85\% |
|  | Sep 2011 | 337 | 237 | 70\% | 0 | 0 | 0\% | 87 | 63 | 72\% | 0 | 0 | 0\% | 55 | 36 | 65\% |
|  | Oct 2011 | 306 | 202 | 66\% | 2 | 0 | 0\% | 86 | 63 | 73\% | 0 | 0 | 0\% | 68 | 45 | 66\% |
|  | Nov 2011 | 300 | 210 | 70\% | 0 | 0 | 0\% | 85 | 60 | 71\% | 0 | 0 | 0\% | 62 | 41 | 66\% |
|  | Dec 2011 | 312 | 210 | 67\% | 0 | 0 | 0\% | 88 | 56 | 64\% | 0 | 0 | 0\% | 73 | 51 | 70\% |
|  | Jan 2012 | 310 | 219 | 71\% | 0 | 0 | 0\% | 108 | 74 | 69\% | 0 | 0 | 0\% | 69 | 43 | 62\% |
|  | Feb 2012 | 300 | 218 | 73\% | 1 | 0 | 0\% | 86 | 60 | 70\% | 0 | 0 | 0\% | 60 | 48 | 80\% |
|  | Mar 2012 | 314 | 222 | 71\% | 0 | 0 | 0\% | 84 | 62 | 74\% | 0 | 0 | 0\% | 61 | 48 | 79\% |
|  | Apr 2012 | 359 | 251 | 70\% | 1 | 0 | 0\% | 118 | 79 | 67\% | 1 | 1 | 100\% | 74 | 48 | 65\% |
|  | May 2012 | 363 | 241 | 66\% | 1 | 0 | 0\% | 98 | 66 | 67\% | 0 | 0 | 0\% | 77 | 51 | 66\% |
|  | Jun 2012 | 299 | 203 | 68\% | 1 | 0 | 0\% | 82 | 58 | 71\% | 0 | 0 | 0\% | 64 | 47 | 73\% |
|  | Jul 2012 | 331 | 226 | 68\% | 0 | 0 | 0\% | 103 | 68 | 66\% | 0 | 0 | 0\% | 52 | 30 | 58\% |
|  | Aug 2012 | 297 | 202 | 68\% | 1 | 1 | 100\% | 102 | 70 | 69\% | 0 | 0 | 0\% | 61 | 44 | 72\% |
|  | Sep 2012 | 283 | 195 | 69\% | 1 | 0 | 0\% | 89 | 58 | 65\% | 1 | 1 | 100\% | 48 | 38 | 79\% |
|  | Oct 2012 | 285 | 179 | 63\% | 0 | 0 | 0\% | 83 | 57 | 69\% | 0 | 0 | 0\% | 60 | 35 | 58\% |
|  | Nov 2012 | 336 | 211 | 63\% | 0 | 0 | 0\% | 105 | 63 | 60\% | 2 | 1 | 50\% | 77 | 48 | 62\% |
|  | Dec 2012 | 286 | 200 | 70\% | 0 | 0 | 0\% | 64 | 37 | 58\% | 0 | 0 | 0\% | 54 | 33 | 61\% |
|  | Jan 2013 | 302 | 198 | 66\% | 2 | 1 | 50\% | 103 | 62 | 60\% | 0 | 0 | 0\% | 64 | 37 | 58\% |
|  | Feb 2013 | 246 | 185 | 75\% | 2 | 0 | 0\% | 64 | 46 | 72\% | 0 | 0 | 0\% | 52 | 39 | 75\% |
|  | Mar 2013 | 248 | 161 | 65\% | 0 | 0 | 0\% | 80 | 50 | 63\% | 0 | 0 | 0\% | 40 | 30 | 75\% |
|  | Apr 2013 | 280 | 197 | 70\% | 0 | 0 | 0\% | 93 | 63 | 68\% | 0 | 0 | 0\% | 59 | 39 | 66\% |
|  | May 2013 | 307 | 203 | 66\% | 1 | 1 | 100\% | 83 | 60 | 72\% | 0 | 0 | 0\% | 54 | 33 | 61\% |
|  | Jun 2013 | 288 | 199 | 69\% | 0 | 0 | 0\% | 89 | 60 | 67\% | 0 | 0 | 0\% | 55 | 36 | 65\% |
|  | Jul 2013 | 272 | 192 | 71\% | 0 | 0 | 0\% | 88 | 66 | 75\% | 0 | 0 | 0\% | 60 | 36 | 60\% |
|  | Aug 2013 | 300 | 204 | 68\% | 0 | 0 | 0\% | 75 | 44 | 59\% | 0 | 0 | 0\% | 39 | 21 | 54\% |
|  | Sep 2013 | 276 | 190 | 69\% | 1 | 0 | 0\% | 75 | 50 | 67\% | 0 | 0 | 0\% | 52 | 32 | 62\% |
|  | Oct 2013 | 274 | 193 | 70\% | 0 | 0 | 0\% | 78 | 52 | 67\% | 0 | 0 | 0\% | 56 | 38 | 68\% |
|  | Nov 2013 | 265 | 166 | 63\% | 0 | 0 | 0\% | 71 | 52 | 73\% | 0 | 0 | 0\% | 57 | 37 | 65\% |
|  | Dec 2013 | 276 | 182 | 66\% | 1 | 0 | 0\% | 67 | 50 | 75\% | 0 | 0 | 0\% | 52 | 38 | 73\% |


| Secondary Tolerance Definition (230 mg per day for seven days in the $\mathbf{3 0}$ days prior) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Dose $112 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $125 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $137 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $150 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $162 \mathrm{mcg} / \mathrm{hr}$ |  |  |
|  |  | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with Prior Tolerance | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with <br> Prior <br> Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with <br> Prior <br> Tolerance | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with Prior Tolerance | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with <br> Prior Tolerance |
| Age (years) | Total | 5 | 4 | 80\% | 179 | 108 | 60\% | 2 | 1 | 50\% | 233 | 143 | 61\% | 2 | 2 | 100\% |
|  | $0-11$ years | 0 | 0 | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | 12-17 years | 0 | 0 | 0\% | 1 | - | 0\% | - | - | 0\% | 2 | - | 0\% | - | - | 0\% |
|  | 18.24 years | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | 5 | 4 | 80\% | 1 | 1 | 100\% |
|  | 25-34 years | 0 | 0 | 0\% | 10 | 8 | 80\% | - | - | 0\% | 13 | 9 | 69\% | - | - | 0\% |
|  | 35-44 years | 1 | 1 | 100\% | 30 | 22 | 73\% | - | - | 0\% | 37 | 26 | 70\% | - | - | 0\% |
|  | 45.54 years | 1 | 1 | 100\% | 72 | 38 | 53\% | 1 | - | 0\% | 88 | 54 | 61\% | - | - | 0\% |
|  | 55-64 years | 3 | 2 | 67\% | 64 | 38 | 59\% | 1 | 1 | 100\% | 88 | 50 | 57\% | 1 | 1 | 100\% |
| Gender | Male | 2 | 2 | 100\% | 83 | 50 | 60\% | - | - | 0\% | 125 | 85 | 68\% | 2 | 2 | 100\% |
|  | Female | 3 | 2 | 67\% | 96 | 58 | 60\% | 2 | 1 | 50\% | 108 | 58 | 54\% | - | - | 0\% |
|  | Ambiguous | 0 | 0 | 0\% | - | - | 0\% | - | - | 0\% | - |  | 0\% | - | - | 0\% |
|  | Unknown | 0 | 0 | 0\% | - | - | 0\% | . | - | 0\% | - | . | 0\% | - | . | 0\% |
| Month and Year of Episode Start Date | Jan 2009 | 1 | 1 | 100\% | 5 | 3 | 60\% | - | - | 0\% | 7 | 3 | 43\% | - | - | 0\% |
|  | Feb 2009 | 0 | 0 | 0\% | 5 | 2 | 40\% | - | - | 0\% | 3 | 3 | 100\% | - | - | 0\% |
|  | Mar 2009 | 0 | 0 | 0\% | 4 | 2 | 50\% | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% |
|  | Apr 2009 | 0 | 0 | 0\% | 5 | 3 | 60\% | - | - | 0\% | 7 | 4 | 57\% | - | - | 0\% |
|  | May 2009 | 0 | 0 | 0\% | 4 | 3 | 75\% | - | - | 0\% | 8 | 5 | 63\% | - | - | 0\% |
|  | Jun 2009 | 0 | 0 | 0\% | 4 | 3 | 75\% | - | - | 0\% | 9 | 7 | 78\% | - | - | 0\% |
|  | Jul 2009 | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 3 | 1 | 33\% | - | - | 0\% |
|  | Aug 2009 | 0 | 0 | 0\% | 3 | 2 | 67\% | - | - | 0\% | 5 | 1 | 20\% | - | - | 0\% |
|  | Sep 2009 | 0 | 0 | 0\% | 1 | - | 0\% | - | - | 0\% | 5 | 4 | 80\% | - | - | 0\% |
|  | Oct 2009 | 0 | 0 | 0\% | 2 | 1 | 50\% | - | - | 0\% | 6 | 2 | 33\% | - | - | 0\% |
|  | Nov 2009 | 0 | 0 | 0\% | 3 | 2 | 67\% | - | - | 0\% | 7 | 5 | 71\% | - | - | 0\% |
|  | Dec 2009 | 0 | 0 | 0\% | 5 | 4 | 80\% | - | - | 0\% | 7 | 5 | 71\% | - | - | 0\% |
|  | Jan 2010 | 0 | 0 | 0\% | 10 | 3 | 30\% | - | - | 0\% | 7 | 3 | 43\% | - | - | 0\% |
|  | Feb 2010 | 0 | 0 | 0\% | 6 | 2 | 33\% | - | - | 0\% | 5 | 4 | 80\% | - | - | 0\% |
|  | Mar 2010 | 0 | 0 | 0\% | 3 | - | 0\% | - | - | 0\% | 5 | 4 | 80\% | - | - | 0\% |
|  | Apr 2010 | 0 | 0 | 0\% | 3 | 1 | 33\% | - | - | 0\% | 6 | 5 | 83\% |  | - | 0\% |
|  | May 2010 | 0 | 0 | 0\% | 2 | 1 | 50\% | - | - | 0\% | 5 | 4 | 80\% | - | - | 0\% |
|  | Jun 2010 | 0 | 0 | 0\% | 6 | 5 | 83\% | - | - | 0\% | 5 | 3 | 60\% |  | - | 0\% |
|  | Jul 2010 | 0 | 0 | 0\% | 4 | 3 | 75\% | - | - | 0\% | 6 | 4 | 67\% | - | - | 0\% |
|  | Aug 2010 | 1 | 0 | 0\% | 3 | 1 | 33\% | - | - | 0\% | 3 | 1 | 33\% | - | - | 0\% |
|  | Sep 2010 | 0 | 0 | 0\% | 1 | - | 0\% | - | - | 0\% | 3 | 1 | 33\% | - | - | 0\% |
|  | Oct 2010 | 0 | 0 | 0\% | 7 | 6 | 86\% | 1 | 1 | 100\% | 5 | 5 | 100\% | - | - | 0\% |
|  | Nov 2010 | 0 | 0 | 0\% | 2 | 2 | 100\% | , | - | 0\% | 3 | 2 | 67\% | - | - | 0\% |
|  | Dec 2010 | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 4 | 2 | 50\% | - | - | 0\% |
|  | Jan 2011 | 0 | 0 | 0\% | 3 | 1 | $33 \%$ | - | - | 0\% | 5 | 3 | 60\% | 1 | 1 | 100\% |
|  | Feb 2011 | 1 | 1 | 100\% | 2 | 1 | 50\% | - | - | 0\% | 3 | 1 | 33\% | - | - | 0\% |
|  | Mar 2011 | 0 | 0 | 0\% | 3 | 2 | 67\% | - | - | 0\% | 4 | 1 | 25\% | - | - | 0\% |
|  | Apr 2011 | 0 | 0 | 0\% | 5 | 3 | 60\% | - | - | 0\% | 7 | 5 | 71\% | - | - | 0\% |
|  | May 2011 | 0 | 0 | 0\% | 5 | 3 | 60\% | - | - | 0\% | 4 | 2 | 50\% | - | - | 0\% |
|  | Jun 2011 | 0 | 0 | 0\% | 2 | 1 | 50\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jul 2011 | 0 | 0 | 0\% | 2 | - | 0\% | - | - | 0\% | 4 | 4 | 100\% | - | - | 0\% |
|  | Aug 2011 | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% |
|  | Sep 2011 | 0 | 0 | 0\% | 4 | 2 | 50\% | 1 | - | 0\% | 5 | 4 | 80\% | 1 | 1 | 100\% |
|  | Oct 2011 | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | 1 |  | 0\% | - | - | 0\% |
|  | Nov 2011 | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 2 | 1 | 50\% | , | - | 0\% |
|  | Dec 2011 | 0 | 0 | 0\% | 4 | 2 | 50\% | - | - | 0\% | 2 | 2 | 100\% | - | - | 0\% |
|  | Jan 2012 | 0 | 0 | 0\% | 3 | 2 | 67\% | - | - | 0\% | 3 | 2 | 67\% | - | - | 0\% |
|  | Feb 2012 | 0 | 0 | 0\% | 2 | 2 | 100\% |  | - | 0\% | 6 | 4 | 67\% |  | - | 0\% |
|  | Mar 2012 | 0 | 0 | 0\% | 3 | 3 | 100\% | - | - | 0\% | 2 | 2 | 100\% | - | - | 0\% |
|  | Apr 2012 | 1 | 1 | 100\% | 5 | 5 | 100\% | - | - | 0\% | 6 | 5 | 83\% | * | - | 0\% |
|  | May 2012 | 0 | 0 | 0\% | 4 | 1 | 25\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jun 2012 | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | 6 | 1 | 17\% | - | - | 0\% |
|  | Jul 2012 | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Aug 2012 | 0 | 0 | 0\% | 4 | 4 | 100\% | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% |
|  | Sep 2012 | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | 2 | 1 | 50\% |  | - | 0\% |
|  | Oct 2012 | 0 | 0 | 0\% | 4 | 3 | 75\% | - | - | 0\% | 2 | 2 | 100\% | - | - | 0\% |
|  | Nov 2012 | 0 | 0 | 0\% | 2 | 2 | 100\% | - | $\cdot$ | 0\% | 5 | 3 | 60\% | - | - | 0\% |
|  | Dec 2012 | 0 | 0 | 0\% | 3 | 1 | 33\% | - | - | 0\% | 1 | - | 0\% | - | - | 0\% |
|  | Jan 2013 | 0 | 0 | 0\% | 4 | - | 0\% | - | - | 0\% | 4 | 1 | 25\% | - | - | 0\% |
|  | Feb 2013 | 1 | 1 | 100\% | 3 | 2 | 67\% | - | - | 0\% | - | - | 0\% |  | - | 0\% |
|  | Mar 2013 | 0 | 0 | 0\% | 2 | 1 | 50\% | - | - | 0\% | 3 | 1 | 33\% | - | - | 0\% |
|  | Apr 2013 | 0 | 0 | 0\% | - | - | 0\% | - | - | 0\% | 5 | 3 | 60\% |  | - | 0\% |
|  | May 2013 | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 3 | 2 | 67\% | - | - | 0\% |
|  | Jun 2013 | 0 | 0 | 0\% | - | - | 0\% | - | - | 0\% | 5 | 2 | 40\% | - | - | 0\% |
|  | Jul 2013 | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | 3 | 3 | 100\% | - | - | 0\% |
|  | Aug 2013 | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% |
|  | Sep 2013 | 0 | 0 | 0\% | 1 | - | 0\% | - | - | 0\% | 3 | 1 | 33\% | - | - | 0\% |
|  | Oct 2013 | 0 | 0 | 0\% | 3 | 1 | 33\% | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% |
|  | Nov 2013 | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 3 | 2 | 67\% | - | - | 0\% |
|  | Dec 2013 | 0 | 0 | 0\% | 1 | . | 0\% | - | - | 0\% | 3 | 2 | 67\% | - | - | 0\% |


| Secondary Tolerance Definition ( 330 mg per day for seven days in the 30 days prior) |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Dose $175 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $200 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $225 \mathrm{mcg} / \mathrm{hr}$ |  |  |
|  |  | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with Prior Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with Prior Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with <br> Prior Tolerance | \% with <br> Prior <br> Tolerance |
| Age (years) | Total | 52 | 30 | 58\% | 5 | 3 | 60\% | 4 | 1 | 25\% |
|  | $0-11$ years | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | 12-17 years | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | 18-24 years | 3 | 3 | 100\% | - | - | 0\% | - | - | 0\% |
|  | 25-34 years | 3 | 2 | 67\% | - | . | 0\% | 1 | 1 | 100\% |
|  | 35-44 years | 7 | 4 | 57\% | 3 | 2 | 67\% | 1 | - | 0\% |
|  | $45-54$ years | 17 | 10 | 59\% | 2 | 1 | 50\% | - | - | 0\% |
|  | $55-64$ years | 21 | 10 | 48\% | - | - | 0\% | 2 | - | 0\% |
| Gender | Male | 17 | 12 | 71\% | 5 | 3 | 60\% | 2 | 1 | 50\% |
|  | Female | 35 | 18 | 51\% | - | - | 0\% | 2 | - | 0\% |
|  | Ambiguous | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Unknown | - | . | 0\% | . | . | 0\% | . | . | 0\% |
| Month and Year of Episode Start Date | Jan 2009 | 2 | 1 | 50\% | - | - | 0\% | - | - | 0\% |
|  | Feb 2009 | 2 | 1 | 50\% | - | - | 0\% | - | - | 0\% |
|  | Mar 2009 | 2 | 2 | 100\% | 1 | - | 0\% | 1 | - | 0\% |
|  | Apr 2009 | 4 | 4 | 100\% | 1 | 1 | 100\% | - | - | 0\% |
|  | May 2009 | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Jun 2009 | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jul 2009 | 2 | 2 | 100\% | - | - | 0\% | 1 | 1 | 100\% |
|  | Aug 2009 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Sep 2009 | 2 | 2 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Oct 2009 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Nov 2009 | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Dec 2009 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jan 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Feb 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Mar 2010 | 1 | 1 | 100\% | 1 | 1 | 100\% | - | - | 0\% |
|  | Apr 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | May 2010 | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jun 2010 | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jul 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Aug 2010 | 2 | 2 | 100\% | - | - | 0\% | 1 | - | 0\% |
|  | Sep 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Oct 2010 | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Nov 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Dec 2010 | 1 | 1 | 100\% | - | - | 0\% |  | - | 0\% |
|  | Jan 2011 | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Feb 2011 | 2 | 1 | 50\% |  | - | 0\% | - | - | 0\% |
|  | Mar 2011 | 2 | 1 | 50\% | - | - | 0\% | - | - | 0\% |
|  | Apr 2011 | 2 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | May 2011 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jun 2011 | 2 | 1 | 50\% | - | - | 0\% | \% | - | 0\% |
|  | Jul 2011 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Aug 2011 | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Sep 2011 | 3 | 2 | 67\% | - | - | 0\% | - | - | 0\% |
|  | Oct 2011 | 2 | - | 0\% | - | - | 0\% | $\cdot$ | - | 0\% |
|  | Nov 2011 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Dec 2011 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jan 2012 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Feb 2012 | - | - | 0\% | - | - | 0\% |  |  | 0\% |
|  | Mar 2012 | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Apr 2012 | 2 | 1 | 50\% | - | - | 0\% | - | - |  |
|  | May 2012 | 1 | 1 | 100\% | - | - | 0\% | - | - |  |
|  | Jun 2012 | 1 | - | 0\% | - | - | 0\% | - | - |  |
|  | Jul 2012 | - | - | 0\% | - | - | 0\% |  | - |  |
|  | Aug 2012 | - | - | 0\% | - | - | 0\% | - | - |  |
|  | Sep 2012 | - | - | 0\% | - | - | 0\% | - | - |  |
|  | Oct 2012 | - | - | 0\% | - | - | 0\% | - | - |  |
|  | Nov 2012 | 1 | - | 0\% | - | - | 0\% | 1 | - |  |
|  | Dec 2012 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jan 2013 | - | - | 0\% | - | - | 0\% | - | - |  |
|  | Feb 2013 | 1 | - | 0\% | - | - | 0\% | - | - |  |
|  | Mar 2013 | 1 | 1 | 100\% | - | - | 0\% | - | - |  |
|  | Apr 2013 | - | - | 0\% | - | - | 0\% | - | - |  |
|  | May 2013 | 1 | 1 | 100\% | - | - | 0\% | - | - |  |
|  | Jun 2013 | 1 | - | 0\% | 2 | 1 | 50\% | - | - |  |
|  | Jul 2013 | - | - | 0\% | - | - | 0\% |  | - |  |
|  | Aug 2013 | - | - | 0\% | - | - | 0\% | - | - |  |
|  | Sep 2013 | 1 | 1 | 100\% | - | - | 0\% | . | - |  |
|  | Oct 2013 | 1 | - | 0\% | - | - | 0\% | - | - |  |
|  | Nov 2013 | - | - | 0\% | - | - | 0\% | - | - |  |
|  | Dec 2013 | 1 | 1 | 100\% | - | - | 0\% | - | - |  |


| Tertiary Tolerance Definition ( $>0 \mathrm{mg}$ per day in the prior 7 consecutive days) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Dose $12 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $24 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $25 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $36 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $37 \mathrm{mcg} / \mathrm{hr}$ |  |  |
|  |  | Total $\mathbf{N}$ of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{gathered} \mathrm{N} \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{gathered}$ | $\begin{gathered} \text { \% with } \\ \text { Prior } \\ \text { Tolerance } \end{gathered}$ | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{aligned} & \text { N with } \\ & \text { Prior } \\ & \text { Tolerance } \end{aligned}$ | $\begin{aligned} & \text { \% with } \\ & \text { Prior } \\ & \text { Tolerance } \end{aligned}$ | Total $\mathbf{N}$ of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{aligned} & \text { N with } \\ & \text { Prior } \\ & \text { Tolerance } \end{aligned}$ | $\begin{aligned} & \text { \% with } \\ & \text { Prior } \\ & \text { Tolerance } \end{aligned}$ | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{gathered} \mathrm{N} \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{gathered}$ | $\begin{gathered} \text { \% with } \\ \text { Prior } \\ \text { Tolerance } \end{gathered}$ | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{gathered} \mathrm{N} \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{gathered}$ | $\begin{array}{\|c\|} \hline \% \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ |
| Age (years) | Total | 17,812 | 8,739 | 49.1\% | 3 |  | 67\% | 49,148 | 26,155 | $53.2 \%$ | 1 | 0 | 0\% | 339 | 200 | 59\% |
|  | $0-11$ years | 34 | 7 | 20.6\% | - |  | 0\% | 25 | 6 | 24.0\% | 0 | 0 | 0\% | 1 | 0 | 0\% |
|  | 12-17 years | 81 | 25 | 30.9\% | - |  | 0\% | 85 | 31 | 36.5\% | 0 | 0 | 0\% | ${ }^{2}$ | 0 | 0\% |
|  | $18-24$ years | 412 | 181 | 43.9\% | - |  | 0\% | 925 | 470 | 50.8\% | 0 | 0 | 0\% | 9 | 4 | 44\% |
|  | $25-34$ years | 1,605 | 945 | 58.9\% | - |  | 0\% | 4,297 | 2,619 | 60.9\% | 1 | 0 | 0\% | 27 | 18 | 67\% |
|  | 35 - 44 years | 3,153 | 1,732 | 54.9\% | 2 |  | 100\% | 8,915 | 5,098 | 57.2\% | 0 | 0 | 0\% | 71 | 39 | 55\% |
|  | 45.54 years | 5,672 | 2,807 | 49.5\% | . |  | 0\% | 16,409 | 8,870 | 54.1\% | 0 | 0 | 0\% | 99 | 60 | 61\% |
|  | 55-64 years | 6,855 | 3,042 | 44.4\% | 1 |  | 0\% | 18,492 | 9,061 | 49.0\% | 0 | 0 | 0\% | 130 | 79 | 61\% |
| Gender | Male | 5,595 | 2,805 | 50.1\% | 1 |  | 100\% | 20,233 | 10,836 | 53.6\% | 0 | 0 | 0\% | 145 | 91 | 63\% |
|  | Female | 12,217 | 5,934 | 48.5\% | 2 |  | 50\% | 28,915 | 15,319 | 53.0\% | 1 | 0 | 0\% | 194 | 109 | 56\% |
|  | Ambiguous | - | - | 0.0\% | - |  | 0\% | . | - | 0.0\% | 0 | 0 | 0\% | 0 | 0 | 0\% |
|  | Unknown | 0 | 0 | 0 | 0 |  | 0\% | - | 0 | 0 | 0 | 0 | 0\% | 0 | 0 | 0\% |
| Month and Year of Episode Start Date | Jan 2009 | 238 | 124 | 52.1\% | - |  | 0\% | 1,070 | 536 | 50.1\% | 0 | 0 | 0\% | 6 | 3 | 50\% |
|  | Feb 2009 | 227 | 102 | 4.9\% | - |  | 0\% | 992 | 484 | 48.8\% | 0 | 0 | 0\% | 9 | 4 | 44\% |
|  | Mar 2009 | 284 | 126 | 44.4\% | - |  | 0\% | 1,072 | 545 | 50.8\% | 0 | 0 | 0\% | 5 | 3 | 60\% |
|  | Apr 2009 | 251 | 117 | 46.6\% | - |  | 0\% | 1,147 | 589 | 51.4\% | 1 | 0 | 0\% | 4 | 2 | 50\% |
|  | May 2009 | 283 | 137 | 48.4\% | - |  | 0\% | 1,039 | 566 | 54.5\% | 0 | 0 | 0\% | 6 | 5 | 83\% |
|  | Jun 2009 | 300 | 130 | 43.3\% | - |  | 0\% | 1,080 | 525 | 48.6\% | 0 | 0 | 0\% | 8 | 7 | 88\% |
|  | Jul 2009 | 267 | 133 | 4.8\% | - |  | 0\% | 966 | 497 | 51.4\% | 0 | 0 | 0\% | 8 | 4 | 50\% |
|  | Aug 2009 | 284 | 128 | 45.1\% | - |  | \% | 946 | 458 | 48.4\% | 0 | 0 | 0\% |  | 2 | 67\% |
|  | Sep 2009 | 318 | 153 | 48.1\% | - |  | 0\% | 1,007 | 516 | 51.2\% | 0 | 0 | 0\% | 5 | 5 | 100\% |
|  | Oct 2009 | 278 | 125 | 45.0\% | - |  | 0\% | 948 | 473 | 4.9\% | 0 | 0 | 0\% | 1 | 1 | 100\% |
|  | Nov 2009 | 244 | 113 | 46.3\% | - |  | 0\% | 898 | 444 | 49.4\% | 0 | 0 | 0\% | 8 | 4 | 50\% |
|  | Dec 2009 | 261 | 120 | 46.0\% | - |  | 0\% | 970 | 533 | 54.9\% | 0 | 0 | 0\% | 8 | 4 | 50\% |
|  | Jan 2010 | 245 | 114 | 46.5\% | . |  | 0\% | 881 | 444 | 50.4\% | 0 | 0 | 0\% | 6 | 0 | 0\% |
|  | Feb 2010 | 254 | 135 | 53.1\% | - |  | 0\% | 790 | 414 | 52.4\% | 0 | 0 | 0\% | 9 | 9 | 100\% |
|  | Mar 2010 | 283 | 137 | 48.4\% | - |  | 0\% | 853 | 448 | 52.5\% | 0 | 0 | 0\% | 8 | 5 | 63\% |
|  | Apr 2010 | 289 | 130 | 45.0\% | - |  | 0\% | 958 | 486 | 50.7\% | 0 | 0 | 0\% | 4 | 2 | 50\% |
|  | May 2010 | 261 | 137 | 52.5\% | - |  | 0\% | 845 | 463 | 54.8\% | 0 | 0 | 0\% | 6 | 2 | 33\% |
|  | Jun 2010 | 285 | 139 | 48.8\% | - |  | 0\% | 884 | 470 | 53.2\% | 0 | 0 | 0\% | 7 | 3 | 43\% |
|  | Jul 2010 | 239 | 115 | 48.1\% | - |  | 0\% | 837 | 462 | 55.2\% | 0 | 0 | 0\% | 5 | 3 | 60\% |
|  | Aug 2010 | 270 | 135 | 50.0\% | - |  | \% | 871 | 457 | 52.5\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Sep 2010 | 320 | 144 | 45.0\% | - |  | \% | 908 | 502 | 55.3\% | 0 | 0 | 0\% | 2 | 2 | 100\% |
|  | Oct 2010 | 313 | 145 | 46.3\% | - |  | \% | 843 | 438 | 52.\% | 0 | 0 | 0\% | 5 | 3 | 60\% |
|  | Nov 2010 | 306 | 147 | 48.0\% | - |  | 0\% | 889 | 455 | 51.2\% | 0 | 0 | 0\% | 8 | 5 | 63\% |
|  | Dec 2010 | 307 | 142 | 46.3\% | . |  | 0\% | 796 | 435 | 54.6\% | 0 | 0 | 0\% | 3 | 1 | 33\% |
|  | Jan 2011 | 264 | 120 | 45.5\% | - |  | 0\% | 774 | 397 | 51.3\% | 0 | 0 | 0\% | 1 | 1 | 100\% |
|  | Feb 2011 | 279 | 130 | 46.6\% | - |  | 0\% | 674 | 344 | 51.0\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Mar 2011 | 292 | 154 | 52.7\% | . |  | 0\% | 845 | 459 | 54.3\% | 0 | 0 | 0\% | 9 | 5 | 56\% |
|  | Apr 2011 | 307 | 156 | 50.8\% | . |  | 0\% | 812 | 439 | 54.1\% | 0 | 0 | 0\% | 10 | 9 | 90\% |
|  | May 2011 | 299 | 135 | 45.2\% | - |  | \% | 795 | 419 | 52.7\% | - | 0 | 0\% | 4 | 3 | 75\% |
|  | Jun 2011 | 316 | 145 | 45.9\% | . |  | 0\% | 777 | 433 | 55.7\% | 0 | 0 | 0\% | 4 | 2 | 50\% |
|  | Jul 2011 | 294 | 148 | 50.3\% | - |  | \% | 728 | 375 | 51.5\% | 0 | 0 | 0\% | 4 | 2 | 50\% |
|  | Aug 2011 | 328 | 171 | 52.1\% | - |  | 0\% | 820 | 418 | 51.0\% | 0 | 0 | 0\% | 5 | 2 | 40\% |
|  | Sep 2011 | 307 | 144 | 46.9\% | - |  | 0\% | 795 | 419 | 52.7\% | 0 | 0 | 0\% | 6 | 4 | 67\% |
|  | Oct 2011 | 279 | 143 | 51.3\% | - |  | 0\% | 768 | 435 | 56.6\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Nov 2011 | 306 | 155 | 50.7\% | - |  | 0\% | 718 | 409 | 57.0\% | 0 | 0 | 0\% | 7 | 2 | 29\% |
|  | Dec 2011 | 323 | 151 | 46.7\% | - |  | 0\% | 747 | 388 | 51.9\% | 0 | 0 | 0\% | 5 | 4 | 80\% |
|  | Jan 2012 | 298 | 134 | 45.0\% | - |  | 0\% | 776 | 423 | 54.5\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Feb 2012 | 269 | 131 | 48.7\% | - |  | 0\% | 696 | 373 | 53.6\% | 0 | 0 | 0\% | 7 | 5 | 71\% |
|  | Mar 2012 | 307 | 152 | 49.5\% | - |  | 0\% | 738 | 383 | 51.9\% | 0 | 0 | 0\% | 7 | 5 | 71\% |
|  | Apr 2012 | 316 | 155 | 49.1\% | - |  | 0\% | 803 | 436 | 54.3\% | 0 | 0 | 0\% | 7 | 3 | 43\% |
|  | May 2012 | 389 | 190 | 48.8\% | - |  | 0\% | 786 | 432 | 55.0\% | 0 | 0 | 0\% | 8 | 6 | 75\% |
|  | Jun 2012 | 293 | 151 | 51.5\% | . |  | 0\% | 683 | 374 | 54.8\% | 0 | 0 | 0\% | 4 | 2 | 50\% |
|  | Jul 2012 | 315 | 158 | 50.2\% | - |  | 0\% | 672 | 373 | 55.5\% | 0 | 0 | 0\% | 5 | 2 | 40\% |
|  | Aug 2012 | 324 | 176 | 54.3\% | - |  | 0\% | 857 | 469 | 54.7\% | 0 | 0 | 0\% | 2 | 1 | 50\% |
|  | Sep 2012 | 290 | 135 | 46.6\% | - |  | 0\% | 705 | 370 | 52.5\% | 0 | 0 | 0\% | 5 | 4 | 80\% |
|  | Oct 2012 | 330 | 173 | 52.4\% | - |  | 0\% | 754 | 453 | 60.1\% | 0 | 0 | 0\% | 3 | 2 | 67\% |
|  | Nov 2012 | 332 | 170 | 51.2\% | - |  | 0\% | 775 | 397 | 51.2\% | 0 | 0 | 0\% | 6 | 4 | 67\% |
|  | Dec 2012 | 316 | 154 | 48.7\% | - |  | 0\% | 666 | 363 | 54.5\% | 0 | 0 | 0\% | 9 | 3 | 33\% |
|  | Jan 2013 | 296 | 151 | 51.0\% | - |  | 0\% | 650 | 354 | 54.5\% | 0 | 0 | 0\% | 5 | 3 | 60\% |
|  | Feb 2013 | 275 | 139 | 50.5\% | - |  | \% | 675 | 394 | 58.4\% | 0 | 0 | 0\% | 3 | 3 | 100\% |
|  | Mar 2013 | 274 | 148 | 54.0\% | - |  | 0\% | 632 | 368 | 58.2\% | 0 | 0 | 0\% | 4 | 3 | 75\% |
|  | Apr 2013 | 327 | 180 | 55.0\% | - |  | 0\% | 724 | 410 | 56.6\% | 0 | 0 | 0\% | 11 | 5 | 45\% |
|  | May 2013 | 293 | 148 | 50.5\% | - |  | 0\% | 754 | 436 | 57.8\% | 0 | 0 | 0\% | 9 | 6 | 67\% |
|  | Jun 2013 | 306 | 168 | 54.9\% | 1 |  | 100\% | 701 | 390 | 55.6\% | 0 | 0 | 0\% | 5 | 3 | 60\% |
|  | Jul 2013 | 345 | 168 | 48.7\% | - |  | 0\% | 719 | 412 | 57.3\% | 0 | 0 | 0\% | 9 | 7 | 78\% |
|  | Aug 2013 | 358 | 171 | 47.8\% | - |  | 0\% | 780 | 428 | 54.9\% | 0 | 0 | 0\% | 7 | 2 | 29\% |
|  | Sep 2013 | 323 | 161 | 49.8\% | - |  | 0\% | 687 | 373 | 54.3\% | 0 | 0 | 0\% | 5 | 4 | 80\% |
|  | Oct 2013 | 366 | 186 | 50.8\% | 1 |  | 100\% | 784 | 426 | 54.3\% | 0 | 0 | 0\% | 4 | 1 | 25\% |
|  | Nov 2013 | 344 | 188 | 54.7\% | 1 |  | 0\% | 702 | 381 | 54.3\% | 0 | 0 | 0\% | 7 | 1 | 14\% |
|  | Dec 2013 | 325 | 172 | 52.9\% | 0 | - | 0\% | 686 | 362 | 52.8\% | 0 | 0 | 0\% | 6 | 4 | 67\% |


| Tertiary Tolerance Definition ( $>0 \mathrm{mg}$ per day in the prior 7 consecutive days) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Dose $50 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $62 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $75 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $87 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $100 \mathrm{mcg} / \mathrm{hr}$ |  |  |
|  |  | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | $\qquad$ | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | $\qquad$ | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with <br> Prior Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | $\begin{aligned} & \text { \% with } \\ & \text { Prior } \\ & \text { Tolerance } \end{aligned}$ | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | \% with <br> Prior Tolerance |
| Age (years) | Total | 21,245 | 12,517 | 59\% | 26 | 7 | 27\% | 6,215 | 3,644 | 59\% | 14 | 4 | 29\% | 4,524 | 2,600 | 57\% |
|  | 0.11 years | 8 | 3 | 38\% | 1 | 0 | 0\% | , | - | 0\% | 0 | 0 | 0\% | 6 | - | 0\% |
|  | 12-17 years | 37 | 13 | 35\% | 0 | 0 | 0\% | 14 | 4 | 29\% | 0 | 0 | 0\% | ${ }^{9}$ | 3 | 33\% |
|  | $18-24$ years | 423 | 229 | 54\% | 2 | 0 | 0\% | 121 | 64 | 53\% | 0 | 0 | 0\% | 91 | 46 | 51\% |
|  | $25-34$ years | 1,911 | 1,240 | 65\% | 2 | 0 | 0\% | 614 | 392 | 64\% | 2 | 2 | 100\% | 375 | 239 | 64\% |
|  | $35-44$ years | 4,031 | 2,563 | 64\% | 6 | 2 | 33\% | 1,229 | 728 | 59\% | 1 | 0 | 0\% | 870 | 520 | 60\% |
|  | 45.54 years | 7,320 | 4,328 | 59\% | 11 | 3 | 27\% | 2,201 | 1,312 | 60\% | - 6 | 2 | 33\% | 1,644 | 956 | 58\% |
|  | 55-64 years | 7,515 | 4,141 | 55\% | 4 | 2 | 50\% | 2,033 | 1,144 | 56\% | 5 | 0 | 0\% | 1,529 | 836 | 55\% |
| Gender | Male | 9,916 | 6,031 | 61\% | 13 | 6 | 46\% | 2,974 | 1,824 | 61\% | 6 | 2 | 33\% | 2,316 | 1,413 | 61\% |
|  | Female | 11,329 | 6,486 | 57\% | 13 | 1 | 8\% | 3,241 | 1,820 | 56\% | 8 | 2 | 25\% | 2,208 | 1,187 | 54\% |
|  | Ambiguous | - | - | 0\% | 0 | 0 | 0\% | - | - | 0\% | 0 | 0 | 0\% | - | - | 0\% |
|  | Unknown | . | . | 0\% | 0 | 0 | 0\% | . | . | 0\% | 0 | 0 | 0\% | . | . | 0\% |
| Month and Year of Episode Start Date | Jan 2009 | 490 | 264 | 54\% | 2 | 2 | 100\% | 189 | 97 | 51\% | 1 | 0 | 0\% | 131 | 62 | 47\% |
|  | Feb 2009 | 484 | 288 | 60\% | 0 | 0 | 0\% | 152 | 79 | 52\% | 0 | 0 | 0\% | 132 | 76 | 58\% |
|  | Mar 2009 | 492 | 298 | 61\% | 0 | 0 | 0\% | 140 | 81 | 58\% | 0 | 0 | 0\% | 101 | 52 | 51\% |
|  | Apr 2009 | 532 | 323 | 61\% | 0 | 0 | 0\% | 147 | 89 | 61\% | , | 0 | 0\% | 120 | 73 | 61\% |
|  | May 2009 | 470 | 264 | 56\% | 0 | 0 | 0\% | 146 | 73 | 50\% | 0 | 0 | 0\% | 122 | 63 | 52\% |
|  | Jun 2009 | 496 | 278 | 56\% | 0 | 0 | 0\% | 138 | 69 | 50\% | 1 | 0 | 0\% | 107 | 73 | 68\% |
|  | Jul 2009 | 440 | 248 | 56\% | 2 | 0 | 0\% | 112 | 62 | 55\% | 1 | 1 | 100\% | 114 | 68 | 60\% |
|  | Aug 2009 | 398 | 240 | 60\% | 0 | 0 | 0\% | 129 | 74 | 57\% | 0 | 0 | 0\% | 98 | 51 | 52\% |
|  | Sep 2009 | 457 | 267 | 58\% | 0 | 0 | 0\% | 108 | 75 | 69\% | 2 | 0 | 0\% | 89 | 45 | 51\% |
|  | Oct 2009 | 486 | 270 | 56\% | 1 | 0 | 0\% | 123 | 72 | 59\% | 0 | 0 | 0\% | 108 | 62 | 57\% |
|  | Nov 2009 | 402 | 233 | 58\% | 1 | 1 | 100\% | 108 | 68 | 63\% | 0 | 0 | 0\% | 93 | 54 | 58\% |
|  | Dec 2009 | 429 | 244 | 57\% | 0 | 0 | 0\% | 135 | 75 | 56\% | 1 | 0 | 0\% | 96 | 56 | 58\% |
|  | Jan 2010 | 406 | 223 | 55\% | 0 | 0 | 0\% | 120 | 65 | 54\% | 0 | 0 | 0\% | 115 | 68 | 59\% |
|  | Feb 2010 | 362 | 197 | 54\% | 1 | 0 | 0\% | 100 | 52 | 52\% | 1 | 0 | 0\% | 74 | 40 | 54\% |
|  | Mar 2010 | 354 | 208 | 59\% | 0 | 0 | 0\% | 132 | 75 | 57\% | 0 | 0 | 0\% | 71 | 40 | 56\% |
|  | Apr 2010 | 368 | 210 | 57\% | 0 | 0 | 0\% | 122 | 77 | 63\% | - | 0 | 0\% | 98 | 68 | 69\% |
|  | May 2010 | 388 | 218 | 56\% | 0 | 0 | 0\% | 109 | 60 | 55\% | 1 | 0 | 0\% | 75 | 46 | 61\% |
|  | Jun 2010 | 402 | 240 | 60\% | 1 | 0 | 0\% | 103 | 58 | 56\% | 0 | 0 | 0\% | 71 | 49 | 69\% |
|  | Jul 2010 | 371 | 237 | 64\% | 0 | 0 | 0\% | 98 | 52 | 53\% | 0 | 0 | 0\% | 66 | 43 | 65\% |
|  | Aug 2010 | 363 | 210 | 58\% | 0 | 0 | 0\% | 116 | 66 | 57\% | 0 | 0 | 0\% | 86 | 55 | 64\% |
|  | Sep 2010 | 373 | 219 | 59\% | 1 | 1 | 100\% | 105 | 69 | 66\% | 0 | 0 | 0\% | 84 | 47 | 56\% |
|  | Oct 2010 | 383 | 243 | 63\% | 0 | 0 | 0\% | 115 | 72 | 63\% | 0 | 0 | 0\% | 75 | 55 | 73\% |
|  | Nov 2010 | 353 | 223 | 63\% | 0 | 0 | 0\% | 102 | 69 | 68\% | 1 | 0 | 0\% | 70 | 42 | 60\% |
|  | Dec 2010 | 404 | 228 | 56\% | 0 | 0 | 0\% | 90 | 54 | 60\% | 0 | 0 | 0\% | 77 | 36 | 47\% |
|  | Jan 2011 | 346 | 186 | 54\% | 1 | 1 | 100\% | 138 | 72 | 52\% | 0 | 0 | 0\% | 115 | 61 | 53\% |
|  | Feb 2011 | 305 | 191 | 63\% | 0 | 0 | 0\% | 109 | 69 | 63\% | 0 | 0 | 0\% | 77 | 48 | 62\% |
|  | Mar 2011 | 371 | 230 | 62\% | 0 | 0 | 0\% | 103 | 69 | 67\% | 0 | 0 | 0\% | 101 | 59 | 58\% |
|  | Apr 2011 | 386 | 211 | 55\% | 0 | 0 | 0\% | 124 | 81 | 65\% | 0 | 0 | 0\% | 70 | 36 | 51\% |
|  | May 2011 | 346 | 195 | 56\% | 0 | 0 | 0\% | 98 | 60 | 61\% | 0 | 0 | 0\% | 69 | 41 | 59\% |
|  | Jun 2011 | 344 | 187 | 54\% | 1 | 0 | 0\% | 96 | 64 | 67\% | 1 | 0 | 0\% | 59 | 35 | 59\% |
|  | Jul 2011 | 350 | 216 | 62\% | 0 | 0 | 0\% | 80 | 55 | 69\% | 0 | 0 | 0\% | 53 | 30 | 57\% |
|  | Aug 2011 | 342 | 195 | 57\% | 0 | 0 | 0\% | 94 | 49 | 52\% | 0 | 0 | 0\% | 52 | 36 | 69\% |
|  | Sep 2011 | 337 | 199 | 59\% | 0 | 0 | 0\% | 87 | 53 | 61\% | 0 | 0 | 0\% | 55 | 34 | 62\% |
|  | Oct 2011 | 306 | 176 | 58\% | 2 | 0 | 0\% | 86 | 61 | 71\% | 0 | 0 | 0\% | 68 | 38 | 56\% |
|  | Nov 2011 | 300 | 181 | 60\% | 0 | 0 | 0\% | 85 | 50 | 59\% | 0 | 0 | 0\% | 62 | 31 | 50\% |
|  | Dec 2011 | 312 | 181 | 58\% | 0 | 0 | 0\% | 88 | 48 | 55\% | 0 | 0 | 0\% | 73 | 43 | 59\% |
|  | Jan 2012 | 310 | 182 | 59\% | 0 | 0 | 0\% | 108 | 66 | 61\% | 0 | 0 | 0\% | 69 | 36 | 52\% |
|  | Feb 2012 | 300 | 190 | 63\% | 1 | 0 | 0\% | 86 | 56 | 65\% | 0 | 0 | 0\% | 60 | 39 | 65\% |
|  | Mar 2012 | 314 | 198 | 63\% | 0 | 0 | 0\% | 84 | 52 | 62\% | 0 | 0 | 0\% | 61 | 41 | 67\% |
|  | Apr 2012 | 359 | 226 | 63\% | 1 | 0 | 0\% | 118 | 67 | 57\% |  | 1 | 100\% | 74 | 41 | 55\% |
|  | May 2012 | 363 | 232 | 64\% | 1 | 0 | 0\% | 98 | 61 | 62\% | 0 | 0 | 0\% | 77 | 50 | 65\% |
|  | Jun 2012 | 299 | 180 | 60\% | 1 | 0 | 0\% | 82 | 51 | 62\% | 0 | 0 | 0\% | 64 | 40 | 63\% |
|  | Jul 2012 | 331 | 207 | 63\% | 0 | 0 | 0\% | 103 | 57 | 55\% | 0 | 0 | 0\% | 52 | 23 | 44\% |
|  | Aug 2012 | 297 | 176 | 59\% | 1 | 0 | 0\% | 102 | 64 | 63\% | 0 | 0 | 0\% | 61 | 40 | 66\% |
|  | Sep 2012 | 283 | 169 | 60\% | 1 | 0 | 0\% | 89 | 54 | 61\% | 1 | 1 | 100\% | 48 | 28 | 58\% |
|  | Oct 2012 | 285 | 166 | 58\% | 0 | 0 | 0\% | 83 | 53 | 64\% | 0 | 0 | 0\% | 60 | 25 | 42\% |
|  | Nov 2012 | 336 | 188 | 56\% | 0 | 0 | 0\% | 105 | 57 | 54\% | 2 | 1 | 50\% | 77 | 40 | 52\% |
|  | Dec 2012 | 286 | 187 | 65\% | 0 | 0 | 0\% | 64 | 30 | 47\% | - | 0 | 0\% | 54 | 24 | 44\% |
|  | Jan 2013 | 302 | 178 | 59\% | 2 | 1 | 50\% | 103 | 51 | 50\% | 0 | 0 | 0\% | 64 | 32 | 50\% |
|  | Feb 2013 | 246 | 149 | 61\% | 2 | 0 | 0\% | 64 | 38 | 59\% | - | 0 | 0\% | 52 | 30 | 58\% |
|  | Mar 2013 | 248 | 153 | 62\% | 0 | 0 | 0\% | 80 | 47 | 59\% | 0 | 0 | 0\% | 40 | 21 | 53\% |
|  | Apr 2013 | 280 | 162 | 58\% | 0 | 0 | 0\% | 93 | 51 | 55\% | 0 | 0 | 0\% | 59 | 34 | 58\% |
|  | May 2013 | 307 | 188 | 61\% | 1 | 1 | 100\% | 83 | 51 | 61\% | 0 | 0 | 0\% | 54 | 34 | 63\% |
|  | Jun 2013 | 288 | 162 | 56\% | 0 | 0 | 0\% | 89 | 57 | 64\% | 0 | 0 | 0\% | 55 | 30 | 55\% |
|  | Jul 2013 | 272 | 161 | 59\% | 0 | 0 | 0\% | 88 | 53 | 60\% |  | 0 | 0\% | 60 | 27 | 45\% |
|  | Aug 2013 | 300 | 186 | 62\% | 0 | 0 | 0\% | 75 | 33 | 44\% | 0 | 0 | 0\% | 39 | 19 | 49\% |
|  | Sep 2013 | 276 | 168 | 61\% | 1 | 0 | 0\% | 75 | 42 | 56\% | 0 | 0 | 0\% | 52 | 28 | 54\% |
|  | Oct 2013 | 274 | 169 | 62\% | 0 | 0 | 0\% | 78 | 48 | 62\% | 0 | 0 | 0\% | 56 | 35 | 63\% |
|  | Nov 2013 | 265 | 156 | 59\% | 0 | 0 | 0\% | 71 | 46 | 65\% | 0 | 0 | 0\% | 57 | 33 | 58\% |
|  | Dec 2013 | 276 | 163 | 59\% | 1 | 0 | 0\% | 67 | 45 | 67\% | 0 | 0 | 0\% | 52 | 34 | 65\% |


| Table 2c: Counts of Transdermal Fentanyl Episodes and Proportions of Transdermal Fentanyl Episodes with Prior Tolerance with a 91-day Washout Period and a Tertiary Definition in the Mini-Sentinel Distributed Database (MSDD) from January 1, 2009 to December 31, 2013 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Tertiary Tolerance Definition (>0 mg per day in the prior 7 consecutive days) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | Dose $112 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $125 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $137 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $150 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $162 \mathrm{mcg} / \mathrm{hr}$ |  |  |
|  |  | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{gathered} \mathrm{N} \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{gathered}$ | $\begin{array}{\|c\|} \hline \text { \% with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{aligned} & \text { N with } \\ & \text { Prior } \\ & \text { Tolerance } \end{aligned}$ | $\begin{aligned} & \text { \% with } \\ & \text { Prior } \\ & \text { Tolerance } \end{aligned}$ | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{array}{\|c\|} \hline \mathbf{N} \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | $\begin{gathered} \text { \% with } \\ \text { Prior } \\ \text { Tolerance } \end{gathered}$ | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{aligned} & \mathrm{N} \text { with } \\ & \text { Prior } \\ & \text { Tolerance } \end{aligned}$ | $\begin{gathered} \text { \% with } \\ \text { Prior } \\ \text { Tolerance } \end{gathered}$ | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{array}{\|c\|} \hline N \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | $\begin{gathered} \text { \% with } \\ \text { Prior } \\ \text { Tolerance } \end{gathered}$ |
| Age (years) | Total | 5 | 4 | 80\% | 179 | 93 | 52\% | 2 | 1 | 50\% | 233 | 121 | 52\% | 2 | 1 | 50\% |
|  | 0.11 years | 0 | 0 | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | 12-17 years | 0 | 0 | 0\% | 1 | - | 0\% | - | - | 0\% | 2 | - | 0\% | - | - | 0\% |
|  | 18-24 years | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | 5 | 4 | 80\% | 1 | - | 0\% |
|  | 25-34 years | 0 | 0 | 0\% | 10 | 8 | 80\% | - | - | 0\% | 13 | 6 | 46\% | - | - | 0\% |
|  | 35-44 years | 1 | 1 | 100\% | 30 | 15 | 50\% | - | - | 0\% | 37 | 22 | 59\% | - | - | 0\% |
|  | 45 - 54 years | 1 | 1 | 100\% | 72 | 35 | 49\% | 1 | - | 0\% | 88 | 46 | 52\% | - | - | 0\% |
|  | $55-64$ years | 3 | 2 | 67\% | 64 | 33 | 52\% | 1 | 1 | 100\% | 88 | 43 | 49\% | 1 | 1 | 100\% |
| Gender | Male | 2 | 2 | 100\% | 83 | 45 | 54\% | - | - | 0\% | 125 | 71 | 57\% | 2 | 1 | 50\% |
|  | Female | 3 | 2 | 67\% | 96 | 48 | 50\% | 2 | 1 | 50\% | 108 | 50 | 46\% | - | - | 0\% |
|  | Ambiguous | 0 | 0 | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Unknown | 0 | 0 | 0\% | - | - | 0\% | . | . | 0\% | - | - | 0\% | - | . | 0\% |
| Month and Year of Episode Start Date | Jan 2009 | 1 | 1 | 100\% | 5 | 3 | 60\% | - | - | 0\% | 7 | 3 | 43\% | - | - | 0\% |
|  | Feb 2009 | 0 | 0 | 0\% | 5 | 1 | 20\% | - | - | 0\% | 3 | 2 | 67\% | - | - | 0\% |
|  | Mar 2009 |  | 0 | 0\% | 4 | 2 | 50\% | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% |
|  | Apr 2009 | 0 | 0 | 0\% | 5 | 3 | 60\% | - | - | 0\% | 7 | 3 | 43\% | - | - | 0\% |
|  | May 2009 | 0 | 0 | 0\% | 4 | 3 | 75\% | - | - | 0\% | 8 | 5 | 63\% | - | - | 0\% |
|  | Jun 2009 | 0 | 0 | 0\% | 4 | 3 | 75\% | - | - | 0\% | 9 | 6 | 67\% | - | - | 0\% |
|  | Jul 2009 | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 3 | 1 | 33\% | - | - | 0\% |
|  | Aug 2009 | 0 | 0 | 0\% | 3 | 2 | 67\% | - | - | 0\% | 5 | - | 0\% | - | - | 0\% |
|  | Sep 2009 | 0 | 0 | 0\% | 1 | - | 0\% | - | - | 0\% | 5 | 3 | 60\% | - | - | 0\% |
|  | Oct 2009 | 0 | 0 | 0\% | 2 | - | 0\% | - | - | 0\% | 6 | 2 | 33\% | - | - | 0\% |
|  | Nov 2009 | 0 | 0 | 0\% | 3 | 2 | 67\% | - | - | 0\% | 7 | 5 | 71\% | - | - | 0\% |
|  | Dec 2009 | 0 | 0 | 0\% | 5 | 2 | 40\% | - | - | 0\% | 7 | 5 | 71\% | - | - | 0\% |
|  | Jan 2010 | 0 | 0 | 0\% | 10 | 2 | 20\% | - | - | 0\% | 7 | 3 | 43\% | - | - | 0\% |
|  | Feb 2010 | 0 | 0 | 0\% | 6 | 1 | 17\% | - | - | 0\% | 5 | 3 | 60\% | - | - | 0\% |
|  | Mar 2010 | 0 | 0 | 0\% | 3 |  | 0\% | - | - | 0\% | 5 | 3 | 60\% | - | - | 0\% |
|  | Apr 2010 |  | 0 | 0\% | 3 | 1 | 33\% | - | - | 0\% | 6 | 5 | 83\% | - | - | 0\% |
|  | May 2010 | 0 | 0 | 0\% | 2 | 1 | 50\% | - | - | 0\% | 5 | 3 | 60\% | - | - | 0\% |
|  | Jun 2010 | 0 | 0 | 0\% | 6 | 3 | 50\% | - | - | 0\% | 5 | 2 | 40\% | - | - | 0\% |
|  | Jul 2010 | 0 | 0 | 0\% | 4 | 3 | 75\% | - | - | 0\% | 6 | 4 | 67\% | - | - | 0\% |
|  | Aug 2010 | 1 | 0 | 0\% | 3 | 1 | 33\% | - | - | 0\% | 3 | 1 | 33\% | - | - | 0\% |
|  | Sep 2010 | 0 | 0 | 0\% | 1 | - | 0\% | - | - | 0\% | 3 | - | 0\% | - | - | 0\% |
|  | Oct 2010 | 0 | 0 | 0\% | 7 | 6 | 86\% | 1 | 1 | 100\% | 5 | 4 | 80\% | - | - | 0\% |
|  | Nov 2010 | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | 3 | 2 | 67\% | - | - | 0\% |
|  | Dec 2010 | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 4 | 2 | 50\% | - | - | 0\% |
|  | Jan 2011 | 0 | 0 | 0\% | 3 | 1 | 33\% | - | - | 0\% | 5 | 2 | 40\% | 1 | - | 0\% |
|  | Feb 2011 | 1 | 1 | 100\% | 2 | 1 | 50\% | - | - | 0\% | 3 | 1 | 33\% | - |  | 0\% |
|  | Mar 2011 | 0 | 0 | 0\% | 3 | 1 | 33\% | * | , | 0\% | 4 | 1 | 25\% | - | - | 0\% |
|  | Apr 2011 | 0 | 0 | 0\% | 5 | 3 | 60\% | - | - | 0\% | 7 | 4 | 57\% | - | - | 0\% |
|  | May 2011 | 0 | 0 | 0\% | 5 | 1 | 20\% | - | - | 0\% | 4 | 1 | 25\% | - | - | 0\% |
|  | Jun 2011 | 0 | 0 | 0\% | 2 | 1 | 50\% | \% | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jul 2011 | 0 | 0 | 0\% | 2 | - | 0\% |  |  | 0\% | 4 | 4 | 100\% | - | - | 0\% |
|  | Aug 2011 | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% |
|  | Sep 2011 | 0 | 0 | 0\% | 4 | 3 | 75\% | 1 | - | 0\% | 5 | 4 | 80\% | 1 | 1 | 100\% |
|  | Oct 2011 | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | 1 | - | 0\% | - | - | 0\% |
|  | Nov 2011 | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% |
|  | Dec 2011 | 0 | 0 | 0\% | 4 | 2 | 50\% | - | - | 0\% | 2 | 2 | 100\% | - | - | 0\% |
|  | Jan 2012 | 0 | 0 | 0\% | 3 | 2 | 67\% | - | - | 0\% | 3 | 2 | 67\% | - | - | 0\% |
|  | Feb 2012 | 0 | 0 | 0\% | 2 | 1 | 50\% |  | - | 0\% | 6 | 4 | 67\% | - | - | 0\% |
|  | Mar 2012 | 0 | 0 | 0\% | 3 | 3 | 100\% | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% |
|  | Apr 2012 | 1 | 1 | 100\% | 5 | 5 | 100\% | \% | - | 0\% | 6 | 3 | 50\% | - | - | 0\% |
|  | May 2012 | 0 | 0 | 0\% | 4 |  | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jun 2012 | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | 6 | 1 | 17\% | - | - | 0\% |
|  | Jul 2012 | 0 | 0 | 0\% | 1 | 1 | 100\% |  | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Aug 2012 | 0 | 0 | 0\% | 4 | 3 | 75\% | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% |
|  | Sep 2012 | 0 | 0 | 0\% | 2 |  | 100\% | - |  | 0\% | 2 | 1 | 50\% | - | - | 0\% |
|  | Oct 2012 | 0 | 0 | 0\% | 4 | 2 | 50\% | - | - | 0\% | 2 | 2 | 100\% | $\pi$ | - | 0\% |
|  | Nov 2012 | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | 5 | 3 | 60\% | - | - | 0\% |
|  | Dec 2012 | 0 | 0 | 0\% | 3 | 1 | 33\% | - | - | 0\% | 1 | - | 0\% |  | - | 0\% |
|  | Jan 2013 | 0 | 0 | 0\% | 4 |  | 0\% | - | - | 0\% | 4 | - | 0\% | - | - | 0\% |
|  | Feb 2013 | 1 | 1 | 100\% | 3 | 1 | 33\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Mar 2013 | 0 | 0 | 0\% | 2 | 1 | 50\% | - | - | 0\% | 3 | 1 | 33\% | - | - | 0\% |
|  | Apr 2013 | 0 | 0 | 0\% | - | - | 0\% | - | - | 0\% | 5 | 2 | 40\% | - | - | 0\% |
|  | May 2013 | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 3 | 1 | 33\% | - | - | 0\% |
|  | Jun 2013 | 0 | 0 | 0\% | - | - | 0\% | - | - | 0\% | 5 | 1 | 20\% | - | - | 0\% |
|  | Jul 2013 | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | 3 | 2 | 67\% | - | - | 0\% |
|  | Aug 2013 | 0 | 0 | 0\% | 2 | , | 100\% | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% |
|  | Sep 2013 | 0 | 0 | 0\% | 1 |  | 0\% | \% | - | 0\% | 3 | 1 | 33\% | - | - | 0\% |
|  | Oct 2013 | 0 | 0 | 0\% | 3 | 1 | 33\% | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% |
|  | Nov 2013 | 0 | 0 | 0\% | 1 | 1 | 100\% | - | , | 0\% | 3 | 2 | 67\% | - | - | 0\% |
|  | Dec 2013 | 0 | 0 | 0\% | 1 |  | 0\% | . | - | 0\% | 3 | 2 | 67\% | . | - | 0\% |


| Tertiary Tolerance Definition (>0 mg per day in the prior 7 consecutive days) |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Dose $175 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $200 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $225 \mathrm{mcg} / \mathrm{hr}$ |  |  |
|  |  | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{array}{\|c\|} \hline N \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | $\begin{aligned} & \text { \% with } \\ & \text { Prior } \\ & \text { Tolerance } \end{aligned}$ | Total N of Transdermal Fentanyl Episodes | $\begin{array}{\|c\|} \hline \mathrm{N} \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | $\begin{array}{\|c\|} \hline \% \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{array}{\|c\|} \hline N \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | $\begin{array}{\|c\|} \hline \text { \% with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ |
|  | Total | 52 | 26 | 50\% | 5 | 3 | 60\% | 4 | - | 0\% |
| Age (years) | $0-11$ years | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | 12-17 years | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | 18.24 years | $3^{3}$ | 3 | 100\% | - | - | 0\% | - | - | 0\% |
|  | 25-34 years | 3 | 2 | 67\% | - | - | 0\% | 1 | - | 0\% |
|  | 35-44 years | 7 | 5 | 71\% | 3 | 2 | 67\% | 1 | - | 0\% |
|  | $45-54$ years | 17 | 7 | 41\% | 2 | 1 | 50\% | - | - | 0\% |
|  | 55-64 years | 21 | 8 | 38\% | - | - | 0\% | 2 | - | 0\% |
| Gender | Male | 17 | 11 | 65\% | 5 | 3 | 60\% | 2 | - | 0\% |
|  | Female | 35 | 15 | 43\% | - | - | 0\% | 2 | - | 0\% |
|  | Ambiguous | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Unknown | . | . | 0\% | . | . | 0\% | . | . | 0\% |
| Month and Year of Episode Start Date | Jan 2009 | 2 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Feb 2009 |  | 1 | 50\% | - | - | 0\% | - | - | 0\% |
|  | Mar 2009 | 2 | 2 | 100\% | 1 | - | 0\% | 1 | - | 0\% |
|  | Apr 2009 | 4 | 4 | 100\% | 1 | 1 | 100\% | - | - | 0\% |
|  | May 2009 | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Jun 2009 | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Jul 2009 | 2 | - | 0\% | - | - | 0\% | 1 | - | 0\% |
|  | Aug 2009 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Sep 2009 | 2 | 1 | 50\% | - | - | 0\% | - | - | 0\% |
|  | Oct 2009 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Nov 2009 | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Dec 2009 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jan 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Feb 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Mar 2010 | 1 | 1 | 100\% | 1 | 1 | 100\% | - | - | 0\% |
|  | Apr 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | May 2010 | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jun 2010 | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jul 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Aug 2010 | 2 | 2 | 100\% | - | - | 0\% | 1 | - | 0\% |
|  | Sep 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Oct 2010 | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Nov 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Dec 2010 | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Jan 2011 | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Feb 2011 | 2 | 1 | 50\% | - | - | 0\% | - | - | 0\% |
|  | Mar 2011 | 2 | 1 | 50\% | - | - | 0\% | - | - | 0\% |
|  | Apr 2011 | 2 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | May 2011 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jun 2011 | 2 | 1 | 50\% | - | - | 0\% | - | - | 0\% |
|  | Jul 2011 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Aug 2011 | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Sep 2011 | 3 | 1 | 33\% | - | - | 0\% | - | - | 0\% |
|  | Oct 2011 | 2 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Nov 2011 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Dec 2011 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jan 2012 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Feb 2012 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Mar 2012 | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Apr 2012 | 2 | 1 | 50\% | - | - | 0\% | - | - | 0\% |
|  | May 2012 | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Jun 2012 | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jul 2012 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Aug 2012 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Sep 2012 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Oct 2012 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Nov 2012 | 1 | - | 0\% | - | - | 0\% | 1 | - | 0\% |
|  | Dec 2012 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jan 2013 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Feb 2013 | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Mar 2013 | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Apr 2013 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | May 2013 | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Jun 2013 | 1 | - | 0\% | 2 | 1 | 50\% | - | - | 0\% |
|  | Jul 2013 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Aug 2013 | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Sep 2013 | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Oct 2013 | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Nov 2013 | - | $\cdot$ | 0\% | - | - | 0\% | - | - | 0\% |
|  | Dec 2013 |  |  | 100\% | - |  | 0\% | - |  | 0\% |


| Quaternary Tolerance Definition (>0 mg per day for seven days in the 30 days prior) |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Dose $12 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $24 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $25 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $36 \mathrm{mcg} / \mathrm{hr}$ |  |  |
|  |  | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | $N$ with Prior Tolerance | \% with <br> Prior <br> Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | $\begin{aligned} & \text { \% with } \\ & \text { Prior } \\ & \text { Tolerance } \end{aligned}$ | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with <br> Prior <br> Tolerance | \% with <br> Prior <br> Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | N with <br> Prior <br> Tolerance |  |
| Age (years) | Total | 17,812 | 12,713 | 71.4\% | 3 |  | 100\% | 49,148 | 37,514 | 76.3\% | 1 | 0 | 0\% |
|  | 0.11 years | 34 | 14 | 41.2\% | - |  | 0\% | 25 | 9 | 36.0\% | 0 | 0 | 0\% |
|  | 12-17 years | 81 | 38 | 46.9\% |  |  | 0\% | 85 | 39 | 45.9\% | 0 | 0 | 0\% |
|  | 18.24 years | 412 | 266 | 64.6\% |  |  | 0\% | 925 | 639 | 69.1\% | 0 | 0 | 0\% |
|  | 25-34 years | 1,605 | 1,259 | 78.4\% | - |  | 0\% | 4,297 | 3,482 | 81.0\% | 1 | 0 | 0\% |
|  | 35-44 years | 3,153 | 2,377 | 75.4\% | 2 |  | 100\% | 8,915 | 7,040 | 79.0\% | 0 | 0 | 0\% |
|  | 45-54 years | 5,672 | 4,072 | 71.8\% | - |  | 0\% | 16,409 | 12,569 | 76.6\% | 0 | 0 | 0\% |
|  | 55-64 years | 6,855 | 4,687 | 68.4\% | 1 |  | 100\% | 18,492 | 13,736 | 74.3\% | 0 | 0 | 0\% |
| Gender | Male | 5,595 | 4,067 | 72.7\% | ${ }^{1}$ |  | 100\% | 20,233 | 15,573 | 77.0\% | 0 | 0 | 0\% |
|  | Female | 12,217 | 8,646 | 70.8\% | 2 |  | 100\% | 28,915 | 21,941 | 75.9\% | 1 | 0 | 0\% |
|  | Ambiguous |  | . | 0.0\% |  |  | 0\% |  | . | 0.0\% | 0 | 0 | 0\% |
|  | Unknown | 0 | 0 | 0 | 0 |  | 0\% | . | 0 | 0 | 0 | 0 | 0\% |
|  | Jan 2009 | 238 | 176 | 73.9\% | - |  | 0\% | 1,070 | 794 | 74.2\% | 0 | 0 | 0\% |
|  | Feb 2009 | 227 | 154 | 67.8\% | - |  | 0\% | 992 | 740 | 74.6\% | 0 | 0 | 0\% |
| Month and Year of | Mar 2009 | 284 | 186 | 65.5\% | . |  | 0\% | 1,072 | 803 | 74.9\% | 0 | 0 | 0\% |
| Episode Start Date | Apr 2009 | 251 | 177 | 70.5\% | - |  | 0\% | 1,147 | 851 | 74.2\% | 1 | 0 | 0\% |
|  | May 2009 | 283 | 207 | 73.1\% | . |  | 0\% | 1,039 | 806 | 77.6\% | 0 | 0 | 0\% |
|  | Jun 2009 | 300 | 195 | 65.0\% | - |  | 0\% | 1,080 | 816 | 75.6\% | 0 | 0 | 0\% |
|  | Jul 2009 | 267 | 189 | 70.8\% | - |  | 0\% | 966 | 717 | 74.2\% | 0 | 0 | 0\% |
|  | Aug 2009 | 284 | 200 | 70.4\% | - |  | 0\% | 946 | 683 | 72.2\% | 0 | 0 | 0\% |
|  | Sep 2009 | 318 | 231 | 72.6\% | - |  | 0\% | 1,007 | 764 | 75.9\% | 0 | 0 | 0\% |
|  | Oct 2009 | 278 | 184 | 66.2\% | - |  | 0\% | 948 | 699 | 73.7\% | 0 | 0 | 0\% |
|  | Nov 2009 | 244 | 163 | 66.8\% | - |  | 0\% | 898 | 642 | 71.5\% | 0 | 0 | 0\% |
|  | Dec 2009 | 261 | 179 | 68.6\% | - |  | 0\% | 970 | 737 | 76.0\% | 0 | 0 | 0\% |
|  | Jan 2010 | 245 | 165 | 67.3\% | - |  | 0\% | 881 | 649 | 73.7\% | 0 | 0 | 0\% |
|  | Feb 2010 | 254 | 180 | 70.9\% | - |  | 0\% | 790 | 588 | 74.4\% | 0 | 0 | 0\% |
|  | Mar 2010 | 283 | 196 | 69.3\% | - |  | 0\% | 853 | 651 | 76.3\% | 0 | 0 | 0\% |
|  | Apr 2010 | 289 | 199 | 68.9\% | - |  | 0\% | 958 | 716 | 74.7\% | 0 | 0 | 0\% |
|  | May 2010 | 261 | 204 | 78.2\% | - |  | 0\% | 845 | 670 | 79.3\% | 0 | 0 | 0\% |
|  | Jun 2010 | 285 | 198 | 69.5\% | . |  | 0\% | 884 | 654 | 74.0\% | 0 | 0 | 0\% |
|  | Jul 2010 | 239 | 170 | 71.1\% | - |  | 0\% | 837 | 645 | 77.1\% | 0 | 0 | 0\% |
|  | Aug 2010 | 270 | 194 | 71.9\% | - |  | 0\% | 871 | 673 | 77.3\% | 0 | 0 | 0\% |
|  | Sep 2010 | 320 | 225 | 70.3\% | - |  | 0\% | 908 | 701 | 77.2\% | 0 | 0 | 0\% |
|  | Oct 2010 | 313 | 213 | 68.1\% | - |  | 0\% | 843 | 625 | 74.1\% | 0 | 0 | 0\% |
|  | Nov 2010 | 306 | 221 | 72.2\% | - |  | 0\% | 889 | 669 | 75.3\% | 0 | 0 | 0\% |
|  | Dec 2010 | 307 | 217 | 70.7\% | - |  | 0\% | 796 | 617 | 77.5\% | 0 | 0 | 0\% |
|  | Jan 2011 | 264 | 176 | 66.7\% | - |  | 0\% | 774 | 585 | 75.6\% | 0 | 0 | 0\% |
|  | Feb 2011 | 279 | 187 | 67.0\% | - |  | 0\% | 674 | 518 | 76.9\% | 0 | 0 | 0\% |
|  | Mar 2011 | 292 | 203 | 69.5\% | - |  | 0\% | 845 | 659 | 78.0\% | 0 | 0 | 0\% |
|  | Apr 2011 | 307 | 227 | 73.9\% | - |  | 0\% | 812 | 624 | 76.8\% | 0 | 0 | 0\% |
|  | May 2011 | 299 | 210 | 70.2\% | - |  | 0\% | 795 | 599 | 75.3\% | 0 | 0 | 0\% |
|  | Jun 2011 | 316 | 221 | 69.9\% | - |  | 0\% | 777 | 600 | 77.2\% | 0 | 0 | 0\% |
|  | Jul 2011 | 294 | 197 | 67.\% | - |  | 0\% | 728 | 548 | 75.3\% | 0 | 0 | 0\% |
|  | Aug 2011 | 328 | 248 | 75.6\% | - |  | 0\% | 820 | 606 | 73.9\% | 0 | 0 | 0\% |
|  | Sep 2011 | 307 | 219 | 71.3\% | - |  | 0\% | 795 | 611 | 76.9\% | 0 | 0 | 0\% |
|  | Oct 2011 | 279 | 206 | 73.8\% | - |  | 0\% | 768 | 600 | 78.1\% | 0 | 0 | 0\% |
|  | Nov 2011 | 306 | 215 | 70.3\% | - |  | 0\% | 718 | 569 | 79.2\% | 0 | 0 | 0\% |
|  | Dec 2011 | 323 | 225 | 69.7\% | - |  | 0\% | 747 | 560 | 75.0\% | 0 | 0 | 0\% |
|  | Jan 2012 | 298 | 205 | 68.\% | - |  | 0\% | 776 | 609 | 78.5\% | 0 | 0 | 0\% |
|  | Feb 2012 | 269 | 198 | 73.6\% | - |  | 0\% | 696 | 538 | 77.3\% | 0 | 0 | 0\% |
|  | Mar 2012 | 307 | 228 | 74.3\% | - |  | 0\% | 738 | 575 | 77.9\% | 0 | 0 | 0\% |
|  | Apr 2012 | 316 | 225 | 71.2\% | - |  | 0\% | 803 | 607 | 75.6\% | 0 | 0 | 0\% |
|  | May 2012 | 389 | 275 | 70.7\% | - |  | 0\% | 786 | 605 | 77.0\% | 0 | 0 | 0\% |
|  | Jun 2012 | 293 | 218 | 74.4\% | - |  | 0\% | 683 | 535 | 78.3\% | 0 | 0 | 0\% |
|  | Jul 2012 | 315 | 240 | 76.2\% | - |  | 0\% | 672 | 506 | 75.3\% | 0 | 0 | 0\% |
|  | Aug 2012 | 324 | 244 | 75.3\% | - |  | 0\% | 857 | 672 | 78.4\% | 0 | 0 | 0\% |
|  | Sep 2012 | 290 | 206 | 71.0\% | - |  | 0\% | 705 | 544 | 77.2\% | 0 | 0 | 0\% |
|  | Oct 2012 | 330 | 240 | 72.7\% | - |  | 0\% | 754 | 603 | 80.0\% | 0 | 0 | 0\% |
|  | Nov 2012 | 332 | 244 | 73.5\% | - |  | 0\% | 775 | 597 | 77.0\% | 0 | 0 | 0\% |
|  | Dec 2012 | 316 | 233 | 73.7\% | - |  | 0\% | 666 | 501 | 75.2\% | 0 | 0 | 0\% |
|  | Jan 2013 | 296 | 212 | 71.6\% | - |  | 0\% | 650 | 495 | 76.2\% | 0 | 0 | 0\% |
|  | Feb 2013 | 275 | 195 | 70.9\% | - |  | 0\% | 675 | 547 | 81.0\% | 0 | 0 | 0\% |
|  | Mar 2013 | 274 | 200 | 73.0\% | - |  | 0\% | 632 | 506 | 80.1\% | 0 | 0 | 0\% |
|  | Apr 2013 | 327 | 248 | 75.8\% | - |  | 0\% | 724 | 568 | 78.5\% | 0 | 0 | 0\% |
|  | May 2013 | 293 | 206 | 70.3\% | - |  | 0\% | 754 | 590 | 78.2\% | 0 | 0 | 0\% |
|  | Jun 2013 | 306 | 226 | 73.9\% | 1 |  | 100\% | 701 | 553 | 78.9\% | 0 | 0 | 0\% |
|  | Jul 2013 | 345 | 250 | 72.5\% | - |  | 0\% | 719 | 566 | 78.7\% | 0 | 0 | 0\% |
|  | Aug 2013 | 358 | 256 | 71.5\% | - |  | 0\% | 780 | 618 | 79.2\% | 0 | 0 | 0\% |
|  | Sep 2013 | 323 | 237 | 73.4\% | - |  | 0\% | 687 | 521 | 75.8\% | 0 | 0 | 0\% |
|  | Oct 2013 | 366 | 270 | 73.\% | 1 |  | 100\% | 784 | 604 | 77.0\% | 0 | 0 | 0\% |
|  | Nov 2013 | 344 | 262 | 76.2\% | 1 |  | 100\% | 702 | 541 | 77.1\% | 0 | 0 | 0\% |
|  | Dec 2013 | 325 | 238 | 73.2\% | 0 | - | 0\% | 686 | 524 | 76.4\% | 0 | 0 | 0\% |


| Quaternary Tolerance Definition (>0 mg per day for seven days in the $\mathbf{3 0}$ days) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Dose $37 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $50 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $62 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $75 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $87 \mathrm{mcg} / \mathrm{hr}$ |  |  |
|  |  | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{array}{\|c\|} \hline \mathrm{N} \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | $\begin{array}{\|c\|} \hline \text { \% with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{array}{\|c\|} \hline \mathbf{N} \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | $\begin{array}{\|c\|} \hline \% \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | Total $N$ of <br> Transdermal <br> Fentany1 <br> Episodes | $\begin{array}{\|c\|} \hline \mathrm{N} \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | \% with Prior Tolerance | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{array}{\|c\|} \hline \mathbf{N} \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | $\begin{array}{\|c\|} \hline \text { \% with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | Total N of <br> Transdermal Fentanyl Episodes | $\begin{array}{\|c\|} \hline \mathrm{N} \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | \% with Prior Tolerance |
|  | Total | 339 | 253 | 75\% | 21,245 | 16,661 | 78\% | 26 | 9 | 35\% | 6,215 | 4,682 | 75\% | 14 | 7 | 50\% |
| Age (years) | $0-11$ years | 1 | 0 | 0\% | 8 | 4 | 50\% | 1 | 0 | 0\% | 3 | 1 | 33\% | 0 | 0 | 0\% |
|  | 12-17 years | 2 | 0 | 0\% | 37 | 20 | 54\% | 0 | 0 | 0\% | 14 | 5 | 36\% | 0 | 0 | 0\% |
|  | 18.24 years | 9 | 6 | 67\% | 423 | 306 | 72\% | 2 | 0 | 0\% | 121 | 83 | 69\% | 0 | 0 | 0\% |
|  | 25 - 34 years | 27 | 22 | 81\% | 1,911 | 1,557 | 81\% | 2 | 0 | 0\% | 614 | 480 | 78\% | 2 | 2 | 100\% |
|  | 35. 44 years | 71 | 47 | 66\% | 4,031 | 3,293 | 82\% | 6 | 3 | 50\% | 1,229 | 928 | 76\% | 1 | 0 | 0\% |
|  | 45.54 years | 99 | 76 | 77\% | 7,320 | 5,753 | 79\% | 11 | 4 | 36\% | 2,201 | 1,668 | 76\% | 6 | 4 | 67\% |
|  | 55-64 years | 130 | 102 | 78\% | 7,515 | 5,728 | 76\% | 4 | 2 | 50\% | 2,033 | 1,517 | 75\% | 5 | 1 | 20\% |
| Gender | Male | 145 | 114 | 79\% | 9,916 | 7,893 | 80\% | 13 | 7 | 54\% | 2,974 | 2,284 | 77\% | 6 | 4 | 67\% |
|  | Female | 194 | 139 | 72\% | 11,329 | 8,768 | 77\% | 13 | 2 | 15\% | 3,241 | 2,398 | 74\% | 8 | 3 | 38\% |
|  | Ambiguous | 0 | 0 | 0\% | - | - | 0\% | 0 | 0 | 0\% | - | - | 0\% | 0 | 0 | 0\% |
|  | Unknown | 0 | 0 | 0\% | . | . | 0\% | 0 | 0 | 0\% | - | . | 0\% | 0 | 0 | 0\% |
| Month and Year of Episode Start Date | Jan 2009 | 6 | 6 | 100\% | 490 | 364 | 74\% | ${ }^{2}$ | 2 | 100\% | 189 | 128 | 68\% | 1 | 0 | 0\% |
|  | Feb 2009 | 9 | 5 | 56\% | 484 | 394 | 81\% | 0 | 0 | 0\% | 152 | 108 | 71\% | 0 | 0 | 0\% |
|  | Mar 2009 | 5 | 5 | 100\% | 492 | 396 | 80\% | 0 | 0 | 0\% | 140 | 98 | 70\% | 0 | 0 | 0\% |
|  | Apr 2009 | 4 | 2 | 50\% | 532 | 413 | 78\% | 0 | 0 | 0\% | 147 | 116 | 79\% | 0 | 0 | 0\% |
|  | May 2009 | 6 | 6 | 100\% | 470 | 342 | 73\% | 0 | 0 | 0\% | 146 | 102 | 70\% | 0 | 0 | 0\% |
|  | Jun 2009 | 8 | 7 | 88\% | 496 | 377 | 76\% | 0 | 0 | 0\% | 138 | 101 | 73\% | 1 | 0 | 0\% |
|  | Jul 2009 | 8 | 6 | 75\% | 440 | 342 | 78\% | 2 | 0 | 0\% | 112 | 80 | 71\% | 1 | 1 | 100\% |
|  | Aug 2009 | 3 | 2 | 67\% | 398 | 321 | 81\% | 0 | 0 | 0\% | 129 | 99 | 77\% | 0 | 0 | 0\% |
|  | Sep 2009 | 5 | 5 | 100\% | 457 | 359 | 79\% | 0 | 0 | 0\% | 108 | 90 | 83\% | 2 | 1 | 50\% |
|  | Oct 2009 | 1 | 1 | 100\% | 486 | 359 | 74\% | 1 | 0 | 0\% | 123 | 95 | 77\% | 0 | 0 | 0\% |
|  | Nov 2009 | 8 | 5 | 63\% | 402 | 312 | 78\% | 1 | 1 | 100\% | 108 | 89 | 82\% | 0 | 0 | 0\% |
|  | Dec 2009 | 8 | 6 | 75\% | 429 | 334 | 78\% | 0 | 0 | 0\% | 135 | 97 | 72\% | 1 | 0 | 0\% |
|  | Jan 2010 | 6 | 0 | 0\% | 406 | 300 | 74\% | 0 | 0 | 0\% | 120 | 80 | 67\% | 0 | 0 | 0\% |
|  | Feb 2010 | 9 | 9 | 100\% | 362 | 268 | 74\% | 1 | 0 | 0\% | 100 | 71 | 71\% | 1 | 1 | 100\% |
|  | Mar 2010 | 8 | 6 | 75\% | 354 | 278 | 79\% | 0 | 0 | 0\% | 132 | 99 | 75\% | 0 | 0 | 0\% |
|  | Apr 2010 | 4 | 2 | 50\% | 368 | 288 | 78\% | 0 | 0 | 0\% | 122 | 99 | 81\% | 0 | 0 | 0\% |
|  | May 2010 | 6 | 2 | 33\% | 388 | 293 | 76\% | 0 | 0 | 0\% | 109 | 78 | 72\% | 1 | 0 | 0\% |
|  | Jun 2010 | 7 | 4 | 57\% | 402 | 318 | 79\% | 1 | 0 | 0\% | 103 | 83 | 81\% | 0 | 0 | 0\% |
|  | Jul 2010 | 5 | 4 | 80\% | 371 | 300 | 81\% | 0 | 0 | 0\% | 98 | 71 | 72\% | 0 | 0 | 0\% |
|  | Aug 2010 | 3 | 2 | 67\% | 363 | 287 | 79\% | 0 | 0 | 0\% | 116 | 81 | 70\% | 0 | 0 | 0\% |
|  | Sep 2010 | 2 | 2 | 100\% | 373 | 291 | 78\% | 1 | 1 | 100\% | 105 | 88 | 84\% | 0 | 0 | 0\% |
|  | Oct 2010 | 5 | 5 | 100\% | 383 | 313 | 82\% | 0 | 0 | 0\% | 115 | 88 | 77\% | 0 | 0 | 0\% |
|  | Nov 2010 | 8 | 6 | 75\% | 353 | 287 | 81\% | 0 | 0 | 0\% | 102 | 85 | 83\% | 1 | 0 | 0\% |
|  | Dec 2010 | 3 | 2 | 67\% | 404 | 315 | 78\% | 0 | 0 | 0\% | 90 | 71 | 79\% | 0 | 0 | 0\% |
|  | Jan 2011 | 1 | 1 | 100\% | 346 | 260 | 75\% | 1 | 1 | 100\% | 138 | 97 | 70\% | 0 | 0 | 0\% |
|  | Feb 2011 | 3 | 3 | 100\% | 305 | 242 | 79\% | 0 | 0 | 0\% | 109 | 83 | 76\% | 0 | 0 | 0\% |
|  | Mar 2011 | 9 | 6 | 67\% | 371 | 294 | 79\% | 0 | 0 | 0\% | 103 | 85 | 83\% | 0 | 0 | 0\% |
|  | Apr 2011 | 10 | 10 | 100\% | 386 | 292 | 76\% | 0 | 0 | 0\% | 124 | 94 | 76\% | 0 | 0 | 0\% |
|  | May 2011 | 4 | 3 | 75\% | 346 | 261 | 75\% | 0 | 0 | 0\% | 98 | 73 | 74\% | 0 | 0 | 0\% |
|  | Jun 2011 | 4 | 3 | 75\% | 344 | 263 | 76\% | 1 | 0 | 0\% | 96 | 79 | 82\% | 1 | 1 | 100\% |
|  | Jul 2011 | 4 | 2 | 50\% | 350 | 279 | 80\% | 0 | 0 | 0\% | 80 | 69 | 86\% | 0 | 0 | 0\% |
|  | Aug 2011 | 5 | 3 | 60\% | 342 | 270 | 79\% | 0 | 0 | 0\% | 94 | 67 | 71\% | 0 | 0 | 0\% |
|  | Sep 2011 | 6 | 5 | 83\% | 337 | 271 | 80\% | 0 | 0 | 0\% | 87 | 70 | 80\% | 0 | 0 | 0\% |
|  | Oct 2011 | 3 | 2 | 67\% | 306 | 240 | 78\% | 2 | 0 | 0\% | 86 | 70 | 81\% | 0 | 0 | 0\% |
|  | Nov 2011 | 7 | 4 | 57\% | 300 | 238 | 79\% | 0 | 0 | 0\% | 85 | 64 | 75\% | 0 | 0 | 0\% |
|  | Dec 2011 | 5 | 5 | 100\% | 312 | 255 | 82\% | 0 | 0 | 0\% | 88 | 61 | 69\% | 0 | 0 | 0\% |
|  | Jan 2012 | 3 | 2 | 67\% | 310 | 246 | 79\% | 0 | 0 | 0\% | 108 | 85 | 79\% | 0 | 0 | 0\% |
|  | Feb 2012 | 7 | 6 | 86\% | 300 | 245 | 82\% | 1 | 0 | 0\% | 86 | 65 | 76\% | 0 | 0 | 0\% |
|  | Mar 2012 | 7 | 6 | 86\% | 314 | 260 | 83\% | 0 | 0 | 0\% | 84 | 68 | 81\% | 0 | 0 | 0\% |
|  | Apr 2012 | 7 | 5 | 71\% | 359 | 284 | 79\% | 1 | 0 | 0\% | 118 | 87 | 74\% | 1 | 1 | 100\% |
|  | May 2012 | 8 | 7 | 88\% | 363 | 284 | 78\% | 1 | 0 | 0\% | 98 | 77 | 79\% | 0 | 0 | 0\% |
|  | Jun 2012 | 4 | 3 | 75\% | 299 | 243 | 81\% | 1 | 0 | 0\% | 82 | 65 | 79\% | 0 | 0 | 0\% |
|  | Jul 2012 | 5 | 4 | 80\% | 331 | 266 | 80\% | 0 | - | 0\% | 103 | 76 | 74\% | 0 | 0 | 0\% |
|  | Aug 2012 | 2 | 2 | 100\% | 297 | 233 | 78\% | 1 | 1 | 100\% | 102 | 77 | 75\% | 0 | 0 | 0\% |
|  | Sep 2012 | 5 | 5 | 100\% | 283 | 229 | $81 \%$ | 1 | - | 0\% | 89 | 67 | 75\% | 1 | 1 | 100\% |
|  | Oct 2012 | 3 | 2 | 67\% | 285 | 229 | 80\% | 0 | 0 | 0\% | 83 | 65 | 78\% | 0 | 0 | 0\% |
|  | Nov 2012 | 6 | 4 | 67\% | 336 | 241 | 72\% | 0 | - | 0\% | 105 | 72 | 69\% | 2 | 1 | 50\% |
|  | Dec 2012 | 9 | 5 | 56\% | 286 | 226 | 79\% | 0 | - | 0\% | 64 | 41 | 64\% | 0 | 0 | 0\% |
|  | Jan 2013 | 5 | 3 | 60\% | 302 | 235 | 78\% | 2 | 1 | 50\% | 103 | 72 | 70\% | 0 | 0 | 0\% |
|  | Feb 2013 | 3 | 3 | 100\% | 246 | 201 | 82\% | 2 | , | 0\% | 64 | 52 | 81\% | 0 | 0 | 0\% |
|  | Mar 2013 | 4 | 4 | 100\% | 248 | 194 | 78\% | 0 | 0 | 0\% | 80 | 57 | 71\% | 0 | 0 | 0\% |
|  | Apr 2013 | 11 | 8 | 73\% | 280 | 225 | 80\% | 0 | 0 | 0\% | 93 | 71 | 76\% | 0 | 0 | 0\% |
|  | May 2013 | 9 | 7 | 78\% | 307 | 241 | 79\% | 1 | 1 | 100\% | 83 | 67 | 81\% | 0 | 0 | \%\% |
|  | Jun 2013 | 5 | 4 | 80\% | 288 | 232 | 81\% | 0 | 0 | 0\% | 89 | 67 | 75\% | 0 | 0 | 0\% |
|  | Jul 2013 | 9 | 7 | 78\% | 272 | 219 | 81\% | 0 | 0 | 0\% | 88 | 73 | 83\% | 0 | 0 | 0\% |
|  | Aug 2013 | 7 | 5 | 71\% | 300 | 249 | 83\% | 0 | - | 0\% | 75 | 48 | 64\% | 0 | 0 | 0\% |
|  | Sep 2013 | 5 | 4 | 80\% | 276 | 225 | 82\% | 1 | 0 | 0\% | 75 | 54 | 72\% | 0 | 0 | 0\% |
|  | Oct 2013 | 4 | 2 | 50\% | 274 | 218 | 80\% | 0 | 0 | 0\% | 78 | 58 | 74\% | 0 | 0 | 0\% |
|  | Nov 2013 | 7 | 3 | 43\% | 265 | 207 | 78\% | 0 | 0 | 0\% | 71 | 56 | 79\% | 0 | 0 | 0\% |
|  | Dec 2013 | 6 | 5 | 83\% | 276 | 213 | 77\% | 1 | 1 | 100\% | 67 | 53 | 79\% | 0 | 0 | 0\% |


| Table 2d: Counts of Transdermal Fentanyl Episodes and Proportions of Transdermal Fentanyl Episodes with Prior Tolerance with a 91-day Washout Period and a Quaternary Definition in the MiniSentinel Distributed Database (MSDD) from January 1, 2009 to December 31, 2013 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Quaternary Tolerance Definition (>0 mg per day for seven days in the $\mathbf{3 0}$ days prior) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | Dose $100 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $112 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $125 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $137 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $150 \mathrm{mcg} / \mathrm{hr}$ |  |  |
|  |  | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{array}{\|c\|} \hline \mathbf{N} \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | $\begin{array}{\|c\|} \hline \text { \% with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{aligned} & \text { N with } \\ & \text { Prior } \\ & \text { Tolerance } \end{aligned}$ | $\begin{aligned} & \text { \% with } \\ & \text { Prior } \\ & \text { Tolerance } \end{aligned}$ | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{array}{\|c\|} \hline \mathrm{N} \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | $\begin{array}{\|c\|} \hline \text { \% with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | N with Prior Tolerance | $\begin{aligned} & \text { \% with } \\ & \text { Prior } \\ & \text { Tolerance } \end{aligned}$ | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{gathered} \text { N with } \\ \text { Prior } \\ \text { Tolerance } \end{gathered}$ | $\begin{aligned} & \text { \% with } \\ & \text { Prior } \\ & \text { Tolerance } \end{aligned}$ |
| Age (years) | Total | 4,524 | 3,253 | 72\% | 5 | 4 | 80\% | 179 | 121 | 68\% | 2 | 1 | 50\% | 233 | 152 | 65\% |
|  | $0-11$ years | 6 | 1 | 17\% | 0 | 0 | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | 12-17 years | 9 | 4 | 44\% | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 2 | - | 0\% |
|  | 18.24 years | 91 | 56 | 62\% | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | 5 | 4 | 80\% |
|  | 25-34 years | 375 | 297 | 79\% | 0 | 0 | 0\% | 10 | 8 | 80\% | - | - | 0\% | 13 | 9 | 69\% |
|  | 35. 44 years | 870 | 640 | 74\% | 1 | 1 | 100\% | 30 | 24 | 80\% | - | - | 0\% | 37 | 27 | 73\% |
|  | 45-54 years | 1,644 | 1,189 | 72\% | 1 | 1 | 100\% | 72 | 43 | 60\% | 1 | - | 0\% | 88 | 57 | 65\% |
|  | 55-64 years | 1,529 | 1,066 | 70\% | 3 | 2 | 67\% | 64 | 43 | 67\% | 1 | 1 | 100\% | 88 | 55 | 63\% |
| Gender | Male | 2,316 | 1,730 | 75\% | 2 | 2 | 100\% | 83 | 57 | 69\% | - | - | 0\% | 125 | 90 | 72\% |
|  | Female | 2,208 | 1,523 | 69\% | 3 | 2 | 67\% | 96 | 64 | 67\% | 2 | 1 | 50\% | 108 | 62 | 57\% |
|  | Ambiguous | - | - | 0\% | 0 | 0 | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Unknown | - | - | 0\% | 0 | 0 | 0\% | - | - | 0\% | . | . | 0\% |  |  | 0\% |
|  | Jan 2009 | 131 | 88 | 67\% | 1 | 1 | 100\% | 5 | 4 | 80\% | - | - | 0\% | 7 | 3 | 43\% |
|  | Feb 2009 | 132 | 100 | 76\% | 0 | 0 | 0\% | 5 | 2 | 40\% | - | - | 0\% | 3 | 3 | 100\% |
| Month and Year of | Mar 2009 | 101 | 68 | 67\% | 0 | 0 | 0\% | 4 | 2 | 50\% | - | - | 0\% | 2 | 1 | 50\% |
| Episode Start Date | Apr 2009 | 120 | 92 | 77\% | 0 | 0 | 0\% | 5 | 3 | 60\% | - | - | 0\% | 7 | 5 | 71\% |
|  | May 2009 | 122 | 83 | 68\% | 0 | 0 | 0\% | 4 | 3 | 75\% | . | - | 0\% | 8 | 5 | 63\% |
|  | Jun 2009 | 107 | 84 | 79\% | 0 | 0 | 0\% | 4 | 3 | 75\% | - | - | 0\% | 9 | 7 | 78\% |
|  | Jul 2009 | 114 | 80 | 70\% | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 3 | 1 | 33\% |
|  | Aug 2009 | 98 | 64 | 65\% | 0 | 0 | 0\% | 3 | 2 | 67\% | - | - | 0\% | 5 | 1 | 20\% |
|  | Sep 2009 | 89 | 58 | 65\% | 0 | 0 | 0\% | 1 | - | 0\% | - | - | 0\% | 5 | 4 | 80\% |
|  | Oct 2009 | 108 | 77 | 71\% | 0 | 0 | 0\% | 2 | 1 | 50\% | - | - | 0\% | 6 | 2 | 33\% |
|  | Nov 2009 | 93 | 67 | 72\% | 0 | 0 | 0\% | 3 | 2 | 67\% | - | - | 0\% | 7 | 5 | 71\% |
|  | Dec 2009 | 96 | 72 | 75\% | 0 | 0 | 0\% | 5 | 4 | 80\% | - | - | 0\% | 7 | 6 | 86\% |
|  | Jan 2010 | 115 | 80 | 70\% | 0 | 0 | 0\% | 10 | 4 | 40\% | - | - | 0\% | 7 | 4 | 57\% |
|  | Feb 2010 | 74 | 50 | 68\% | 0 | 0 | 0\% | 6 | 3 | 50\% | - | - | 0\% | 5 | 4 | 80\% |
|  | Mar 2010 | 71 | 48 | 68\% | 0 | 0 | 0\% | 3 | - | 0\% | - | - | 0\% | 5 | 4 | 80\% |
|  | Apr 2010 | 98 | 78 | 80\% | 0 | 0 | 0\% | 3 | 2 | 67\% | - | - | 0\% | 6 | 5 | 83\% |
|  | May 2010 | 75 | 56 | 75\% | 0 | 0 | 0\% | 2 | 1 | 50\% | - | - | 0\% | 5 | 4 | 80\% |
|  | Jun 2010 | 71 | 56 | 79\% | 0 | 0 | 0\% | 6 | 5 | 83\% | - | - | 0\% | 5 | 3 | 60\% |
|  | Jul 2010 | 66 | 53 | 80\% | 0 | 0 | 0\% | 4 | 4 | 100\% | - | - | 0\% | 6 | 4 | 67\% |
|  | Aug 2010 | 86 | 65 | 76\% | 1 | 0 | 0\% | 3 | 2 | 67\% | - | - | 0\% | 3 | 2 | 67\% |
|  | Sep 2010 | 84 | 63 | 75\% | 0 | 0 | 0\% | 1 | - | 0\% | - | - | 0\% | 3 | 1 | 33\% |
|  | Oct 2010 | 75 | 63 | 84\% | 0 | 0 | 0\% | 7 | 6 | 86\% | 1 | 1 | 100\% | 5 | 5 | 100\% |
|  | Nov 2010 | 70 | 53 | 76\% | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | 3 | 2 | 67\% |
|  | Dec 2010 | 77 | 45 | 58\% | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 4 | 2 | 50\% |
|  | Jan 2011 | 115 | 82 | 71\% | 0 | 0 | 0\% | 3 | 1 | 33\% | - | - | 0\% | 5 | 3 | 60\% |
|  | Feb 2011 | 77 | 57 | 74\% | 1 | 1 | 100\% | 2 | 2 | 100\% | - | - | 0\% | 3 | 2 | 67\% |
|  | Mar 2011 | 101 | 73 | 72\% | 0 | 0 | 0\% | 3 | 2 | 67\% | - | - | 0\% | 4 | 2 | 50\% |
|  | Apr 2011 | 70 | 49 | 70\% | 0 | 0 | 0\% | 5 | 4 | 80\% | - | - | 0\% | 7 | 5 | 71\% |
|  | May 2011 | 69 | 46 | 67\% | 0 | 0 | 0\% | 5 | 3 | 60\% | - | - | 0\% | 4 | 2 | 50\% |
|  | Jun 2011 | 59 | 44 | 75\% | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Jul 2011 | 53 | 41 | 77\% | 0 | 0 | 0\% | 2 | - | 0\% | - | - | 0\% | 4 | 4 | 100\% |
|  | Aug 2011 | 52 | 45 | 87\% | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 1 | 1 | 100\% |
|  | Sep 2011 | 55 | 41 | 75\% | 0 | 0 | 0\% | 4 | 3 | 75\% | 1 | - | 0\% | 5 | 4 | 80\% |
|  | Oct 2011 | 68 | 47 | 69\% | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | 1 | - | 0\% |
|  | Nov 2011 | 62 | 43 | 69\% | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 2 | 1 | 50\% |
|  | Dec 2011 | 73 | 54 | 74\% | 0 | 0 | 0\% | 4 | 2 | 50\% | - | - | 0\% | 2 | 2 | 100\% |
|  | Jan 2012 | 69 | 45 | 65\% | 0 | 0 | 0\% | 3 | 2 | 67\% | - | - | 0\% | 3 | 2 | 67\% |
|  | Feb 2012 | 60 | 50 | 83\% | 0 | 0 | 0\% | 2 |  | 100\% | - | - | 0\% | 6 | 4 | 67\% |
|  | Mar 2012 | 61 | 52 | 85\% | 0 | 0 | 0\% | 3 | 3 | 100\% | - | - | 0\% | 2 | 2 | 100\% |
|  | Apr 2012 | 74 | 52 | 70\% | 1 | 1 | 100\% | 5 | 5 | 100\% | - | - | 0\% | 6 | 5 | 83\% |
|  | May 2012 | 77 | 57 | 74\% | 0 | 0 | 0\% | 4 |  | 50\% | - | - | 0\% | - | - | 0\% |
|  | Jun 2012 | 64 | 49 | 77\% | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | 6 | 1 | 17\% |
|  | Jul 2012 | 52 | 31 | 60\% | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Aug 2012 | 61 | 46 | 75\% | 0 | 0 | 0\% | 4 | 4 | 100\% | - | - | 0\% | 1 | 1 | 100\% |
|  | Sep 2012 | 48 | 39 | 81\% | 0 | 0 | 0\% | 2 | , | 100\% | - | - | 0\% | 2 | 1 | 50\% |
|  | Oct 2012 | 60 | 40 | 67\% | 0 | 0 | 0\% | 4 | 3 | 75\% | - | - | 0\% | 2 | 2 | 100\% |
|  | Nov 2012 | 77 | 51 | 66\% | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | 5 | 4 | 80\% |
|  | Dec 2012 | 54 | 37 | 69\% | 0 | 0 | 0\% | 3 | 1 | 33\% | - | - | 0\% | 1 | - | 0\% |
|  | Jan 2013 | 64 | 39 | 61\% | 0 | 0 | 0\% | 4 | - | 0\% | - | - | 0\% | 4 | 1 | 25\% |
|  | Feb 2013 | 52 | 40 | 77\% | 1 | 1 | 100\% | 3 | 2 | 67\% | - | - | 0\% | - | - | 0\% |
|  | Mar 2013 | 40 | 30 | 75\% | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | 3 | 1 | 33\% |
|  | Apr 2013 | 59 | 41 | 69\% | 0 | 0 | 0\% | - | - | 0\% | - | - | 0\% | 5 | 3 | 60\% |
|  | May 2013 | 54 | 35 | 65\% | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 3 | 2 | 67\% |
|  | Jun 2013 | 55 | 38 | 69\% | 0 | 0 | 0\% | - | - | 0\% | - | - | 0\% | 5 | 4 | 80\% |
|  | Jul 2013 | 60 | 39 | 65\% | 0 | 0 | 0\% | 2 | 2 | 100\% | \% | - | 0\% | 3 |  | 100\% |
|  | Aug 2013 | 39 | 23 | 59\% | 0 | 0 | 0\% | 2 | 2 | 100\% | - | - | 0\% | 2 | 1 | 50\% |
|  | Sep 2013 | 52 | 37 | 71\% | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 3 | 1 | 33\% |
|  | Oct 2013 | 56 | 38 | 68\% | 0 | 0 | 0\% | 3 | 1 | 33\% | - | - | 0\% | 1 | 1 | 100\% |
|  | Nov 2013 | 57 | 39 | 68\% | 0 | 0 | 0\% | 1 | 1 | 100\% | - | - | 0\% | 3 | 2 | 67\% |
|  | Dec 2013 | 52 | 40 | 77\% | 0 | 0 | 0\% | 1 | - | 0\% | - | - | 0\% | 3 | 2 | 67\% |


| Table 2d: Counts of Transdermal Fentanyl Episodes and Proportions of Transdermal Fentanyl Episodes with Prior Tolerance with a 91-day Washout Period and a Quaternary Definition in the Mini-Sentinel Distributed Database (MSDD) from January 1, 2009 to December 31, 2013 |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Quaternary Tolerance Definition (>0 mg per day for seven days in the 30 days prior) |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | Dose $162 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $175 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $200 \mathrm{mcg} / \mathrm{hr}$ |  |  | Dose $225 \mathrm{mcg} / \mathrm{hr}$ |  |  |
|  |  | Total N of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{aligned} & \mathrm{N} \text { with } \\ & \text { Prior } \\ & \text { Tolerance } \end{aligned}$ | $\begin{aligned} & \text { \% with } \\ & \text { Prior } \\ & \text { Tolerance } \end{aligned}$ | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{array}{\|c\|c\|} \hline N \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | $\begin{array}{\|c} \begin{array}{c} \% \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array} \end{array}$ | Total $N$ of <br> Transdermal <br> Fentanyl <br> Episodes | $\begin{array}{\|c} \hline N \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | $\begin{aligned} & \text { \% with } \\ & \text { Prior } \\ & \text { Tolerance } \end{aligned}$ | Total $\mathbf{N}$ of Transdermal Fentanyl Episodes | $\begin{array}{\|c\|} \hline \mathbf{N} \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ | $\begin{array}{\|c\|} \hline \% \text { with } \\ \text { Prior } \\ \text { Tolerance } \end{array}$ |
| Age (years) | Total | 2 | 2 | 100\% | 52 | 33 | 63\% | 5 | 3 | 60\% | 4 | 1 | 25\% |
|  | $0-11$ years | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | 12 -17 years | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | 18.24 years | 1 | 1 | 100\% | ${ }^{3}$ | 3 | 100\% | - | - | 0\% | - | - | 0\% |
|  | 25.34 years | - | - | 0\% | ${ }^{3}$ | 2 | 67\% | - | - | 0\% | 1 | 1 | 100\% |
|  | 35.44 years | - | - | 0\% | 7 | 6 | 86\% | 3 | 2 | 67\% | 1 | - | 0\% |
|  | 45.54 years | - | - | 0\% | 17 | 10 | 59\% | 2 | 1 | 50\% | - | - | 0\% |
|  | 55.64 years | 1 | 1 | 100\% | 21 | 11 | 52\% | - | - | 0\% | 2 | - | 0\% |
| Gender | Male | 2 | 2 | 100\% | 17 | 12 | 71\% | 5 | 3 | 60\% | 2 | 1 | 50\% |
|  | Female | - | - | 0\% | 35 | 21 | 60\% | - | - | 0\% | 2 | - | 0\% |
|  | Ambiguous | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Unknown | . | . | 0\% | . | . | 0\% | . | - | 0\% | - | - | 0\% |
|  | Jan 2009 | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% | - | - | 0\% |
|  | Feb 2009 | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% | - | - | 0\% |
| Month and Year of | Mar 2009 | - | - | 0\% | ${ }^{2}$ | 2 | 100\% | 1 | - | 0\% | 1 | - | 0\% |
| Episode Start Date | Apr 2009 | - | - | 0\% | ${ }^{4}$ | 4 | 100\% | 1 | 1 | 100\% | - | - | 0\% |
|  | May 2009 | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Jun 2009 | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Jul 2009 | - | - | 0\% | 2 | 2 | 100\% | - | - | 0\% | 1 | 1 | 100\% |
|  | Aug 2009 | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Sep 2009 | - | - | 0\% | 2 | 2 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Oct 2009 | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Nov 2009 | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Dec 2009 | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jan 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Feb 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Mar 2010 | - | - | 0\% | 1 | 1 | 100\% | 1 | 1 | 100\% | - | - | 0\% |
|  | Apr 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | May 2010 | - | - | 0\% | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jun 2010 | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Jul 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Aug 2010 | - | - | 0\% | 2 | 2 | 100\% | - | - | 0\% | 1 | - | 0\% |
|  | Sep 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Oct 2010 | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Nov 2010 | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Dec 2010 | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Jan 2011 | 1 | 1 | 100\% | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Feb 2011 | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% | - | - | 0\% |
|  | Mar 2011 | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% | - | - | 0\% |
|  | Apr 2011 | - | - | 0\% | 2 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | May 2011 | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jun 2011 | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% | - | - | 0\% |
|  | Jul 2011 | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Aug 2011 | - | - | 0\% | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Sep 2011 | 1 | 1 | 100\% | 3 | 2 | 67\% | - | - | 0\% | - | - | 0\% |
|  | Oct 2011 | - | - | 0\% | 2 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Nov 2011 | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Dec 2011 | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jan 2012 | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Feb 2012 | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Mar 2012 | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Apr 2012 | - | - | 0\% | 2 | 1 | 50\% | - | - | 0\% | - | - | 0\% |
|  | May 2012 | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Jun 2012 | - | - | 0\% | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jul 2012 | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Aug 2012 | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Sep 2012 | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Oct 2012 | , | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Nov 2012 | - | - | 0\% | 1 | - | 0\% | - | - | 0\% | 1 | - | 0\% |
|  | Dec 2012 | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Jan 2013 |  | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Feb 2013 | - | - | 0\% | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Mar 2013 | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Apr 2013 | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | May 2013 | - | - | 0\% | 1 | 1 | 100\% | - | - | 0\% | - | - | 0\% |
|  | Jun 2013 | - | - | 0\% | 1 | - | 0\% | 2 | 1 | 50\% | - | - | 0\% |
|  | Jul 2013 | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Aug 2013 | - | - | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Sep 2013 | , | - | 0\% | 1 | 1 | 100\% | - | - | 0\% | , | - | 0\% |
|  | Oct 2013 | - | - | 0\% | 1 | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Nov 2013 | - | , | 0\% | - | - | 0\% | - | - | 0\% | - | - | 0\% |
|  | Dec 2013 | - | - | 0\% | 1 | 1 | 100\% | - |  | 0\% | - |  | 0\% |

Appendix A: Latest Date of Available Data for Each Data Partner up to Request Send Date (April 20, 2016)

| DP ID | Start Date | End Date |
| :---: | :---: | :---: |
| DP0001 | $1 / 1 / 2009$ | $12 / 31 / 2013$ |
| DP0002 | $1 / 1 / 2009$ | $12 / 31 / 2013$ |
| DP0003 | $1 / 1 / 2009$ | $12 / 31 / 2013$ |
| DP0004 | $1 / 1 / 2009$ | $12 / 31 / 2013$ |
| DP0005 | $1 / 1 / 2009$ | $12 / 31 / 2013$ |
| DP0006 | $1 / 1 / 2009$ | $6 / 30 / 2012$ |
| DP0007 | $1 / 1 / 2009$ | $12 / 31 / 2013$ |
| DP0008 | $1 / 1 / 2009$ | $12 / 31 / 2013$ |
| DP0009 | $1 / 1 / 2009$ | $12 / 31 / 2013$ |
| DP0010 | $1 / 1 / 2009$ | $12 / 31 / 2013$ |
| DP0011 | $1 / 1 / 2009$ | $12 / 31 / 2013$ |
| DP0012 | $1 / 1 / 2009$ | $12 / 31 / 2013$ |
| DP0013 | $1 / 1 / 2009$ | $12 / 31 / 2013$ |
| DP0014 | $1 / 1 / 2009$ | $12 / 31 / 2013$ |
| DP0015 | $1 / 1 / 2009$ | $12 / 31 / 2013$ |

Appendix B: List of Drugs Used to Define Exposures in this Request

| Generic Name | Form | Route | Strength | Unit |
| :--- | :--- | :--- | :--- | :--- |
| Fentanyl Patch |  |  |  |  |
| FENTANYL | PATCH 72 HOUR | TRANSDERMAL | 25 | $\mathrm{MCG} / \mathrm{HR}$ |
| FENTANYL | PATCH 72 HOUR | TRANSDERMAL | 50 | $\mathrm{MCG} / \mathrm{HR}$ |
| FENTANYL | PATCH 72 HOUR | TRANSDERMAL | 75 | $\mathrm{MCG} / \mathrm{HR}$ |
| FENTANYL | PATCH 72 HOUR | TRANSDERMAL | 100 | $\mathrm{MCG} / \mathrm{HR}$ |
| FENTANYL | PATCH 72 HOUR | TRANSDERMAL | 12 | $\mathrm{MCG} / \mathrm{HR}$ |

Appendix C: List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) Codes Used to Define Exclusion Criteria in this Request

| Opioid Poisoning | Description | Code Type |
| :--- | :--- | :--- |
| 965.0 | Poisoning by opiates and related narcotics | ICD-9-CM Diagnosis Code |
| 965.00 | Poisoning by opium (alkaloids), unspecified | ICD-9-CM Diagnosis Code |
| 965.01 | Poisoning by heroin | ICD-9-CM Diagnosis Code |
| 965.02 | Poisoning by methadone | ICD-9-CM Diagnosis Code |
| 965.09 | Poisoning by other opiates and related narcotics | ICD-9-CM Diagnosis Code |

